UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934

Filed by the Registrant  ☒

Filed by a Party other than the Registrant


(Amendment No.  )
Filed by the Registrant ☒
Filed by a Party other than the Registrant  ☐
Check the appropriate box:

Preliminary Proxy Statement
Confidential, for useUse of the Commission onlyOnly (as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement
Definitive Additional Materials
Soliciting Material under Rule 14a-12Pursuant to §240.14a-12

METHODE ELECTRONICS, INC.


(Exact Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other thanOther Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1)
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
(1)
Title of each class of securities to which transaction applies:

(2)
(2)
Aggregate number of securities to which transaction applies:

(3)
(3)
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4)
(4)
Proposed maximum aggregate value of transaction:

(5)
(5)
Total fee paid:

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1)
Fee paid previously with preliminary materials.
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
(1)
Amount Previously Paid:

(2)
(2)
Form, Schedule or Registration Statement No.:

(3)
(3)
Filing Party:

(4)
(4)
Date Filed:


METHODE ELECTRONICS, INC.

7401

8750 West WilsonBryn Mawr Avenue,

Suite 1000

Chicago, Illinois 60706

60631

(708) 867-6777

NOTICE OF ANNUAL MEETING OF SHAREHOLDERS

STOCKHOLDERS


TO BE HELD ON SEPTEMBER 14, 2017

______________________

15, 2021

To the Shareholdersour Stockholders:
The 2021 Annual Meeting of Stockholders of Methode Electronics, Inc.:

Notice is hereby given that (“Methode” or the annual meeting of shareholders of Methode Electronics, Inc.“Company”) will be held on Thursday,‎Wednesday, September 14, 201715, 2021 at 11:00 a.m., Central Daylight Time, at Methode’s corporate offices at 7401 West Wilson Avenue, Chicago, Illinois, 60706 forTime‎. The 2021 Annual Meeting will be a virtual meeting conducted via live webcast. You will be able to attend the Annual Meeting as well as vote and submit your questions during the live webcast of the meeting by visiting www.virtualshareholdermeeting.com/MEI2021 and entering the 16-digit control number included in the Notice of Internet Availability of Proxy Materials, on your proxy card or in the instructions that accompanied your proxy materials.

At the Annual Meeting, stockholders will be asked to consider and vote on the following purposes:

matters, each as more fully described in the accompanying proxy statement:
1.
To elect each director nominee to hold office until the Company’s 2022 Annual Meeting of Stockholders or until such director’s earlier resignation, or a Board of Directors;respective successor is duly elected and appointed;
2.
To ratify the Audit Committee’s selection of Ernst & Young LLP to serve as our independent registered public accounting firm for the fiscal year ending April 28, 2018;30, 2022;
3.
To provideapprove, on a non-binding, advisory approvalbasis, the compensation of Methode’s named executive officer compensation;
4.To cast an advisory vote on the frequency of future advisory votes on Methode’s named executive officer compensation;officers; and
5.4.
To transact such other business as may properly come before the annual meetingAnnual Meeting or any adjournment or postponement thereof.

Only stockholders of record at the close of business on July 19, 2021, the record date, are entitled to notice of and to vote at the Annual Meeting.
Your vote is important. Whether or not you plan to attend the Annual Meeting, you are requested to vote your shares via the internet, by telephone or by completing and returning the proxy card if you requested paper copies of the Company’s proxy materials. Any person giving a proxy has the power to revoke it at any time prior to the Annual Meeting and stockholders who attend the Annual Meeting may withdraw their proxies and vote online at the Annual Meeting.
By Order of the Board of Directors,
Walter J. Aspatore
Chairman
Chicago, Illinois
July 27, 2021
Important Notice Regarding the Availability of Proxy Materials for the
Annual Meeting of Stockholders to Be Held on September 15, 2021
We are furnishing the proxy materials for the Annual Meeting electronically using the internet through the mailing to our stockholders of a Notice of Internet Availability of Proxy Materials (the “Notice and Access Card”). The Notice and Access Card will be mailed to stockholders of record on July 19, 2021‎. Please visit the website www.proxyvote.com to view electronic versions of our Proxy Statement and our 2021 Annual Report on Form 10-K, and to request electronic delivery of future proxy materials.

METHODE ELECTRONICS, INC.
8750 West Bryn Mawr Avenue, Suite 1000
Chicago, Illinois 60631
(708) 867-6777

PROXY STATEMENT

ANNUAL MEETING OF STOCKHOLDERS
September 15, 2021
This proxy statement is being furnished by and on behalf of the Board of Directors of Methode Electronics, Inc. (“Methode” or the “Company”), in connection with the solicitation of proxies to be voted at the 2021 Annual Meeting of Stockholders (the “Annual Meeting”). The 2021 Annual Meeting will be a virtual meeting conducted via live webcast.‎
We are furnishing the proxy materials for the Annual Meeting electronically using the internet through the mailing to our stockholders of a Notice of Internet Availability of Proxy Materials (the “Notice and Access Card”). The Notice and Access Card was mailed to stockholders of record on July 19, 2021. Please visit the website www.proxyvote.com to view electronic versions of this proxy statement and our 2021 Annual Report on Form 10-K, and to request electronic delivery of future proxy materials.
GENERAL INFORMATION ABOUT THE ANNUAL MEETING
Where and when will the Annual Meeting be held?
The Annual Meeting will be held at ‎11:00 a.m., Central Daylight Time‎, on Wednesday, September 15, 2021‎. The Annual Meeting will be a virtual meeting via live webcast on the internet.
Who can vote at, and participate in, the Annual Meeting?
Holders of record of our common stock as of the close of business on July 19, 2021‎, the record date, are the only stockholders who are entitled to vote at, and participate in, the Annual Meeting. On that date‎, there were 38,194,209 shares of Methode common stock outstanding.
How can I vote my shares at, and participate in, the Annual Meeting?
The Annual Meeting will be held entirely online. You will be able to attend the Annual Meeting as well as vote and submit your questions during the live ‎webcast of ‎the meeting by visiting www.virtualshareholdermeeting.com/MEI2021 and entering the 16-digit control number included in the ‎Notice and ‎Access Card, on your proxy card or in the instructions that accompanied your ‎proxy materials.
If you are not a stockholder of record but hold shares as a beneficial owner in street name, you may be required to provide proof of beneficial ownership, such as your account statement as of the record date, a copy of the voting instruction form provided by your broker, bank, trustee, or nominee, or other similar evidence of ownership. If you do not comply with the procedures outlined above, you will not be admitted to the virtual Annual Meeting.
How can I vote my shares without attending the Annual Meeting?
To vote your shares without attending the Annual Meeting, please follow the instructions for internet or telephone voting on the Notice and Access Card. You will need the 16-digit control number included on your Notice and Access Card to authorize a proxy ‎‎to vote your shares via the internet or by telephone. You can authorize a proxy to vote your shares at any time prior to 10:59 p.m., Central Daylight Time, on September 14, 2021, the day before the Annual ‎Meeting.‎ ‎‎If you request printed copies of the proxy materials by mail, you may also vote by signing your proxy card and returning it by mail.‎
What do I do if my shares are held in “street name”?
If your shares are held in a brokerage account or by a bank or other holder of record, you are considered the “beneficial owner” of shares held in “street name.” The Notice and Access Card or proxy materials, if you elected to receive a hard copy, has been forwarded to you by your broker, bank or other holder of record who is considered, with respect to those shares, the stockholder of record. As the beneficial owner, you have the right to direct your broker, bank or other holder of record on how to vote your shares by following their instructions for voting.
2

How many votes do I have?
Each share of Methode common stock that you own entitles you to one vote.
What am I voting on at the Annual Meeting?
At the Annual Meeting, stockholders are being asked to consider and vote on the following three proposals:
Proposal 1: The election of twelve directors, each to hold office until the Company’s 2022 Annual Meeting of Stockholders or until any such director’s earlier resignation, or until his or her successor is duly elected and qualified;
Proposal 2: The ratification of the appointment of Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm for fiscal 2022; and
Proposal 3: Approval, on a non-binding, advisory basis, of the compensation of the Company’s named executive officers, as disclosed in this proxy statement (the “Say-on-Pay Proposal”).
How does the Board recommend I vote on the proposals?
The Board of Directors recommends that you vote “FOR” each of Methode’s nominees for director “FOR”(Proposal 1), ‎‎“FOR” the ratification of Ernst & Young LLPEY as our independent registered public accounting firm ‎(Proposal 2) ‎and “FOR” advisory approval of Methode’s named executive officer compensation andthe Say-on-Pay Proposal ‎(Proposal 3).‎
If you submit a proxy without indicating your vote on any matter, the designated proxies will vote in favor of a “ONE-YEAR” frequency forall three proposals.‎
How many votes are needed to approve each of the advisory vote on executive compensation.

Our Board of Directors has fixed the close of business on July 17, 2017 as the record date for the determination of shareholders entitled to notice of and to vote at the annual meeting and at any adjournment or postponement thereof.

We are furnishing materials for our annual meeting on the Internet. Youproposals?

On each proposal, stockholders may vote your shares(1) ‎‎“for,” (2) “against,” or (3) “abstain” from voting. The affirmative vote of a majority of the voting power present in person by attending our annual meeting, or by proxy. To voterepresented by proxy you may vote using‎at the Internet,Annual Meeting is required to approve each proposal. Broker non-votes will not be counted for purposes of determining the number of votes present in person or represented by toll-free telephone number or, if you request‎proxy with respect to the election of directors ‎(Proposal 1)‎ and receive a paper copy of the proxy card by mail, by signing, dating and mailing the proxy card in the self-addressed, postage-paid envelope provided.Information regarding voting by using the Internet or by telephone is contained in the Notice of Internet Availability of Proxy Materials. Instructions regarding voting by mail are contained on the proxy card.

It is important that your sharesSay-on-Pay Proposal ‎(Proposal 3)‎. Abstentions will be represented and voted at the annual meeting. Whether orconsidered as present but will not you plan to attend the annual meeting, please vote on the matters to be considered. Thank you for your interest and cooperation.

By Order of the Board of Directors,

Walter J. Aspatore


Chairman

Chicago, Illinois

August 1, 2017

METHODE ELECTRONICS, INC.

7401 West Wilson Avenue

Chicago, Illinois 60706

(708) 867-6777

PROXY STATEMENT

ANNUAL MEETING OF SHAREHOLDERS
September 14, 2017

GENERAL INFORMATION

We are furnishing this proxy statement to you in connection with the solicitation of proxies on behalf of Methode Electronics, Inc. (“Methode” or the “Company”) for use at our annual meeting of shareholders to be held on Thursday, September 14, 2017 at 11:00 a.m., Central Daylight Time, at Methode’s corporate offices at 7401 West Wilson Avenue, Chicago, Illinois, 60706 and at any adjournment or postponement of the annual meeting. On August 1, 2017, we mailed our Notice of Internet Availability of Proxy Materials, which contains instructions for our shareholders to access our proxy statement and annual report over the Internet or request a paper copy of the proxy materials.

At the annual meeting, we will ask our shareholders to (i) elect our Board of Directors, (ii) ratify the Audit Committee’s selection of Ernst & Young LLP (“Ernst & Young”) to serveconsidered as our independent registered public accounting firm for fiscal 2018, (iii) provide advisory approval of Methode’s named executive officer compensation, (iv) cast an advisory vote on the frequency of future advisory votes on Methode’s named executive officer compensation, and (v) consider and vote upon any other business which properly comes before the annual meeting.

The Board of Directors recommends that you vote “FOR” each of Methode’s nominees for director, “FOR” the ratification of Ernst & Young as our independent registered public accounting firm, “FOR” advisory approval of Methode’s named executive officer compensation and in favor of any ‎proposal. Consequently, abstentions have the effect of voting against all proposals, while broker non-votes have no effect as to voting for or against Proposal 1 or Proposal 3.‎

What is a “ONE-YEAR” frequency“broker non-vote”?
A “broker non-vote” occurs when a nominee holding shares for the advisorya beneficial owner does not vote on executive compensation.

You may votea proposal because the nominee has not received instructions from the beneficial owner‎ and does not have discretionary voting power. Under the rules of the New York Stock Exchange (the “NYSE”), brokerage firms have the authority to cast votes on certain “routine” matters if they do not receive instructions from their customers. The auditor ratification proposal (Proposal 2) is considered a “routine” matter and your shares may be voted on such proposal if they are held in person, by attending our annual meeting, or by proxy. To vote by proxy, you may vote using the Internet, by toll-free telephone number or,name of a ‎brokerage firm even if you request and receive a paper copy of the proxy card by mail, by signing, dating and mailing the proxy card in the self-addressed, postage-paid envelope provided.Information regarding voting by using the Internet or by telephone is contained in the Notice of Internet Availability of Proxy Materials. Instructions regarding voting by mail are contained on the proxy card. Please do not submit a proxy card if you have voted by telephone or the Internet.

It is important that your shares be representedprovide voting instructions.‎ The other proposals being considered and voted on at the annual meeting. Whether orAnnual Meeting are “non-routine” matters for which brokers may not you plan to attendvote absent voting instructions from the annual meeting in person, please vote on the matters to be considered.

Record Date; Shares Outstanding

Our Board of Directors has fixed the close of business on July 17, 2017 as the record date for the determination of shareholders entitled to notice of and to vote at the annual meeting and at any adjournment or postponement thereof. As of the record date, there were 36,810,853 shares of our common stock outstanding and entitled to vote at the annual meeting.

Quorum; Votes Required

In deciding all questions, assumingbeneficial owner.

What constitutes a quorum is present, a holder of Methode’s common stock is entitled to one vote, in person or by proxy, for each share held in such holder’s name on the record date. quorum?
The presence, in person or by proxy, of the holders of a majority of the outstanding shares of Methode’s common stock‎stock is necessary to constitute a quorum at the annual meeting. BothAnnual Meeting. Broker non-votes and abstentions and broker non-votes are counted aswill be considered present for the purpose of determining the presence ofwhether we have a quorumquorum.
What if other matters come up at the annual meeting. Generally, broker non-votes occur when shares held by a broker for a beneficial owner areAnnual Meeting?
At the time the Notice and Access Cards were mailed to our stockholders, we were not voted with respectaware of any matters to a particular proposal because the broker lacks discretionary power to vote such shares.

With respect to the election of directors, the ratification of the selection of Ernst & Young as our independent registered public accounting firm and providing advisory approval of our executive compensation, shareholders may vote (1) “for,” (2) “against,” or (3) to “abstain” from voting on each matter and each such matter requires approval by a majority of the shares of common stock representedbe properly presented at the meeting and entitledAnnual Meeting other than those referred to vote. On the proposal regarding an advisory vote on the frequency of future advisory votes on executive compensation, shareholders may vote to hold such votes (A) each year, (B) every two years, (C) every three years, or (D) may abstain from voting. On this proposal, the frequency option that receives the affirmative vote of a majority of the shares of common stock represented at the meeting and entitled to vote will be deemed to be approved by the shareholders. If none of the options for this proposal receives a majority vote, we will consider the alternative that receives the highest number of votes cast by the shareholders to be the frequency that has been selected by the shareholders. Both abstentions and broker non-votes will be considered as present but will not be considered as votes in favor of any matter. Broker non-votes are excluded from the “for,” “against” and “abstain” counts, and instead are reported as simply “broker non-votes.” Consequently, abstentions have the effect of voting against these matters, while broker non-votes have no effect as to voting for or against any such matter.

Under New York Stock Exchange rules, the proposal to ratify the selection of Ernst & Young is considered a routine item. Therefore, brokers may vote in their discretion on this matter on behalf of clients who have not furnished voting instructions to the broker. In contrast, all other proposals set forth in this proxy statementstatement. If other matters are considered non-routine items, and brokers who have not received voting instructions from their clients may not vote on these proposals.

All properly executed and timely delivered proxies will be voted in accordance with the instructions provided. Unless contrary instructions are indicated, proxies will be voted “FOR” each of Methode’s nominees for director, “FOR” the ratification of the selection of Ernst & Young, “FOR” advisory approval of Methode’s named executive officer compensation and in favor of a “ONE-YEAR” frequency for the advisory vote on executive compensation. The Board of Directors knows of no other business that will be presented for consideration at the annual meeting. If any other matter is properly presented, it is the intentionAnnual Meeting, and you are a stockholder of record and have authorized a proxy to vote your shares, the persons named inas proxies will have the discretion to vote on those matters for you.

3

Can I revoke my proxy after I authorize a proxy to vote in accordance with their best judgment.

Voting Procedures

It is important that your shares be represented at the annual meeting. You may vote your shares in person, by attending our annual meeting, or by proxy. To vote by proxy, you may vote using the Internet, by toll-free telephone number or, if you request and receive a paper copy of the proxy card by mail, by signing, dating and mailing the proxy card in the self-addressed, postage-paid envelope provided. Information regarding voting by using the Internet or by telephone is contained in the Notice of Internet Availability of Proxy Materials. Instructions regarding voting by mail are contained on the proxy card. Please do not submit a proxy card if you have voted by telephone or the Internet. You may revoke your proxy as described below.

Revoking Your Proxy

If you decide to change your vote, you may revoke your proxy at any time before the annual meeting.my shares?

Yes. You may revoke your proxy by notifying our Corporate Secretary in writing that you wish to revoke your proxy at the‎the following address: Methode Electronics, Inc., 74018750 West WilsonBryn Mawr Avenue, Suite 1000, Chicago, Illinois 60706, attention: Corporate Secretary.‎‎60631. You may also revoke your proxy by submitting a later-datedlater dated and properly executed‎executed proxy (including by means of the telephone or Internet)internet) or by voting in person at the annual meeting. AttendanceAnnual Meeting. New paper proxy cards should be sent to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY ‎‎11717.‎ Your attendance at the annual meetingvirtual Annual Meeting will not, by itself, revoke a proxy.

Proxy Solicitation Expenses

The proxy is being solicited on behalf of Methode.previously authorized by you. We will bearhonor the entire costproxy card or authorization with the latest date.

Why did I receive a notice in the mail regarding the internet availability of the proxy materials instead of a paper copy of the proxy materials?
Under the ‎“Notice and Access” rules of the Securities and Exchange Commission (the “SEC”), we are permitted to furnish proxy materials to our stockholders by providing access to such documents on the internet instead of mailing printed copies. The Notice and Access Card mailed to our stockholders provides instructions regarding how to access and review all the proxy materials on the internet. The Notice and Access Card also instructs you as to how you may authorize a proxy to vote your shares via the internet or by telephone. If you would like to receive a paper copy of our proxy materials, you should follow the instructions for requesting such materials printed on the Notice and Access Card.
How can I find the voting results of the Annual Meeting?‎
We intend to announce preliminary voting results at the Annual Meeting and disclose final voting results in a Current Report on Form 8-K filed with the SEC within ‎four business days following the Annual Meeting.‎
Who pays for this proxy solicitation?
Methode will pay for this proxy solicitation. Our directors, officers or other regular employees may solicit proxies by telephone, by e-mail by fax or in person. No additional compensation will be paid to directors, officers and other regular employees for such services. We have retained the services of Innisfree M&A IncorporatedAlliance Advisors, LLC (“Innisfree”Alliance”) to serve as our proxy solicitor in connection with the annual meeting. InnisfreeAnnual Meeting. Alliance may assist us in soliciting proxies by telephone, email and by other means, and we expect to pay InnisfreeAlliance a fee of $20,000, plus reasonable expenses.

In the event that beneficial owners of our shares request paper copies of our proxy materials, banks, brokerage houses, fiduciariesWhat is “householding” and custodians holding shares of our common stock beneficially owned by others as of the record date will be requested to forward such proxy soliciting material to the beneficial owners of such shares and will be reimbursed by Methode for their reasonable out-of-pocket expenses.

Householding of Annual Meeting Materials

how does it affect me?

We are sending only one copy of our Notice of Internet Availability of Proxy Materialsand Access Card and, if applicable, our proxy materials, to shareholdersstockholders who share the same last name and address, unless they have notified us that they want to continue receiving multiple copies. This practice is known as “householding,“householding.is designed to reduce duplicate mailings and save printing and postage costs. ShareholdersStockholders who participate in householding will continue to be able to access and receive separate proxy cards. If you received a householded mailing this year and you would like to have additional copies of our Notice of Internet Availability of Proxy Materials and if applicable, ourAccess Card and proxy materials, mailed to you; if you received multiple copies of our Notice of Internet Availability of Proxy Materials and would preferlike to participate in householding;householding or if you would like to opt out of householding, for future mailings, you may do so at any time by contactingplease contact us at: Methode Electronics, Inc., 74018750 West WilsonBryn Mawr Avenue, Suite 1000, Chicago, Illinois 60706,60631, Attention: Corporate Secretary, or telephonically at 708-867-6777.

4


CORPORATE GOVERNANCE

We are committed to maintaining high standards of corporate governance in order to serve the long-term interests of Methode and our shareholders.

stockholders.

Director Independence

Our Nominating and Governance Committee conducts an annual review and makes a recommendation to the full Board as to whether each of Directors has considered the independence of theour nominees for director undermeets the applicable independence standards of the U.S. Securities and Exchange Commission (“SEC”)SEC and the New York Stock Exchange. OurNYSE. The Board has determined that all of the nominees for director are independent under the applicable standards, except for Donald Duda, our President and Chief Executive Officer. Mr. Duda’s lack of independence relates solely to his service as an executive officer and is not due to any other transactions or relationships.

In addition, our Board of Directors has determined that each member of our Audit Committee, our Compensation Committee and our Nominating and Governance Committee satisfies the independence requirements of the applicable standards, if any, of the SEC and the New York Stock Exchange.

NYSE.

Board Committees

The following chart sets forth the committeesmembership, principal functions and number of meetings held in fiscal 2021 for each of our Board for fiscal 2017.

Committees.

Committee

Members

Committee

Members
Principal Functions

Number of
Meetings in
Fiscal 20172021
Audit

Isabelle C. Goossen

Audit
Mary A. Lindsey (Chair)

Walter J. Aspatore
Stephen F. Gates

Paul G. Shelton

Therese M. Bobek‎
Angelo V. Pantaleo
Mark D. Schwabero
Lawrence B. Skatoff

Oversees accounting and financial reporting processes, and audits of financial statements.

14

Monitors performance of internal audit function and our system of internal control.

controls.

Monitors performance, qualifications and independence of our independent registered public accounting firm, and makes decisions regarding the retention, termination and compensation of the independent registered public accountingsuch firm and approves services provided by the independent registered public accounting firm.

related services.

Monitors compliance with legal and regulatory requirements pertaining to financial statements.

Reviews our financial press releases and certain SEC filings.

Discusses with management major financial risk exposures and the steps taken to monitor and control such exposures, and discussdiscusses guidelines and policies by which risk assessment and risk management is undertaken.

If applicable, reviews related party transactions and potential conflict of interest situations.

9
5

Committee
Members
Principal Functions
Number of
Meetings in
Fiscal 2021
Compensation

Stephen F. Gates

Compensation
Bruce K. Crowther (Chair)

Warren L. Batts


Walter J. Aspatore‎
Brian J. Cadwallader
Darren M. Dawson

Martha Goldberg Aronson

Isabelle C. Goossen

Paul G. Shelton


Oversees our executive compensation policies and plans.

9

Approves goals and incentives for the compensation of our Chief Executive Officer and, with the advice of the Chief Executive Officer, the other executive officers.

Approves grants under our stock and bonus plans.

plan.

Makes decisions regarding the retention, compensation and termination of any Committee compensation consultants,consultant, and monitors their independence.

Evaluates whether risks arising from our compensation policies and practices are reasonably likely to have a material adverse effect.

5

Nominating and

Governance

Christopher

Brian J. HornungCadwallader (Chair)


Walter J. Aspatore

Warren L. Batts

Stephen F. Gates

Aspatore‎

Therese M. Bobek
Mark D. Schwabero
Lawrence B. Skatoff

Recommends director candidates for election to our Board at the annual meeting or to fill vacancies.

Board.

4

Recommends Board committee assignments.

Recommends compensation and benefits for directors.

Oversees our Enterprise Risk Management (ERM) program.
Reviews succession planning for our executive officers.
Oversees our Environmental, Social and Governance (ESG) program‎.
Reviews and recommends revisions to our Corporate Governance Guidelines.

Oversees an annual evaluation by the independent directors of the performance of the CEO.
Conducts an annual assessment of Board and committee performance.

Reviews our risk management policies and practices.

Reviews succession planning for our Chief Executive Officer.

performance
5

Committee

Members

Principal Functions

Number of Meetings in Fiscal 2017
Technology

Technology
Darren M. Dawson (Chair)

Walter J. Aspatore

Warren L. Batts

Martha Goldberg Aronson

Christopher J. Hornung


David P. Blom
Janie Goddard
Angelo V. Pantaleo

Reviews with management our technology assets and future needs.

4

Reviews technology research and development activities and possible acquisitions of technology.

4
Medical Products
David P. Blom (Chair)
Bruce K. Crowther
Donald W. Duda
Janie Goddard
Mary A. Lindsey
‎•
Reviews with management our business strategies for developing and marketing our medical device products.‎
6
‎•‎
Evaluates industry and market trends that may affect our medical device business.‎

Mr. Gates passed away in July, 2017. Subsequently, the size of the Board was reduced from ten directors to nine directors and Ms. Goldberg Aronson was appointed Chair of our Compensation Committee. The Board expressed its great appreciation for all of the contributions Mr. Gates made over the years.

6

If applicable, our Audit Committee reviews related party transactions and potential conflict of interest situations in accordance with the Audit Committee Charter and our Code of Business Conduct. We do not have a separate written policy regarding related party transactions and potential conflict of interest situations. Our Code of Business Conduct states that conflicts of interest are prohibited, except as approved by our Board of Directors. In reviewing any such transaction, our Audit Committee and Board of Directors would consider Methode’sthe rationale for entering into the transaction, alternatives to the transaction, whether the transaction is on terms at least as fair to Methode as would be the case were the transaction entered into with a third party and other relevant factors.

During the 2017 fiscal year,2021, our Board of Directors held twelvesix meetings, and no director attended less than 75% of the aggregate of the total number of meetings of our Board and the total number of meetings held by the respective committees on which he or she served. Under our Corporate Governance Guidelines, our directors are expected to attend Board and shareholderstockholder meetings and meetings of committees on which they serve. Our directors are expected to meet as frequently as necessary to properly discharge their responsibilities.

Our independent directors hold regularly scheduled executive sessions at which only independent directors are present. Pursuant to our Corporate Governance Guidelines, our Chairman of the Board is the Presiding Director of such sessions.

Our Audit, Compensation, Nominating and Governance and Technology Committeescommittees operate pursuant to charters adopted by the Board, whichBoard. Our committee charters and our Corporate Governance Guidelines are available on the Investors page of our website atwww.methode.com or in print upon any shareholder’sstockholder’s request. Our Corporate Governance Guidelines are also available on our website atwww.methode.com or in print upon any shareholder’s request.

Board Leadership Structure, Evaluations, Risk Oversight and Compensation Policy Risks

The Board of Directors has determined that having an independent director serve as Chairman of the Board is in the best interests of our shareholders.stockholders‎. This structure provides for a greater role for the independent directors in the oversight of Methode and active participation of the independent directors in setting agendas and establishing priorities and procedures for the work of the Board.

The Nominating and Governance Committee oversees the annual Board and committee evaluation process. Each year, our independent directors complete a written evaluation which focuses on Board practices, processes and skills, and seeks input on opportunities for improvement. To protect the directors’ anonymity and the integrity of the process, outside legal counsel reviews the directors send their completed evaluations directly to outside legal counsel. Legal counseland compiles the responses into a written report, which is then distributed to, and discussed by, the Nominating and Governance Committee and the full Board.

Our Board of Directors oversees Methode’s risk management practices. Our Board and committees review information regarding Methode’s markets, competition and financial risks, as well as risks associated with Methode’s operations Methode’s employees and political risks encountered by Methode throughout the world. Our Audit Committee discusses with management Methode’s major financial risk exposures and the steps management has taken to monitor and control such exposures and reviews the process by which risk is managed and assessed. Our Audit Committee also reviews the Company’s cyber-securitycybersecurity and information technology practices and policies.policies and is briefed quarterly by management. Our Compensation Committee evaluates risks arising from Methode’s compensation practices and policies. Our Nominating and Governance Committee reviews and evaluates Methode’s policies and practices with respect to risk management and risk assessment in areas such as business operations, human resources, international operations and

intellectual property.oversees the Company’s Enterprise Risk Management (ERM) program. The entire Board of Directors is regularly informed about the risk management policies and practices monitored by the various committees. The Board of Directors also receives reports directly from officers responsible for assessing and managing particular risks within Methode.

We believe that risks arising from our compensation policies and practices for our employees are not reasonably likely to have a material adverse effect on Methode. The Compensation Committee monitors the mix and design of the elements of executive compensation and believes that our compensation programs do not encourage management to assume excessive risks.

Nominating Process of the Nominating and Governance Committee

Our Nominating and Governance Committee is responsible for identifying and recommending to our Board of Directors individuals qualified to become directors consistent with criteria approved by our Board. In considering potential candidates for our Board, including with respect to nominations for re-election of incumbent directors, the Committee considers the potential candidate’s integrity and business ethics; strength of character, judgment and experience consistent with our needs; specific areas of expertise and leadership roles; and the ability to bring diversity to our Board.Board, including racial and gender diversity. The Committee seeks an appropriate balance between newer directors and longer-serving directors. While the Nominating and Governance Committee charter and our Corporate
7

Governance Guidelines do not prescribe diversity standards, the Committee considers diversity in the context of the Board as a whole, including whether the potential candidate brings complementary skills and viewpoints.
The Committee also considers the ability of the individual to allocate the time necessary to carry out the tasks of Board membership, including membership on appropriate committees.

The Committee identifies We believe that our directors’ outside directorships enable them to contribute valuable knowledge and experience to the Board. Nonetheless, the Board is sensitive to the potential nominees by asking currentfor overboarding to compromise the ability of these directors and others to notify the Committee if they become aware of persons, meeting the criteria described above, who may be available toeffectively serve on our Board and Committees. Our Corporate Governance Guidelines limit each director’s service on the boards of public companies to no more than three other boards. Our Audit Committee Charter limits each member’s service on audit committees of public companies to no more than two other audit committees, unless approved by the Board.

The Committee has adopted a process for identifying new director candidates. Recommendations may be received by the Committee from various sources, including directors and Company contacts. The Committee uses a search firm to assist with the independent director recruitment process and has sole authority to retain and terminate any such search firm used to identify director candidates and has sole authority to approve the search firm’s fees and other retention terms. Historically, the Committee has not engaged third parties to assist in identifying and evaluating potential nominees, but would do so in those situations where particular qualifications are required to fill a vacancy and our Board’s contacts are not sufficient to identify an appropriate candidate.

fees.

The Committee will also consider suggestions from our shareholders. Any recommendations received from shareholders will be evaluated in the same manner that potential nominees suggested by Board members are evaluated. Upon receiving a shareholder recommendation, the Committee will initially determine the need for additional or replacement Board members and evaluate the candidate based on the information the Committee receives with the shareholder recommendation or may otherwise acquire, and may, in its discretion, consult with the other members of our Board. If the Committee determines that a more comprehensive evaluation is warranted, the Committee may obtain additional information about the director candidate’s background and experience, including by means of interviews with the candidate.

Our shareholdersstockholders. Stockholders may recommend candidates at any time, but the Committee requires recommendations for election at an annual meeting of shareholdersour Annual Meeting to be submitted to the Committee no later than 120 days before the first anniversary of the date of the proxy statement in connection withfrom the previous year’s annual meeting. The Committee believes this deadline is appropriate and in the best interests of Methode and our shareholders because it ensures that the Committee has sufficient time to properly evaluate all proposed candidates. Therefore, to submit a candidate for consideration for nomination at the 2018 annual meeting of shareholders, a shareholder must submit the recommendation, in writing, by April 3, 2018.Annual Meeting. The written notice must include:

include (i) the name, age, business address and residential address of each proposed nominee and the principal occupation or employment of each nominee;
the proposed nominee, (ii) the number of shares of our common stock that eachowned by such nominee, beneficially owns;
(iii) a statement that eachthe nominee is willing to be nominated;nominated, and
(iv) any other information concerning each nominee that would be required under the rules of the SEC in a proxy statement soliciting proxies forunder the election of those nominees.

SEC’s rules. Recommendations must be sent to the Nominating and Governance Committee, Methode Electronics, Inc., 74018750 West WilsonBryn Mawr Avenue, Suite 1000, Chicago, Illinois 60706.60631. Any recommendations from stockholders will be evaluated in the same manner that potential nominees suggested by directors or Company contacts are evaluated. Information regarding the requirements to nominate a director at our 20182021 Annual Meeting areis set forth below under “Other Information -- Shareholder– Stockholder Proposals and Director Nominations.”

Corporate Responsibility
The Company is committed to being a responsible steward to the environment, its employees, and the communities in which it operates and conducting its operations in an ethical manner with honesty and integrity. In fiscal 2021, we moved to expand our Environmental, Social and Governance (ESG) efforts by developing a more integrated ESG program under the oversight of our Nominating and Governance Committee. As we move forward on our ESG journey, we intend to regularly evaluate our ESG program and focus on the areas that are most important to our business and our stakeholders and where we can have the greatest impact. Below are some of our key ESG initiatives.
Environmental. The Company practices responsible environmental management to protect its employees, customers, communities, and the environment. We are dedicated to pursuing environmental and socially sustainable practices through initiatives such as utilizing reusable shipping containers, material recycling and reuse, and vertically integrated manufacturing to reduce logistics. We are attentive to climate change concerns and several of our new business development efforts are focused on electric and hybrid vehicles and LED lighting solutions. The Company adheres to the latest standards in our industries for quality, safety and manufacturing processes. All of our manufacturing facilities are certified to the ISO 14001 environmental management standard. Additionally, the Company was awarded the Supplier Quality Excellence Award by General Motors and the Q1 Preferred Quality Status Award by Ford Motor Company in 2019.
Social. The Company takes pride in its relationships with its employees, suppliers, and customers and the communities in which it operates.
Diversity and Inclusion. As highlighted in our Diversity & Inclusion Statement, we believe that diversity and inclusion are business imperatives that will enable us to build and empower our future workforce. We strive to maintain a diverse and inclusive workforce that reflects our global customer base and the communities that we serve. We also strive for diversity in leadership, which has the power to drive innovation and to encompass a wide variety of perspectives in company decision-making. We recently added a female director to our Board for a total of three female Directors, and we have one female executive officer.
8

Values and Ethics. Our corporate culture is committed to doing business with integrity, teamwork, and performance excellence. Our core values include innovation, continuous improvement and passion. All of our salaried employees and directors are required to review and certify our Code of Conduct each year. Our Code of Conduct addresses topics such as anti-corruption, discrimination, harassment, privacy, appropriate use of company assets, protecting confidential information, and reporting violations anonymously. In addition, our U.S. employees participate in annual training on preventing, identifying, reporting, and stopping any type of unlawful discrimination or other unethical actions and we offer an employee hotline for reporting violations.
Health and Safety. The success of our business is fundamentally connected to the well-being of our employees. We maintain a work environment with a safety culture grounded on the premise of eliminating workplace incidents, risks, and hazards. We have created and implemented processes to help eliminate safety events and reduce their frequency and severity. Our employees are regularly trained on safety-related topics and we monitor our effectiveness at all of our global facilities. Additionally, we offer the Vitality Wellness Program to our full-time U.S. employees and their spouses. This program provides individualized health-enhancement plans, including online support programs for mental and behavioral health.
In the face of an everchanging global landscape, we consistently adapt our operations to prioritize employee safety. Since the onset of the COVID-19 pandemic, our management team has prioritized the health and safety of our employees and their families. The Company adopted numerous safety procedures at our 40 global facilities, including hygiene and disinfection protocols, testing and contact tracing, social distancing and wearing personal protective equipment (PPE). The Company implemented the sharing of best practices at its global facilities, resulting in effective and standardized safety guidelines and procedures.
Supply Chain Standards. The Company’s global supply chain management team seeks suppliers who will maintain the Company’s ethical business values. The Company has adopted a Supplier Code of Conduct, which includes topics such as anti-corruption, discrimination, health and safety, protecting confidential information, and legal compliance, and references our Conflicts Mineral Policy.
Governance. We are committed to maintaining high standards of corporate governance in order to serve the long-term interests of Methode and our stockholders. Our corporate governance policies promote transparency, accountability and engagement, and include our Code of Business Conduct, Corporate Governance Guidelines and Anti-Corruption Policy. As highlighted above, we have strong corporate governance practices, including engaged independent directors and committee members, an independent Chairman of the Board and annual board and committee evaluations. Additionally, our Board is responsible for overall risk oversight of the Company, which includes certain environmental, social, supply chain, cybersecurity and other governance matters.
Communications with Directors

Our annual meeting of shareholders

The Annual Meeting provides an opportunity each year for shareholdersstockholders to ask questions of, or otherwise communicate directly with, members of our Board of Directors on appropriate matters. All of our directors attended the 2016 annual meeting.2020 Annual Meeting. We anticipate that all of our directors will attend the 2017 annual meeting.

2021 Annual Meeting.

In addition, interested parties may, at any time, communicate in writing with any particular director, or our independent directors as a group, by sending such written communication to the Corporate Secretary of Methode Electronics, Inc. at 74018750 West WilsonBryn Mawr Avenue, Suite 1000, Chicago, Illinois 60706.60631. Copies of written communications received at such address will be provided to the relevant director or the independent directors as a group unless such communications are considered, in the reasonable judgment of the Corporate Secretary, to be improper for submission to the intended recipient(s). Examples of shareholderstockholder communications that would be considered improper for submission include, without limitation, customer complaints, solicitations, communications that do not relate directly or indirectly to us or our business or communications that relate to other improper or irrelevant topics.

Stockholder Engagement
We believe that effective corporate governance should include engagement with our stockholders through investor conferences, non-deal roadshows, meetings and phone calls. In response to the COVID-19 pandemic, we successfully shifted our stockholder engagement efforts to virtual forums. We believe that regular engagement with our stockholders helps us to better understand stockholders’ views on a variety of topics, including our corporate governance practices.
9

Code of Business Conduct and Ethics

Our Board of Directors has adopted a Code of Business Conduct that applies to our directors, principal executive officer, principal financial officer, principal accounting officer or controller and persons performing similar functions, as well as other employees. The codeCode is available on the Investors page of‎ our website atwww.methode.com or in print upon any shareholder’sstockholder’s request.

If we make any substantive amendments to the Code of Business Conduct or grant any waiver, including any implicit waiver, from a provision of the Code of Business Conduct to our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions, we will disclose the nature of such amendment or waiver on our website or in a report on Form 8-K in accordance with applicable rules and regulations.

Director Stock Ownership Guidelines

Our Compensation Committee considers stock ownership by directors to be an important means of linking their interests with those of our shareholders.stockholders. We maintain stock ownership guidelines for our directors. All directors are expected to own stock with a value equal to at least five times the annual cash retainer paid to Methode directors. The requirements aredirectors, subject to a five-year phase-in period.period for new directors. All of our directors were in compliance with our stock ownership guidelines for fiscal 2017.

2021, subject to the phase-in-period. ‎Our Insider Trading Policy prohibits our directors from engaging in certain transactions involving our common stock, including options trading, short sales, derivative transactions and hedging transactions. In addition, our directors are prohibited from holding our common stock in a margin account or otherwise pledging our common stock as collateral for a loan.
10


DIRECTOR COMPENSATION

We use a combination of cash and common stock to compensate our non-employee directors. Directors who are also our full-time employees are not paid for their services as directors or for attendance at meetings.

For the fiscal year ended April 29, 2017,2021, our non-employee directors received an annual cash retainer, of $44,000meeting fees and an attendance feeannual stock award with immediate vesting. Our Chairman, Vice Chairman, committee chairs and members of $1,000 per committeethe Audit and Compensation Committees received additional cash retainers for their service in these capacities. In connection with the Company’s cost-cutting measures related to the ‎COVID-19 pandemic, the retainers and meeting fees for our non-employee directors were reduced twenty percent (20%) for our first and for each board meeting other than the regularly scheduled quarterly meetings. In addition, in July 2016, the Compensation Committee, upon the recommendationsecond quarters of thefiscal 2021.

The Nominating and Governance Committee granted eachoversees and makes recommendations to the Board regarding our non-employee director serving at such timecompensation program. Non-employee directors can defer receipt of all or a stock award for 3,000 sharesportion of common stock. Our Chairmantheir cash or equity compensation to our Deferred Compensation Plan.
Upon the recommendation of the Board and the Chair of each of our board committees received supplemental annual retainers in the following amounts: Chairman of the Board, $30,000; Chair of each of the Audit Committee and the Compensation Committee, $24,000; and Chair of each of the Nominating and Governance Committee, and the Technology Committee, $12,000. In addition, members of our Audit Committee and Compensation Committee (other than the Chair) received an additional annual retainer of $10,000. PursuantBoard approved changes to our Deferred Compensation Plan,compensation program for non-employee directors for fiscal 2022. In reviewing our directors may elect to defer up to 100%director compensation program, the Board considered peer and market data, as well as the advice and recommendations of their retainersFrederic W. Cook & Co., Inc., our independent compensation consultant.
The following table shows the non-employee director compensation elements and attendance fees per year. Additional information regarding the Deferred Compensation Plan is described under “Executive Compensation — Nonqualified Deferred Compensation” below.

amounts for fiscal 2021 and fiscal 2022.‎

Compensation Component
Fiscal 2021 Amount
Fiscal 2022 Amount
Annual Cash Retainer
$52,000
$80,000
Additional Annual Chairman of the Board Cash Retainer
$30,000
$80,000
Additional Annual Vice Chairman of the Board Cash Retainer
$12,000
$12,000
Additional Annual Committee Chair Cash Retainer
 
 
Audit Committee
$24,000
$24,000
Compensation Committee
$24,000
$24,000
Nominating and Governance Committee
$12,000
$12,000
Technology Committee
$12,000
$12,000
Medical Products Committee
$12,000
$12,000
Additional Annual Committee Member Cash Retainer
Audit Committee
$10,000
$0
Compensation Committee
$10,000
$0
Fee for Each Committee and Special Board Meeting
$1,000
$1,500
Annual Stock Grant
3,000 Shares
Shares valued at $140,000
11

The following table sets forth certain information regarding compensation earned by ourthe non-employee directors who served during theour fiscal year ended April 29, 2017.

Name

Fees Earned

or Paid in Cash

($)

Stock Awards

($) (1)

Total

($)

Walter J. Aspatore111,270 102,870  214,140
Warren L. Batts70,770   102,870   173,640
Darren M. Dawson84,270   102,870  187,140
Stephen F. Gates101,770   102,870   204,640
Martha Goldberg Aronson69,770  102,870   172,640
Isabelle C. Goossen101,270   102,870   204,140
Christopher J. Hornung78,770  102,870   181,640
Paul G. Shelton87,270   102,870   190,140
Lawrence B. Skatoff80,770   102,870  183,640
         
           
May 1, 2021.
Name
Fees Earned
or Paid in Cash
($)
Stock Awards
($)(1)
Total
($)(2)
Walter J. Aspatore
97,000
86,280
183,280
David P. Blom
62,800
86,280
149,080
Therese M. Bobek
78,400
86,280
164,680
Brian J. Cadwallader
77,400
86,280
163,680
Bruce K. Crowther
82,400
86,280
168,680
Darren M. Dawson
85,400
86,280
171,680
Janie Goddard(3)
7,500
0
7,500
Isabelle C. Goossen(3)
33,600
86,280
119,880
Mary A. Lindsey
86,200
86,280
172,480
Angelo V. Pantaleo
63,800
86,280
150,080
Mark D. Schwabero
65,600
86,280
151,880
Lawrence B. Skatoff
80,200
86,280
166,480
(1)
The reported amounts reflect the fair value at the date of grant calculated in accordance with the Financial Accounting Standards Board’s Accounting Standards Codification Topic 718. Details of the assumptions used in valuing these awards are set forth in Note 413 to our audited financial statements included in our Annual Report on Form 10-K for the fiscal year ended April 29, 2017.May 1, 2021.

(2)
The amounts in the table above reflect the 20% reduction in the first and second quarters in connection with the Company’s cost-cutting measures related to the ‎COVID-19 pandemic.
(3)
Ms. Goossen retired from the Board in September 2020 and Ms. Goddard was elected to the Board in March 2021.
12


SECURITY OWNERSHIP

Five Percent Shareholders

Stockholders

The following table sets forth information regarding all persons known by Methode as of July 19, 2021, to be the beneficial owners of more than 5% of Methode’s common stock as of July 17, 2017.

Name and Address of Beneficial OwnerAmount and Nature
of Beneficial Ownership
Percent of Class (%)

BlackRock, Inc. (1)

55 East 52nd Street

New York, New York 10055

4,106,67011.2

The Vanguard Group (2)

100 Vanguard Blvd.

Malvern, Pennsylvania 19355

3,040,5638.3

The Bank of New York Mellon Corporation (3)

225 Liberty Street

New York, New York 10286

2,853,7387.8

Dimensional Fund Advisors LP (4)

Building One

6300 Bee Cave Road

Austin, TX 78746

2,049,4465.6

stock.
Name and Address of Beneficial Owner
Amount and Nature
of Beneficial Ownership
Percent of Class (%)
BlackRock, Inc.(1)
55 East 52nd Street
New York, New York 10055
6,036,730
16.1
The Vanguard Group(2)
100 Vanguard Blvd.
Malvern, Pennsylvania 19355
3,828,459
10.2
Dimensional Fund Advisors LP(3)
Building One
6300 Bee Cave Road
Austin, TX 78746
2,032,885
5.4
(1)
Information is based on a Schedule 13G/A filed with the SECSecurities and Exchange Commission (“SEC”) on January 12, 2017.25, 2021. In the Schedule 13G/A, BlackRock, Inc. reported that, as a parent holding company, as of December 31, 2016,2020, it had sole voting power with respect to 4,027,4685,940,010 shares and sole dispositive power with respect to 4,106,670‎6,036,730‎ shares. According to the Schedule 13G/A, the subsidiary BlackRock Fund Advisors beneficially owns 5% or greater of the Company’s outstanding shares.
(2)
Information is based on a Schedule 13G/A filed with the SEC on February 10, 2017.2021. In the Schedule 13G/A, The Vanguard Group reported that, as of December 31, 2016,2020, it had sole voting power with respect to 70,194 shares, shared voting power with respect to 5,55946,638 shares, sole dispositive power with respect to 2,966,7153,748,382 shares and shared dispositive power with respect to 73,84880,077 shares.  Vanguard Fiduciary Trust Company, a wholly-owned subsidiary of The Vanguard Group, Inc., is the beneficial owner of 68,289 shares of the Company’s common stock as a result of its serving as investment manager of collective trust accounts.  Vanguard Investments Australia, Ltd., a wholly-owned subsidiary of The Vanguard Group, Inc., is the beneficial owner of 7,464 shares of the Company’s common stock as a result of its serving as investment manager of Australian investment offerings.
(3)
Information is based on a Schedule 13G/A filed with the SEC on February 3, 2017.  In the Schedule 13G/A, The Bank of New York Mellon Corporation reported that, as of December 31, 2016, it had sole voting power with respect to 2,759,957 shares, sole dispositive power with respect to 2,826,838 shares and shared dispositive power with respect to 26,900 shares.  The Schedule 13G/A reported that all of the shares are beneficially owned by The Bank of New York Mellon Corporation and its direct or indirect subsidiaries in their various fiduciary capacities (including as an investment adviser or a broker or dealer).
(4)Information is based on a Schedule 13G/A filed with the SEC on February 9, 2017.12, 2021. In the Schedule 13G/A, Dimensional Fund Advisors LP reported that it is an investment advisor and, as of December 31, 2016,2020, it had sole voting power with respect to 1,949,2761,941,401 shares and sole dispositive power with respect to 2,049,446‎2,032,885‎ shares.

13



Directors and Executive Officers

The following table sets forth information regarding our common stock beneficially owned as of July 17, 201719, 2021, by (i) each director and nominee, (ii) each of the named executive officers, and (iii) all current directors and executive officers as a group.

Name of Beneficial OwnerAmount and Nature of Beneficial Ownership (1)Percent of Class (%)
Walter J. Aspatore27,000(2) *
Warren L. Batts76,000 *
Darren M. Dawson13,000 *
Donald W. Duda631,364(3) 1.7
Martha Goldberg Aronson6,000 (4) *
Isabelle C. Goossen43,450 *
Christopher J. Hornung37,850 *
Paul G. Shelton42,850 *
Lawrence B. Skatoff39,350(5) *
Timothy R. Glandon43,079(6) *
John R. Hrudicka72,000(7) *
Joseph E. Khoury240,600(8) *
Theodore P. Kill211,830(9) *
Douglas A. Koman119,792(10) *
All current directors and executive officers as a group1,604,165(11) 4.4

Name of Beneficial Owner
Amount and Nature of
Beneficial Ownership(1)
Percent of Class (%)
*
Walter J. Aspatore
29,955(2)(3)
*
David P. Blom
5,955
*
Therese M. Bobek‎
‎5,955‎(3)
*
Brian J. Cadwallader
11,955(3)
*
Bruce K. Crowther
9,855(4)
*
Darren M. Dawson
12,955(3)
*
Donald W. Duda
830,055(5)
2.2
Janie Goddard
2,955
*
Mary A. Lindsey
‎5,955‎(3)
*
Angelo V. Pantaleo
‎5,955‎
*
Mark D. Schwabero
8,955(3)
*
Lawrence B. Skatoff
42,305‎(6)‎
*
Andrea J. Barry
‎66,023(7)‎
*
Joseph E. Khoury
‎292,420(8)‎
*
Kevin M. Martin
‎50,500(9)‎
*
Ronald L.G. Tsoumas
‎141,589(10)‎
*
All current directors and executive officers as a group (18 persons)
‎1,638,852(11)‎
4.3
*
Percentage represents less than 1% of the total shares of common stock outstanding.
(1)
Beneficial ownership arises from sole voting and dispositive power unless otherwise indicated by footnote.
(2)
Includes 15,00027,000 shares held jointly with Mr. Aspatore’s wife.
(3)
Includes 19,5522,955 shares of phantom stock held jointlyin the Company’s Deferred Compensation Plan.
(4)
Shares are held in a trust pursuant to which Mr. Crowther shares voting and investment power with Mr. Duda’s wife,his wife.‎
(5)
Includes options to purchase 40,000 shares of common stock exercisable within 60 days, 201,812195,055 shares of vested restricted stock units for which common stock will be delivered to Mr. Duda at such time as the value of the award is deductible by us or Mr. Duda’s employment terminates, 100,000220,000 shares of vested restricted stock units for which common stock will be delivered to Mr. Duda in the event of termination from Methode under any circumstance and 270,000375,000 shares of performance-based restricted stock subject to forfeiture.
(4)Shares are held in a trust pursuant to which Ms. Goldberg Aronson shares voting and investment power with her husband.
(5)(6)
Shares are held in a trust pursuant to which Mr. Skatoff shares voting and investment power with his wife.
(6)(7)
Includes 52,500 shares of performance-based restricted stock subject to forfeiture.
(8)
Includes options to purchase 12,000 shares of common stock exercisable within 60 days, 1,079 shares of common stock held in our 401(k) Plan and 30,000 shares of vested restricted stock units for which common stock will be delivered to Mr. Glandon in the event of termination from Methode under any circumstance. 
(7)Includes 72,000 shares of performance-based restricted stock subject to forfeiture. 
(8)Includes options to purchase 12,000 shares of common stock exercisable within 60 days, 30,00090,000 shares of vested restricted stock units for which common stock will be delivered to Mr. Khoury in the event of termination from Methode under any circumstance and 135,000144,000 shares of performance-based restricted stock subject to forfeiture.
(9)
Reflects shares of performance-based restricted stock subject to forfeiture.
(10)
Includes 34,830 shares held jointly with Mr. Kill’s wife, options to purchase 12,0008,000 shares of common stock exercisable within 60 days, 30,00042,000 shares of vested restricted stock units for which common stock will be delivered to Mr. KillTsoumas in the event of termination from Methode under any circumstance, and 135,00075,500 shares of performance-based restricted stock subject to forfeiture.forfeiture and ‎12,038 shares of common stock held in our 401(k) Plan.
(10)(11)
Includes 94,32227,000 shares held jointly, with Mr. Koman’s wife and 25,470 shares of performance-based restricted stock subject to forfeiture.
(11)Includes 163,704 shares held jointly, 34,83052,160 shares held in trust with voting and investment power shared with a spouse, options to purchase 76,00060,000 shares of common stock exercisable within 60 days, 1,079577,055 shares of vested restricted stock units, 765,500 shares of performance-based restricted stock subject to forfeiture, 17,730 shares of phantom stock held in the Company’s Deferred Compensation Plan and 12,038 shares of common stock held in our 401(k) Plan, 391,812 shares of vested restricted stock units and 637,470 shares of performance-based restricted stock subject to forfeiture. 

10 Plan.
14


PROPOSAL ONE
ELECTION OF DIRECTORS

A Board of eighttwelve directors will be elected at the annual meeting.Annual Meeting. Each director will hold office until the next annual meeting of shareholders andstockholders, or until any such director’s earlier resignation or until his or her successor is elected and qualified. All of the nominees listed below currently serve as directors. All of the nominees were recommended unanimously to our Board of Directors by our Nominating and Governance Committee and were nominated by our Board of Directors. Mr. Batts will not be standing for re-election, and the Board expressed its great appreciation for all of the contributions he has made over the years. The size of the Board will be reduced from nine directors to eight directors as of the date of the annual meeting. If any of these nomineesnominee is notunwilling or unable to serve as a candidate for election at the annual meeting,director, an event which our Board of Directors does not anticipate, shares represented by the proxies will be voted for a substitutethe election of another nominee recommended tonominated by our Board upon the recommendation of Directors by our Nominating and Governance Committee, or the Board may reduce the size of the Board and nominated by our Boardthe number of Directors.

directors to be elected at the Annual Meeting.

OUR BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” THE ELECTION OF THE FOLLOWING NOMINEES.

Walter J. Aspatore, Chairman

Chairman Emeritus,

Amherst Partners, LLC

Director since 2008

Age 74

Mr. Aspatore has served as Chairman Emeritus of Amherst Partners, LLC, a business consulting firm, since 2010. Prior thereto, Mr. Aspatore was Chairman of Amherst Partners from 1994 through 2010. Mr. Aspatore has served as Chairman of our Board since 2012. Prior to co-founding Amherst Partners, Mr. Aspatore served in various officer positions at diversified manufacturing and technology businesses, including Cross and Trecker Corporation, the Warner and Swasey Company, Bendix Corporation and TRW Corporation. He also served as Vice Chairman and President of Onset BIDCO, a venture capital and subordinated debt fund, from 1992 to 1994. Mr. Aspatore also serves as a director of Mackinac Financial Corporation, a bank holding company. Mr. Aspatore’s consulting experience and service at various consulting, manufacturing and technology businesses has resulted in continued contributions to the Board.

Dr. Darren M. Dawson

Leroy C. and Aileen H. Paslay Dean,

College of Engineering,

Kansas State University

Director since 2004

Age 54

Dr. Dawson has served as the Dean of the College of Engineering of Kansas State University since July, 2014. Prior thereto, Dr. Dawson served as a Professor in the Electrical and Computer Engineering Department at Clemson University, where he held various professor positions since 1990. His research interests include nonlinear control techniques for mechatronic systems, robotic manipulator systems and vision-based systems. Dr. Dawson’s work has been recognized by several awards, including the Clemson University Centennial Professorship in 2000. Dr. Dawson’s academic and technical background has provided the basis for continued contributions to the Board’s operations and deliberations.

Donald W. Duda

Chief Executive Officer and President,

Methode Electronics, Inc.

Director since 2001

Age 62

Mr. Duda has served as our Chief Executive Officer since 2004 and our President since 2001. Mr. Duda joined us in 2000 and served as our Vice President - Interconnect Products Group. Prior to joining Methode, Mr. Duda held several positions with Amphenol Corporation, a manufacturer of electronic connectors, most recently as General Manager of its Fiber Optic Products Division from 1988 through 1998. Mr. Duda has used his executive background and unique understanding of Methode to contribute to the Board.

11 

Martha Goldberg Aronson

Former Executive Vice President and President of Global Healthcare

Ecolab, Inc.

Director since April 2016

Age 49

Ms. Goldberg Aronson served from 2012 to 2016 as Executive Vice President and President, Global Healthcare, at Ecolab, Inc., a specialty chemical company. From 2010 to 2012, Ms. Goldberg Aronson was President, North America at Hill-Rom Holdings, Inc., a global medical technology company. Prior to Hill-Rom, Ms. Goldberg Aronson spent 18 years at Medtronic, Inc., a medical technology provider, most recently serving as Senior Vice President and Chief Talent Officer. Ms. Goldberg Aronson is currently a member of the Board of Directors of Cardiovascular Systems, Inc., Conmed Corporation and the Guthrie Theater. Ms. Goldberg Aronson served as a director of Hutchinson Technology, Inc. from 2010 through 2016. Based on her extensive leadership experience and experience in the global health care markets, Ms. Goldberg Aronson has provided valuable insights to the Board.

Isabelle C. Goossen

Retired Vice President and Chief Financial Officer,

Chicago Symphony Orchestra Association

Director since 2004

Age 65

Ms. Goossen served as the Chief Financial Officer for the Chicago Symphony Orchestra Association from March, 2011 thru March, 2017. Ms. Goossen served as the Vice President for Finance and Administration for the Chicago Symphony Orchestra Association from 2001 thru March, 2017. From 1986 through 1999, Ms. Goossen held several management positions with Premark International, Inc., a diversified consumer products company, most recently as Vice President and Treasurer from 1996 through 1999. Ms. Goossen serves as a director of the Columbian Financial Group, the parent company of Columbian Mutual Life Insurance and Columbian Life Insurance Company, each a life insurance company. In addition, Ms. Goossen is a trustee of Knox College and a director of the Cook County Health Foundation. Ms. Goossen has used her financial expertise and management background to make continued contributions to the Board.

Christopher J. Hornung, Vice Chairman

Co-Founder,

Sturbridge Capital

Director since 2004

Age 65

Mr. Hornung co-founded Sturbridge Capital, an investment fund, in 2011. Mr. Hornung served as Chairman of Doskocil Manufacturing Company Inc., doing business as Petmate, a producer and distributor of pet products, from 2010 to May, 2017. Prior thereto, Mr. Hornung served as Chief Executive Officer of Next Testing, Inc., a provider of comprehensive, sport-specific athletic testing programs, from January 2007 to November 2013. From February 2004 through December 2006, Mr. Hornung served as President of the Pacific Cycle Division of Dorel Industries, Inc., a global consumer products company. Prior to the acquisition of Pacific Cycle by Dorel Industries Inc., Mr. Hornung served as the Chairman and Chief Executive Officer of Pacific Cycle. Mr. Hornung is a recipient of the Ernst & Young Entrepreneur of the Year Award and serves on an advisory board of the University of Wisconsin School of Business. His executive and entrepreneurial experience as well as his expertise regarding international sourcing and distribution has resulted in continued contributions to the Board. 

12 
Walter J. Aspatore, Chairman

Paul G. Shelton

Retired Vice President and Chief Financial Officer,

FleetPride, Inc.

Director since 2004

Age 67

Mr. Shelton retired in 2003 as Vice President and Chief Financial Officer of FleetPride Inc., an independent heavy-duty truck parts distributor. From 1981 through 2001, Mr. Shelton served in various management positions at AMCOL International Corporation, a supplier of specialty minerals and chemicals, most recently as Senior Vice President from 1994 through 2001 and Chief Financial Officer from 1984 through 2001. Mr. Shelton serves on two private company boards and was a former member of the board of directors of AMCOL International Corporation and six private companies. Mr. Shelton has used his executive, financial and board experience to contribute to the operations and deliberations of the Board. 

Lawrence B. Skatoff

Retired Executive Vice President and Chief Financial Officer,

BorgWarner Inc.

Director since 2004

Age 77

Mr. Skatoff retired in 2001 as Executive Vice President and Chief Financial Officer of BorgWarner Inc., a manufacturer of highly engineered systems and components for the automotive industry. Prior to joining BorgWarner Inc., Mr. Skatoff was Senior Vice President and Chief Financial Officer of Premark International, Inc., a diversified consumer products company, from 1991 through 1999. Before joining Premark, Mr. Skatoff was Vice President-Finance of Monsanto Company, a worldwide manufacturer of chemicals and pharmaceuticals. Mr. Skatoff’s executive experience and financial background has led to continued contributions to the Board.

13 
Director since 2008
Age 78

Mr. Aspatore has served as Chairman of our Board since 2012 and as Chairman Emeritus of Amherst Partners, LLC, a business consulting firm, since 2010. Prior thereto, Mr. Aspatore was Chairman of Amherst Partners from 1994 through 2010. Prior to co-founding Amherst Partners, Mr. Aspatore served in various officer positions at diversified manufacturing and technology businesses, including Cross and Trecker Corporation, the Warner and Swasey Company, Bendix Corporation and TRW Corporation. He also served as Vice Chairman and President of Onset BIDCO, a venture capital and subordinated debt fund, from 1992 to 1994. Mr. Aspatore also serves as Lead Director of Mackinac Financial Corporation, a bank holding company. Mr. Aspatore’s executive leadership experience, finance and M&A expertise and knowledge of the automotive industry bring valuable perspectives to our Board.
Lawrence B. Skatoff, Vice Chairman
Director since 2004
Age 81
Mr. Skatoff retired in 2001 as Executive Vice President and Chief Financial Officer of BorgWarner Inc. Prior to joining BorgWarner, Mr. Skatoff was Senior Vice President and Chief Financial Officer of Premark International, Inc. from 1991 through 1999. Before joining Premark, Mr. Skatoff was Vice President-Finance of Monsanto Company. Mr. Skatoff’s executive experience and financial background bring valuable perspectives to our Board.
David P. Blom
Director since 2019
Age 66
Mr. Blom served as President and Chief Executive Officer of OhioHealth ‎Corporation, a not-for-profit healthcare system, Ohio, from 2002 until his retirement in ‎2019. Mr. Blom serves as a director of Worthington Industries, Inc.‎, an industrial manufacturing company. Mr. Blom’s extensive leadership experience as chief executive officer of a large healthcare system and healthcare industry expertise bring valuable perspectives to our Board.
Therese M. Bobek
Director since 2020
Age 60
Ms. Bobek served as an Assurance Partner of PricewaterhouseCoopers LLP (“PwC”) from 1997 until her ‎retirement in 2018. Ms. Bobek most recently served in PwC’s national office where she directed a ‎nationwide network of partners and managers supporting audit quality. Ms. Bobek has served ‎as an Adjunct Lecturer in the Master of Accountancy Program at the University of Iowa's Tippie ‎College of Business since 2018. Ms. Bobek also serves on the Boards of Trustees and the Audit ‎Committees of the Northern Funds and Northern Institutional Funds.‎ Ms. Bobek’s extensive leadership experience at a major professional services firm, as well as her experience with audit quality oversight, bring valuable perspectives to our Board.‎
15

Brian J. Cadwallader
Director since 2018
Age 62
Mr. Cadwallader served as Vice President, Corporate Secretary and General Counsel of Johnson Controls, Inc., a global diversified technology and industrial company, from 2014 to 2016. Prior thereto, Mr. Cadwallader served as Vice President and Assistant General Counsel of Johnson Controls from 2011 to 2014. Mr. Cadwallader served as Group Vice President and General Counsel of Johnson Controls’ Building Efficiency business from 2010 to 2011. Prior to joining Johnson Controls, Mr. Cadwallader served as Associate General Counsel and Assistant Secretary at International Paper Company. In addition to his other responsibilities, Mr. Cadwallader was responsible for international legal and regulatory affairs for Johnson Controls and International Paper for over 15 years. Mr. Cadwallader’s legal background with expertise in international operations, corporate governance, M&A and executive compensation brings valuable perspectives to our Board.
Bruce K. Crowther
Director since 2019
Age 69
Mr. Crowther served as President and Chief Executive Officer of Northwest Community Healthcare, a not-for-profit healthcare system, from 1992 until his retirement in 2013. Prior thereto, Mr. Crowther served as Executive Vice President and Chief Operating Officer of Northwest Community Healthcare from 1989 to 1991. Mr. Crowther is the past Chairman of the board of directors of the Illinois Hospital Association. Mr. Crowther serves on the Board, Audit Committee, and Compliance Committee (Chair) of NeoGenomics, Inc., a company specializing in cancer genetic testing and information services. In addition, Mr. Crowther serves on the Board, Compensation Committee (Chair), Executive Committee, Finance Committee, and Nominating and Corporate Governance Committee of Wintrust Financial Corporation, a financial services company. Mr. Crowther’s extensive executive and board leadership experiences and significant knowledge regarding the healthcare industry bring valuable perspectives to our Board.
Dr. Darren M. Dawson
Director since 2004
Age 58
Dr. Dawson has served as the President of The University of Alabama in Huntsville since 2019. Prior thereto, Dr. Dawson served as Dean of the College of Engineering of Kansas State University since 2014. From 1990 to 2014, Dr. Dawson served as a Professor in the Electrical and Computer Engineering Department at Clemson University. His research interests included nonlinear control techniques for mechatronic systems, robotic manipulator systems and vision-based systems. Dr. Dawson’s work has been recognized by several awards. Dr. Dawson’s leadership experience as president of a large university and engineering expertise bring valuable perspectives to our Board.
Donald W. Duda
Director since 2001
Age 66
Mr. Duda has served as our Chief Executive Officer since 2004 and our President since 2001. Mr. Duda joined us in 2000 and served as our Vice President - Interconnect Products Group. Prior to joining Methode, Mr. Duda held several positions with Amphenol Corporation, a manufacturer of electronic connectors, most recently as General Manager of its Fiber Optic Products Division. Mr. Duda’s understanding of Methode’s operations, philosophy and culture, and his demonstrated success and proven quality of leadership bring important perspectives to our Board.
Janie Goddard
Director since March 2021‎
Age 50
Ms. Goddard has served as a Divisional Chief Executive of the Environmental and Analysis Sector at Halma plc, a global group of technology companies, since April 2021 and as a Divisional Chief Executive of Halma’s Medical and Environmental Sector since November 2019. Before joining Halma, Ms. Goddard served as Divisional President of the Detection and Analysis Business Unit at Novanta Inc., a global supplier of core technology solutions, from 2016 to 2019, where she led a portfolio of solutions for medical device OEMs. Prior to Novanta, Ms. Goddard served
16

in leadership roles at Welch Allyn (acquired by Hill-Rom), Covidien (acquired by Medtronic), and Johnson & Johnson. Ms. Goddard also serves on the Board, Audit Committee, Compensation Committee and Nominating Committee of ACON S2 Acquisition Corp., a special purpose acquisition corporation. Ms. Goddard’s background in international strategic marketing and product development brings valuable perspective to our Board.
Mary A. Lindsey
Director since 2020‎
Age 65
Ms. Lindsey served as Chief Financial Officer of Commercial Metals ‎Company, a global ‎‎manufacturer and recycler of steel and other metals, from ‎January 2016 until her retirement in ‎‎2019. In addition, Ms. Lindsey ‎served as Senior Vice President since 2017 and Vice President-Tax from ‎‎2009 ‎to 2016. Ms. Lindsey ‎serves on the Board, Audit Committee (Chair), and Corporate Governance and Nominating Committee of ‎Lindsay ‎Corporation, a provider of water ‎management and road infrastructure ‎products and services. In addition, Ms. Lindsey serves on the Board and Audit Committee of Orion Engineered Carbons S.A., a supplier of carbon products. Ms. Lindsey’s experience as a chief financial officer of a publicly traded company and her financial and tax expertise bring valuable perspectives to our Board.
Angelo V. Pantaleo
Director since 2019
Age 61
Mr. Pantaleo has served as Chairman and Chief Executive Officer of Marmon ‎Holdings, Inc., a Berkshire Hathaway company and global industrial organization, since 2019 and as President of Marmon since 2017. Prior thereto, Mr. Pantaleo ‎served as Chairman and Chief Executive Officer of Duracell, a Berkshire Hathaway company and ‎leading manufacturer of alkaline batteries, since 2014.‎ ‎Mr. Pantaleo’s significant strategic and operational leadership experience with a major global company, along with his extensive international experience, bring valuable perspectives to our Board.
Mark D. Schwabero
Director since 2019
Age 68
Mr. Schwabero served as Chairman, Chief Executive Officer and Director of Brunswick Corporation, a recreational marine products company, from 2016 until his retirement in 2018. Prior thereto, Mr. Schwabero served as President and Chief Operating Officer of Brunswick from 2014 to 2016 and as President of its Mercury Marine subsidiary from 2008 to 2014. Mr. Schwabero serves as Lead Director of 1st Source Corporation, parent company of‎ 1st Source Bank, as well as a member of the Audit Committee, Executive Compensation and Human Resources Committee, Executive Committee, and Governance and Nominating Committee of 1st Source. In addition, Mr. Schwabero serves on the Advisory Committee of The Ohio State University Center for Automotive Research. Mr. Schwabero’s leadership experience, international expertise and detailed knowledge of the automotive and industrial industries bring valuable perspectives to our Board.
17

PROPOSAL TWO
RATIFICATION OF SELECTION OF
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Audit Committee of our Board of Directors is directly responsible for the appointment, termination, compensation, evaluation and oversight of our independent registered public accounting firm. Our Audit Committee has selected Ernst & YoungEY to serve as our independent registered public accounting firm for the fiscal year ending April 28, 2018,30, 2022, subject to ratification of the selection by our shareholders. Ernst & Youngstockholders. EY has served as our independent registered public accounting firm for many years and is considered to be well qualified.

Representatives of Ernst & YoungEY will be present atattend the annual meeting,Annual Meeting, will have the opportunity to make a statement and will be available to respond to appropriate questions.

If our shareholdersstockholders do not ratify the selection of Ernst & Young,EY, our Audit Committee will reconsider the selection. Even if the selection is ratified, our Audit Committee may select a different independent registered public accounting firm at any time during the year if it determines that a change would be in the best interests of Methode and our shareholders.

stockholders.

OUR BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” THE RATIFICATION OF OUR AUDIT COMMITTEE’S SELECTION OF ERNST & YOUNGEY AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM.

14 
18

proposal


PROPOSAL THREE
advisorY
ADVISORY APPROVAL OF METHODE’S executive compensation

EXECUTIVE COMPENSATION

Section 14A of the Securities Exchange Act of 1934 requires that we provide our shareholdersstockholders with the opportunity to vote to approve, on a nonbinding, advisory basis, the compensation of our named executive officers as disclosed in this proxy statement, commonly known as a “say-on-pay” vote.

As described under “Executive Compensation – Compensation“Compensation Discussion and Analysis,” we seek to align the interests of our executives with the interests of our shareholdersstockholders and reward performance.

The advisory vote on this resolution is not intended to address any specific element of compensation, but rather the overall compensation of our named executive officers as disclosed in this proxy statement. The vote is advisory, which means that the vote is not binding on Methode, our Board of Directors or our Compensation Committee. Although this vote is nonbinding, our Board of Directors and our Compensation Committee value the opinions of our shareholdersstockholders and our Compensation Committee will consider the outcome of the vote when making decisions concerning executive compensation.

Shareholders may vote for or against the following resolution, or may abstain from voting. The affirmative vote of a majority of the shares present or represented at the annual meeting and entitled to vote is required to approve the proposed resolution.

We ask our shareholdersstockholders to approve the following resolution:

“RESOLVED, that the compensation of Methode’s named executive officers, as disclosed in Methode’s Proxy Statement for the 20172021 Annual Meeting of ShareholdersStockholders pursuant to the SEC’s compensation disclosure rules, including the Compensation Discussion and Analysis, the Summary Compensation Table and the other related tables and disclosure, is hereby approved.”

Our Board of Directors recommends a vote

OUR BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” the approval of theTHE APPROVAL OF THE FOREGOING RESOLUTION.

15 
19

PROPOSAL FOUR
ADVISORY VOTE ON THE FREQUENCY OF
FUTURE ADVISORY VOTES ON EXECUTIVE COMPENSATION

Section 14A of the Securities Exchange Act of 1934 provides that shareholders must be given the opportunity to vote, on a non-binding, advisory basis, on how frequently the advisory vote on executive compensation should be presented to our shareholders, commonly known as “say-on-pay” votes. Shareholders may indicate whether they would prefer that we conduct future “say-on-pay” votes once every one, two or three years. Shareholders also may abstain from casting a vote on this proposal.

We are required to hold an advisory vote regarding the frequency of “say-on-pay” votes every six years. The Company’s shareholders were provided with the opportunity to vote on the frequency of “say-on-pay” votes in 2011. At such time, the shareholders voted in favor of holding “say-on-pay” votes annually and the Board adopted this standard.

After consideration of each alternative, the Board recommends that the advisory vote on executive compensation continue to be submitted to the shareholders every year. Our Board of Directors has determined that an annual advisory vote on executive compensation will allow our shareholders to provide timely input on Methode’s executive compensation philosophy, policies and practices as disclosed in the proxy statement each year.

The proxy card provides shareholders with the opportunity to choose among four options (holding the vote every one, two or three years, or abstaining). Shareholders will not be voting to approve or disapprove the recommendation of the Board of Directors.

While this vote is advisory and not binding on Methode, the Board and the Compensation Committee expect to consider the outcome of the vote, along with other relevant information, in determining the frequency of future advisory votes on executive compensation. Notwithstanding the Board’s recommendation and the outcome of the shareholder vote, the Board may in the future decide to conduct advisory votes on a less frequent basis.

Our Board of Directors recommends a vote for a one-year frequency of the advisory vote on executive compensation. 

16 

AUDIT COMMITTEE MATTERS

Report of the Audit Committee

The Audit Committee oversees our financial reporting process on behalf of our Board of Directors. Our management has the primary responsibility for the financial statements and the reporting process, including the system of internal controls. Our Board has determined that each member of our Audit Committee meets the requirements as to independence, experience and expertise established by the New York Stock Exchange. Our Board has designated Ms. Goossen,Bobek, Ms. Lindsey, Mr. SheltonSchwabero and Mr. Skatoff as audit committee financial experts as defined by the SEC. In fulfilling its oversight responsibilities, our Audit Committee reviewed and discussed the audited financial statements in the Annual Report on Form 10-K for the year ended April 29, 2017May 1, 2021 with management, including a discussion of the quality, not just the acceptability, of the accounting principles; the reasonableness of significant judgments; and the clarity of disclosures in the financial statements.

Our Audit Committee reviewed and discussed with our independent registered public accounting firm, Ernst & Young,EY, which is responsible for expressing an opinion on the conformity of the audited financial statements with U.S. generally accepted accounting principles, the firm’s judgments as to the quality, not just the acceptability, of our accounting principles and such other matters as are required to be discussed under the standards of the Public Company Accounting Oversight Board (United States).

The Committee has received the written disclosures and the letter from Ernst & YoungEY required by applicable requirements of the Public Company Accounting Oversight Board regarding Ernst & Young’sEY’s communications with the Committee concerning independence, and has discussed with Ernst & YoungEY the firm’s independence from management and Methode and considered the compatibility of nonauditnon-audit services with the firm’s independence.

Our Audit Committee discussed with our internal auditors and Ernst & YoungEY the overall scope and plans for their respective audits. Our Audit Committee met with the internal auditors and Ernst & Young,EY, with and without management present, to discuss the results of their examinations, their evaluations of our internal controls, and the overall quality of our financial reporting. The Committee also discussed with Ernst & YoungEY the matters required to be discussed byunder the Public Company Accounting Oversight Board Auditing Standard No. 1301, Communications with Audit Committees - Public Company Accounting Oversight Board.

(AS 1301). In reliance on the reviews and discussions referred to above, the Committee recommended to our Board of Directors (and our Board has approved) that the audited financial statements be included in the Annual Report on Form 10-K for the year ended April 29, 2017May 1, 2021 filed with the SEC.

AUDIT COMMITTEE

Isabelle C. Goossen, Chair

Walter J. Aspatore

Paul G. Shelton

Lawrence B. Skatoff

17 
AUDIT COMMITTEE
Mary A. Lindsey (Chair)
Therese M. Bobek‎
Angelo V. Pantaleo
Mark D. Schwabero
Lawrence B. Skatoff
20


Auditing and Related Fees

Our Audit Committee engaged Ernst & YoungEY to examine our consolidated financial statements for the fiscal year ended April 29, 2017.May 1, 2021. Fees paid to Ernst & YoungEY for services performed during the 20172021 and 20162020 fiscal years were as follows:

  Fiscal 2017 Fiscal 2016
Audit Fees (1) $2,589,140 $1,960,702
Tax Fees (2) $25,593 $52,039
All Other Fees -- --
Total $2,614,733 $2,012,741

 
Fiscal 2021
Fiscal 2020
Audit Fees(1)
$2,775,303
$2,868,035
Audit-Related Fees
Tax Fees(2)
$32,261
$27,821‎
All Other Fees
—‎
Total
$2,807,564
$2,895,856
(1)
Audit fees represent aggregate fees billed for professional services rendered by Ernst & YoungEY for the audit of our annual financial statements and review of our quarterly financial statements, audit services provided in connection with other statutory and regulatory filings and consultation with respect to various accounting and financial reporting matters and transaction advisory services.matters.
(2)
Tax fees primarily include fees for consultations regarding intercompany transfer pricing.

Pre-Approval Policy

Our Audit Committee is responsible for reviewing and pre-approving all audit and non-audit services provided by Ernst & YoungEY and shall not engage Ernst & YoungEY to perform non-audit services proscribed by law or regulation. In fiscal 2017,2021, 100% of audit and non-audit services were approved by the Audit Committee.

18 
21


COMPENSATION DISCUSSION AND ANALYSIS

Overview

This Compensation Discussion and Analysis describes the key elements of our executive compensation program, including an analysis of compensation awarded to, earned by or paid to our named executive officers in fiscal 2017.2021. Our fiscal 20172021 named executive officers included Donald W. Duda, President and Chief Executive Officer; John R. Hrudicka,Ronald L.G. Tsoumas, Chief Financial Officer; Joseph E. Khoury, Senior Vice President; Theodore P. Kill,Chief Operating Officer; Andrea J. Barry, Executive Vice President Worldwideand Chief Human Resources Officer; and Kevin M. Martin, Vice President, North America. Mr. Martin was appointed an executive officer in September 2020 and Ms. Barry was promoted to Executive Vice President in June 2021.
Executive Summary
Our Business. We are a leading global developer of custom-engineered solutions with sales, engineering and manufacturing locations in North America, Europe, Middle East, and Asia. We design, engineer, and produce mechatronic products for OEMs utilizing our broad range of technologies for user interface, LED lighting system, power distribution and sensor applications.
Our solutions are found in the end markets of transportation (including automotive, commercial vehicle, e-bike, aerospace, bus and rail), cloud computing infrastructure, construction equipment, consumer appliance, and medical devices. Our business is managed on a segment basis, with those segments being Automotive, Industrial, Interface and Medical.
We strive to create a company with a diverse customer base, high and consistent cash flow, and a strong balance sheet. We are committed to world class manufacturing quality, and our global footprint puts us in close proximity to key markets and customers.
In fiscal 2021, we continued to capitalize on key market trends, such as new business focused on electric and hybrid vehicles (EVs) and LED lighting solutions. In the EV market, our combination of user interface, LED lighting and power distribution solutions positions us well for continued growth. Sales in fiscal 2021 from EV applications represented over 12% of our total sales.
We employ a balanced and President of Dabir Surfaces; Timothy Glandon, Vice President;growth-focused capital allocation strategy. We maintain a strong balance sheet and Douglas Koman,pay down indebtedness when appropriate to reduce leverage. We return capital to our retired Chief Financial Officer. In July 2016, Mr. Koman resigned as Chief Financial Officerstockholders through dividends and Mr. Hrudicka was hiredstock buyback programs, such as our new Chiefrecently announced $100 million stock buyback program. We invest in organic growth through R&D and capital expenditures. We actively seek accretive acquisitions to enhance and grow our businesses.
Our strong commitment to financial management focuses on, among other things, margin expansion through improved product mixes and operational efficiencies, leverage of SG&A on sales volume growth, and reduction of working capital percentage of sales through lean manufacturing.
Impact of the COVID-19 Pandemic on Performance. Beginning in the fourth quarter of our fiscal 2020, and continuing in fiscal 2021, the global COVID-19 pandemic has negatively affected the global economy, disrupted supply chains and substantially impacted our business. We first experienced the impacts of the pandemic in the fourth quarter of fiscal 2020 at our China manufacturing facilities, which were initially closed after the Chinese New Year. Our facilities in China resumed operations later in the fourth quarter of fiscal 2020, but at lower capacity utilization. More significantly, in mid-March 2020, and continuing into the start of our fiscal 2021, many of our North American and European customers suspended their manufacturing operations due to government directives. Our operations in North America and Europe gradually resumed during the first quarter, with significantly reduced production levels. Our global production levels returned to pre-COVID levels by the end of our second quarter as a result of increased demand from customers, which continued for the remainder of the year. Starting in our third quarter, our global team had to address additional challenges related to the global semiconductor supply shortage and other supply chain disruptions, as well as international transportation capacity restraints.
Response to the COVID-19 Pandemic. In fiscal 2021, our executive officers continued to effectively manage the unprecedented challenges and uncertainties of the pandemic on a global basis. In reviewing what was required to keep our facilities operating, management prioritized the health and safety of our employees and their families. We adopted numerous safety procedures at our 40 global facilities, including hygiene and disinfection protocols, testing and contact tracing, social distancing and wearing personal protective equipment (PPE). We implemented the sharing of best practices throughout the Company’s global facilities, resulting in effective and standardized safety guidelines and procedures, updated on a regular basis, promoting the health and safety of our employees.
22

Management evaluated and redesigned the Company’s staffing requirements and structures to reflect the ongoing impact of the pandemic on the Company’s business and operations. Among other actions, management successfully implemented several important business consolidations and successfully managed pandemic-related labor issues at our facilities in Mexico. We implemented processes to continuously monitor and strengthen the Company’s supply chain to proactively mitigate potential disruptions due to the pandemic. As a result, we did not experience any significant production issues due to the pandemic during fiscal 2021. We experienced certain supply chain interruptions related to the worldwide semi-conductor shortage and other global supply chain issues, which were mitigated by our global sourcing strategies.
Management also instituted heightened and effective procedures and practices to successfully manage liquidity, cash, accounts receivable, accounts payable, capital expenditures and indebtedness during the pandemic.
Fiscal 2021 Financial Officer. Mr. Koman retired asHighlights. Despite the impact from the COVID-19 pandemic and supply chain disruptions, we reported record fiscal 2021 net sales of $1.09 billion and reported net income of $‎122.3 million. For fiscal 2021, our quarterly dividend rate was $0.11 per share, and we distributed dividends of $16.5 million to our ‎stockholders.‎ In addition, we purchased 167,949 shares of our common stock in fiscal 2021 through our stock buyback program, for an employee in September 2016.

Executive Summary

aggregate purchase price of $7.5 million.

Key Compensation Decisions and Highlights. Our Compensation Committee strives to provide compensation programs that align our executives’ interests with those of our shareholdersstockholders and appropriately reward our executives for performance against annual and multi-yearlong-term objectives.

The key elements of our the ‎‎fiscal 20172021 compensation program for our named‎named executive officers included the following:

are as follows:
Salary. In reviewing fiscal 2017April 2020, the salaries forof our named executive officers our Compensation Committee discussed retention issues, reviewed advice from its compensation consultant regarding market practices and considered Mr. Duda’s recommendations for officers other than himself. The Compensation Committee also considered other relevant factors, includingwere reduced twenty percent (20%) in connection with cost-cutting measures related to the individual performance, skills and experience of each executive, internal pay equity issues, and‎COVID-19 pandemic. ‎In July 2020, the Company’s performance. The Compensation Committee decided not to increase the base salaries of our named executive officers for fiscal 2021 and to continue the twenty percent (20%) salary reduction. The executive officers’ full base salaries were reinstated at the end of each of Messrs. Duda, Khoury, KillAugust 2020 for Mr. Martin and Koman by 3.0%. Thein mid-September 2020 for our other named executive officers. In September 2020, the Compensation Committee setincreased Mr. Hrudicka’sMartin’s salary by approximately 14% in connection with hiring him as our Chief Financial Officer.his promotion to executive officer and the related increase in his responsibilities. ‎Details regarding these salaries are described below under “Components of Fiscal 2021 Compensation – Salary‎.”‎
Annual Performance-Based Cash Bonus. After considering the guideline benchmark target,Our named executive performance, retention issues, internal pay equity, market conditions, the advice of our independent compensation consultant and Mr. Duda’s recommendations for the other officers the Compensation Committee made fiscal 2017were awarded annual performance-based cash bonus awards. For Messrs. Duda, Hrudicka, Khoury and Koman, 70% of theopportunities for fiscal 2021. The target bonus was based on an adjusted pre-tax income measure for the Company and 30% was based on sales objectives and/or individual objectives. For Mr. Kill, 25% of the target bonus was based on the Company pre-tax income measure and 75% was based on performance measures related to our Dabir Surface medical device products. The maximum amount payable with respect to the Company pre-tax income measure was set at 100% of base salary for Mr. Duda, 75% for Mr. Khoury and 66% for our other named executive officers. The threshold and maximum amounts payable were set at 50% and 200%, respectively, of the amount payable at the target level of performance. The annual performance measures included new business bookings, management of the uncertainties and challenges of the COVID-19 pandemic, financial objectives and individual performance objectives. Details regarding these awards are described below under “Components of Fiscal 2021 Compensation – Annual Performance-Based Bonuses‎.”‎.
Transition Awards. In June 2020, after considering the need to retain management talent in a highly competitive job market in order to aligntransition the Company from the pre-pandemic economy through the extended recovery and to provide a bridge of unvested value for the period between the vesting of the 2015 LTI program awards and the adoption of the 2021 LTI Program, the Compensation ‎Committee granted transition awards to our executive officers. The award with competitive practice among the peer group. Due to Mr. Koman’s retirement, he was entitledis a cash opportunity equal to a pro-rata paymentmultiple ‎of the executive’s base salary as follows: Mr. Duda, 2.0 times; Mr. ‎Khoury, 1.75 times; Mr. Tsoumas and Ms. Barry, 1.5 times; and Mr. Martin, 1.25 times.‎ If the executive remains employed by the Company and maintains ‎satisfactory job ‎performance, forty percent (40%) of his annual bonus basedthe transition award will be paid on his retirement date‎April 30, 2022‎, and the performance achieved with respect to the measuressixty percent (60%) will be paid ‎on April 29, 2023. Details regarding these awards are described below. In connection with his hiring, Mr. Hrudicka was guaranteed a minimum bonusbelow under “Components of $150,000 for fiscal 2017.Fiscal 2021 Compensation – Transition Awards‎.”
Fiscal 20162021 LTI Program. OurIn September 2020, after reviewing various design alternatives and market practices and considering the performance of our two prior five-year, equity program consists of a mix of 60% performance-based restricted stock awards (“RSAs”), at target performance, and 40% time-based restricted stock units (“RSUs”). Thelong-term incentive programs, our Compensation Committee expects the Fiscal 2016 LTI Program to cover alladopted a five-year, long-term incentive grants toprogram (the “2021 LTI Program”). After careful consideration, the participants throughCompensation Committee determined that another five-year program was appropriate after reviewing our shareholders’ strong say-on-pay support of the end of fiscal 2020 (i.e., five fiscal years). The number of RSAs earned will be based onprior programs, the achievement of established goals for the Company’s earnings before net interest, taxes, fixed asset depreciation and intangible asset amortization (“EBITDA”) for fiscal 2020. The EBITDA performance goals under the Fiscal 2016 LTI Program were designed to align with the Company’s targeted annual growth rate for EBITDA of 9% to 10% for the period. The RSUs are subject to vesting based on continued service with no RSUs vesting prior to the end of fiscal 2018, subject to acceleration in certain limited circumstances.positive

23

reviews of the participants in the prior programs, as well as the lengthy sales and product development cycles and significant upfront capital requirements for many of the Company’s products. The Compensation Committee intends for these stock awards to be the only equity-based awards made to our executive officers during the five-year program period ending on May 3, 2025. This is consistent with our prior programs where no additional equity awards were made to the program participants during the five-year program terms.
The 2021 LTI Program consists of performance-based restricted stock awards (“RSAs”), performance units (“Performance Units”) and time-based restricted stock units (“RSUs”). The number of RSAs and Performance Units earned will be based on the achievement of established goals for the Company’s earnings before net interest, taxes, fixed asset depreciation and intangible asset amortization (“EBITDA”) for fiscal 2025. The target EBITDA performance goal aligns with the Company’s targeted EBITDA compound annual growth rate of approximately 8% for the five-year program period. The RSUs are subject to a five-year vesting period based on continued service with no RSUs vesting prior to the end of fiscal 2023. The Performance Units represent an opportunity for participants to receive a cash payment based on the price of Methode’s common stock only to the extent that fiscal 2025 EBITDA exceeds target performance for the RSAs. At the discretion of the Compensation Committee, the Performance Units may be settled in shares of our common stock. See “Components of Fiscal 2021 Compensation – 2021 LTI Program” below for additional information regarding this program.
Compensation Governance Practices. Our executive compensation program contains the following components and features that are designed to reflect compensation governance best practices and align the interests of our named executive officers and shareholders.

19 
stockholders.
What We Do
No excessive post-termination benefits: Our executives do not participate in pension plans or receive other post-retirement benefits, nor do they generally have employment or severance agreements (other than in connection with
Provide for a change‎significant amount of control).‎compensation that is “at ‎risk” based on ‎performance
No “single trigger” change
Provide an appropriate mix of control benefits: We maintain “double-trigger” change of control agreements,short-term and the executives are only entitled tolong-term compensation
Utilize an ‎independent ‎compensation ‎consultant
Require significant executive ‎officer and director stock ‎ownership
Maintain a severance payment if“clawback” policy ‎for incentive ‎compensation
‎Conduct an executive is terminated without cause orannual “say-‎on-pay” advisory vote
Conduct an executive terminates for good reason subsequent to a change of control. In addition, awardsannual ‎compensation risk ‎assessment
Disclose EBITDA performance measures under our Fiscal 20162021 LTI Program do not automatically vest upon a change in control.Program‎
What We Don’t Do
No excessive ‎post-termination ‎benefits
No excise tax gross ups: We do not provide for gross-up payments for excise taxes our executive officers may incur upon change in connection with a changecontrol
No “single trigger” ‎change of control.‎control benefits
NoRobust performance-based incentives: In general, a significant amount of each of our named executive officer’s compensation is variable compensation and “at risk” for non-payment if we fail dividends or the executive fails to meet performance targets. Consistent with our pay-for-performance philosophy, approximately 56.5% of our Chief Executive Officer’s fiscal 2017 compensation is composed of performance-based compensation, consisting of one-fifth of the grant date fair value of the fiscal 2016 performance-based RSAs (at target performance), and the annual performance-based cash bonus.
Disclosure of performance measures: We disclose the performance measures for the RSAs awarded pursuant to the Fiscal 2016 LTI Program and our fiscal 2017 performance-based annual bonuses in this Compensation Discussion and Analysis.
Equity compensation best practices: Our 2014 Omnibus Incentive Plan contains certain restrictions that reflect sound corporate governance principles, including the following:
dividends‎dividend ‎equivalents on performance-based‎unearned stock awards and dividend equivalents on performance-based
No hedging ‎or pledging of ‎our stock unit awards are paid only to the extent the underlying awards vest; andby ‎executives or directors
awards to employees are subject to the following minimum vesting requirements: (i) stock options, performance-based restricted stock, restricted stock units or performance units − at least one year; and (ii) time-based restricted stock, restricted stock units or performance units − at least three years, with no more frequent than ratable vesting over the vesting period. The minimum vesting requirements are not applicable in the event vesting is accelerated under certain circumstances such as death or disability, and the plan provides for an exception to the minimum vesting requirement for up to ten percent (10%) of the number of shares authorized for issuance under the plan.

NoUse of an independent compensation consultant: The Compensation Committee directly engages an independent compensation consultant to review the competitiveness and effectiveness of our executive compensation program. excessive perquisites
Executive officer stock ownership requirements: We require all of our executive officers to hold substantial amounts of our common stock. Our Chief Executive Officer is expected to own stock with a value at least equal to six (6) times his base salary. In addition, shares of common stock underlying the RSUs awarded under the Fiscal 2011 LTI Program (described below) and the Fiscal 2016 LTI Program will not be delivered to the executive until the earlier of the executive’s termination of employment or a change of control of Methode.
Incentive “clawback” policy: In the event we are required to restate our financial statements due to material noncompliance, our Incentive Compensation Recoupment Policy requires us to recover from our current or former executive officers certain amounts of incentive-based compensation paid within the prior three years.
Policy prohibiting hedging or pledging our stock: Our Insider Trading Policy prohibits our directors, executive officers and certain key employees from engaging in certain transactions involving our common stock, including options trading, short sales, derivative transactions and hedging transactions. In addition, these directors, executive officers and key employees are
20 
24

prohibited from holding


Pay Mix. A significant amount of our common stock innamed executive officers’ compensation is “at risk” for non-payment ‎if we fail or the executive fails to meet established performance targets. The following charts illustrate the components of ‎fiscal 2021 compensation as a margin account or otherwise pledgingpercentage of total target compensation for our common stockChief Executive Officer and for our other named executive officers as collaterala group. For this purpose, total target compensation is the sum of an ‎executive officer’s salary, target ‎annual performance-based cash bonus ‎opportunity, and one-fifth of the market value of the target RSA’s as of the grant dates ‎and one-fifth of the grant date fair value of the RSUs.‎ Performance Units are not included as they are only earned for above-target performance; below target performance will yield a loan.

zero payout.



Objectives and Measurement Principles

Our executive compensation program supports our objective of enhancing shareholderstockholder value through a competitive program that attracts and retains high-quality talent and rewards executives for demonstrating strong leadership and delivering results. Our executive compensation program is designed to:

Provide executives with a competitive pay arrangement.
Link short-term cash incentive pay to achievement of company objectives, for pre-tax incomeincluding new business bookings and new sales, and in certain cases, individual objectives.
Link long-term equity incentives to achievement of EBITDA objectives, as adjusted for certain acquisitions and divestitures.objectives.
Align executive interests with shareholderstockholder interests by providing for capital accumulation through awards of RSAs and RSUs and encourage significant ownership of our common stock by our executive officers.

Our Compensation Process

Our Overall Process.Our Compensation Committee is comprised entirely of independent directors and meetsthat meet as often as necessary to perform itstheir duties. In fiscal 2017,2021, our Compensation Committee met fivenine times. Our
25

Compensation Committee typically meets with Donald W. Duda, our Chief Executive Officer, and our Chief Human Resources Officer.

The Compensation Committee regularly holds executive sessions without any members of management present.

Our Compensation Committee annually engages a compensation consultant to review the competitiveness and effectiveness of our executive compensation program and annually reviews summaries of our named executive officers’ compensation.compensation relative to peers and survey data. Our Compensation Committee also annually reviews company performance relative to peers and survey data.

peers.

Our Chief Executive Officer’s compensation is determined by our Compensation Committee. Management does not make recommendations to our Compensation Committee regarding compensation elements with respect to Mr. Duda’s compensation. For named executive officers other than Mr. Duda, compensation packages are developed and recommended by Mr. Duda, in consultation with the Chief FinancialHuman Resources Officer, based on guidelines provided by our Compensation Committee. Our Compensation Committee determines whether to approve these recommendations, subject to any modifications that it may deem appropriate.

Role of Compensation Consultant. Since 2013, Frederic W. Cook & Co., Inc. (“FWC”FW Cook”) has provided independent executive compensation consulting services to the Compensation Committee. FWCFW Cook is retained by and reports to the Compensation Committee. During fiscal 2017, FWC2021, FW Cook provided the following services:

assisted the Compensation Committee in evaluating the linkage between pay and performance;
assisted the Compensation Committee in developing a compensation peer group to be used for evaluating compensation decisions;group;
provided and reviewed market data and advised the Compensation Committee on setting executive compensation and the competitiveness and reasonableness of the Company’s executive compensation program;program, including the 2021 LTI Program;
reviewed and advised the Compensation Committee regarding the elements of the Company’s executive compensation program, each as relative to the Company’s peers and survey data;
advised the Compensation Committee on setting compensation for Mr. Hrudicka, our new Chief Financial Officer;
provided information regarding realizable pay in light of our Fiscal 2016multi-year LTI Program;Programs;
evaluated the Company’s compensation programs and practices in relation to potential compensation risk areas to confirm that the risks inherent in the executive compensation program are not reasonably likely to have a material adverse effect on the Company; and
21 
reviewed and advised the Compensation Committee regarding regulatory, governance, disclosure and other technical matters.

The Compensation Committee reviewed information provided by FWCFW Cook addressing the independence of FWCFW Cook and the representatives serving the Committee. Based on this information, the Compensation Committee concluded that the work performed by FWCFW Cook and its representatives involved in the engagement did not raise any conflict of interest and that FWCFW Cook and such representatives are independent from the Company’s management.

Consideration of 20162020 Say-on-Pay Vote Results. At our 2016 annual meeting,2020 Annual Meeting, our shareholdersstockholders approved our fiscal 20162020 executive compensation, with approximately 95% of voted shares cast in favor of the say-on-pay resolution. Our Compensation Committee considered the results of the 20162020 say-on-pay vote along with other factors when making executive compensation decisions.

Market Benchmarking

Risk Assessment. The Compensation Committee, together with the Chief Executive Officer and Positioning of Fiscal 2017 Executive Compensation

We strive to provideits independent compensation opportunities that are market competitive. In order to assistconsultant, annually considers potential risks when reviewing our compensation programs for all employees, including our executive officers. Based on this assessment, the Compensation Committee in achieving this objective forconcluded that our fiscal 2017, FWC was retained to conduct a review of our executive2021 compensation peer group and benchmark our executive compensation program using a custom peer group and third-party survey data. The Compensation Committee considers this benchmarking information in reviewing each element of our compensation program.

After considering the advice of FWC, the Compensation Committee approved using the fiscal 2016 peer group for fiscal 2017, subject to a few modifications. One former peer company, Remy International, Inc., was eliminated since it had been acquired. Two new peer companies, AVX Corporation and Multi-Fineline Electronix, Inc., were added. Each of the new peer companies satisfies the Compensation Committee’s criteria for the peer group as summarized below.

The peer group used for benchmarking purposes in fiscal 2017 was selected using the following criteria:

Size as measured by revenue – we generally targeted companies with revenueprograms do not less than half nor more than two times our annual revenue.
Size as measured by market capitalization – we generally targeted companies with market capitalization not less than one-third nor more than three times our market capitalization.
Similar-type businesses – we generally targeted companiescreate risks that are multinational and engage in businesses with similar technology, products and markets.

For compensation decisions affecting fiscal 2017 compensation,reasonably likely to have a material adverse effect on the peer group included the following companies:

AVX CorporationIPG Photonics CorporationRogers Corporation
CTS CorporationLittelfuse, Inc.Standard Motor Products, Inc.
Dorman Products, Inc.MTS Systems CorporationStoneridge, Inc.
Drew Industries, IncorporatedMulti-Fineline Electronix, Inc.TTM Technologies, Inc.
Franklin Electric Company, Inc.OSI Systems, Inc.Universal Electronics Inc.
Gentherm Incorporated


Company. In benchmarking our compensation program for fiscal 2017,making this determination, the Compensation Committee reviewed information compiled by FWC from the following third-party executive pay surveys: (i) 2015 Mercer Executive Benchmark; (ii) 2015 Aon Hewitt Total Compensation Management; (iii) 2015 Willis Towers Watson U.S. Compensation Data Bank;key features of our compensation programs and (iv) 2015 Willis Towers Watson Top Management.

As a general policy, we targeted fiscal 2017 executive officer total direct compensation (salary, annual cash bonus and long-term incentive compensation) and each component thereof inpolicies, including the 50th to 75th percentile range of competitive practice, which aligned with the Company’s relative positioning in terms of revenues, net income and market capitalization versus its peer group. In making benchmarking determinations for fiscal 2017 compensation, thefollowing:

The Compensation Committee assumed that each executive would achieve the target level of performance under all performance-based awards. In addition, in valuing the RSAis independent and RSU awards outstanding under the Fiscal 2016 LTI

22 
utilizes an independent compensation consultant.

Program, the Compensation Committee assumed each executive would achieve the target level of performance under the RSAs and included one-fifth of the grant date fair value of these shares in these comparative calculations since the Fiscal 2016 LTI Program is intended to cover all long-term incentive grants to the participants through fiscal 2020. For Mr. Hrudicka, one-fourth of the grant date fair value of these shares is included due to his mid-cycle hiring date.

In setting each compensation component for our executive officers the Compensation Committee considered the competitive market data, together with other relevant factors, including the individual performancerepresents a balanced mix of short-term, long-term and experience of each executive, retention issues, internal pay equity and consistency issues, the Company’s performance, expected future contributions of each executive, historical compensation levels, tenure and industry conditions. These and other factors may affect whether one or more of the compensation components for any of our executive officers falls outside of the benchmark range. In addition, the total direct compensation, annual cash bonus and long-termat-risk compensation.

Our short-term incentive compensation for one or more of our executive officers could be above or below this target range depending on the amounts earned under the performance-based awards.

Consistent with our pay-for-performance philosophy, our executive compensation program is generally structured so that a significant amount of each of our named executive officers’ compensation is variable compensation and “at risk” for non-payment if we fail, or the executive fails,programs are designed to meet performance targets.

Components of Fiscal 2017 Compensation

Salary. Our Compensation Committee establishes salaries onavoid an annual basis, taking into account the guideline benchmark target, levels of responsibility, prior experience and breadth of knowledge, potential for advancement, recent promotions, past performance, internal equity issues and external pay practices. In setting fiscal 2017 salary levels, the Compensation Committee reviewed advice from FWC regarding market practices and considered Mr. Duda’s recommendations for officers other than himself.

After deliberation, the Compensation Committee decided to increase the salary of each of Messrs. Duda, Khoury, Kill and Koman by 3.0%. The Compensation Committee set Mr. Hrudicka’s salary in connection with hiring him as Chief Financial Officer. The Compensation Committee maintained Mr. Glandon’s salary at the same level for fiscal 2017 as fiscal 2016.

Annual Performance-Based Bonuses. In July 2016, our Compensation Committee established fiscal 2017 annual performance-based cash bonus opportunities for certain of our executive officers after considering the guideline benchmark target, the individual performance and experience of each executive, retention issues, internal pay equity and industry conditions. The Compensation Committee reviewed advice from FWC regarding market practices and considered Mr. Duda’s recommendations for officers other than himself. In setting the performance measures, our Compensation Committee considered, among other matters, past performance, the fiscal 2017 operating budget, Methode’s strategic plan, product development matters and general economic conditions. The Compensation Committee determined that 70% of the target annual performance-based cash bonus for Messrs. Duda, Hrudicka, Khoury and Koman would be basedover emphasis on a Company pre-tax income measure (as adjusted for acquisitions and related expenses and divestitures and related gains/losses and expenses) and 30% would be based on sales objectives and/or individual objectives. For Mr. Kill, 25% of the target annual performance-based cash bonus would be based on the Company pre-tax income measure and 75% would be based onsingle performance measures related to our Dabir Surface medical device products described below. metric.

26

The maximum amount payable with respect to the Company pre-tax income measure was set at 200% of the amount payable at the target level of performance in order to align the award with competitive practice among the peer group. Due to Mr. Koman’s retirement, he was entitled to a pro-rata payment of his annual bonus based on his retirement date and the performance achieved with respect to the measures described below. In connection with his hiring, Mr. Hrudicka was guaranteed a minimum bonus of $150,000 for fiscal 2017. The Compensation Committee did not provide for an annual performance-based bonus opportunity for Mr. Glandon for fiscal 2017.

Set forth below is an outline ofunder the annual performance-based cash bonus awards for fiscal 2017 performance, including the maximum bonus, the relevant performance measures and the bonus paid. As a resultbonuses is capped at 200% of Mr. Koman’s retirement, the amounts set forth below have been adjusted pro rata based on his September retirement date.

23 
target.


Executive
Maximum BonusPerformance Measures and Amounts Payable*Bonus Earned

Donald W. Duda

 

$1,217,383

(1) Achieve consolidated pre-tax income (as adjusted for business acquisitions or dispositions) of $104.0 million (threshold), $109.5 million (target) and $125.9 million (maximum), with $250,638, $501,276 and $1,002,551 payable at threshold, target and maximum, respectively. The Company achieved consolidated pre-tax income of $117.3 million and Mr. Duda earned $740,709.

(2) Achieve $60.0 million in certain new business annual sales with a minimum established pre-tax margin ($214,832 payable). The Company achieved annual sales of $74.0 million for such new business.

$955,541
John R. Hrudicka$504,900

(1) Achieve consolidated pre-tax income (as adjusted for business acquisitions or dispositions) of $104.0 million (threshold), $109.5 million (target) and $125.9 million (maximum), with $103,950, $207,900 and $415,800 payable at threshold, target and maximum, respectively. The Company achieved consolidated pre-tax income of $117.3 million and Mr. Hrudicka earned $307,203.

(2) Implement changes to the ERP system related to foreign currency conversions ($89,100 payable). This performance measure was achieved.

$396,303
Joseph E. Khoury$408,020

(1) Achieve consolidated pre-tax income (as adjusted for business acquisitions or dispositions) of $104.0 million (threshold), $109.5 million (target) and $125.9 million (maximum), with $84,004, $168,008 and $336,016 payable at threshold, target and maximum, respectively. The Company achieved consolidated pre-tax income of $117.3 million and Mr. Khoury earned $248,257.

(2) Achieve $60.0 million in certain new business annual sales with a minimum established pre-tax margin ($72,004 payable). The Company achieved annual sales of $74.0 million for such new business.

$320,261
Theodore P. Kill$263,210

(1) Achieve consolidated pre-tax income (as adjusted for business acquisitions or dispositions) of $104.0 million (threshold), $109.5 million (target) and $125.9 million (maximum), with $26,321, $52,642 and $105,284 payable at threshold, target and maximum, respectively. The Company achieved consolidated pre-tax income of $117.3 million and Mr. Kill earned $77,786.

(2) Achieve $2.0 million in revenue from our Dabir Surface medical device products ($78,963 payable). This performance measure was not met.

(3) Obtain a reimbursement code for our Dabir Surface medical device products ($78,963 payable). This performance measure was not met due to the Company’s decision to defer acceptance of the reimbursement code until a later year. After reviewing the basis for this decision, the Compensation Committee determined that it would be appropriate to approve the payout for fiscal 2017 with the understanding that Mr. Kill would not be eligible to be rewarded for the same performance in the future.

$156,749
Douglas A. Koman$175,788

(1) Achieve consolidated pre-tax income (as adjusted for business acquisitions or dispositions) of $104.0 million (threshold), $109.5 million (target) and $125.9 million (maximum), with $36,250, $72,499 and $144,999 payable at threshold, target and maximum, respectively. The Company achieved consolidated pre-tax income of $117.3 million and Mr. Koman earned $107,137.

(2) Implement changes to the ERP system related to foreign currency conversions ($31,171 payable). This performance measure was achieved.

$138,307

*               Payouts are interpolated for performance falling between established performance objectives.

Other Benefits and Perquisites. Our U.S.-based executive officers are eligible to participate in allA significant component of our employee benefit plans, such as medical, dental, vision, group life, disability and, as applicable, our 401(k) savings plan (with a company contribution equal to three percent (3%) of salary, subject to certain limitations), in each case,

24 

on the same basis as our other employees. Our U.S.-based executive officers are also provided deferred compensation opportunities through a non-qualified Deferred Compensation Plan. We have never contributed any amounts to the Deferred Compensation Plan on behalf of any of the named executive officers. For a description of the Deferred Compensation Plan, please see “Executive Compensation — Nonqualified Deferred Compensation,” below. In addition, a few perquisites are provided to the named executive officers. Perquisites include a company car allowance, professional association dues and provision for an annual physical exam.

Change of Control Arrangements. We have entered into change of control agreements with all of our named executive officers, other than Mr. Khoury, that provide certain benefits upon termination in connection with a change of control event, including Mr. Hrudicka upon his hiring in fiscal 2017. As a Lebanese resident, Mr. KhouryLTI Programs is entitled to certain payments in the event of his termination under the Lebanese Labor Laws. These change of control agreements are designed to promote stability and continuity of senior management if a change of control event were to occur, both of which are in the best interest of Methode and our shareholders. Our executives are not entitled to a gross-up payment for excise taxes under our change of control agreements. In addition, our change of control agreements are “double trigger” whereby the executives are only entitled to a severance payment if an executive is terminated without cause or an executive terminates for good reason subsequent to a change of control. Our change of control provisions for the named executive officers are summarized below under “Executive Compensation − Potential Payments Upon Termination or Change of Control.”

Fiscal 2016 Long-Term Incentive Program

During fiscal 2016, our Compensation Committee adopted a five-year, long-term incentive program consisting of a mix of 60% performance-based RSAs, at target performance, and 40% time-based RSUs (the “Fiscal 2016 LTI Program”). Mr. Hrudicka received an award under the Fiscal 2016 LTI Program in fiscal 2017. The number of RSAs earned will vary based on performance relative to established goals for threshold, target and maximum performance. Performance will be based on the Company’s earnings before net interest, taxes, fixed asset depreciation and intangible asset amortization (“EBITDA”) for fiscal 2020, subject to certain adjustments, including adjustments for certain acquisitions and divestitures. The RSUs are subject to a vesting period based on continued service with no RSUs vesting prior to the end of fiscal 2018, subject to acceleration in certain limited circumstances. The Compensation Committee intends for the Fiscal 2016 LTI Program to cover all long-term equity incentive grants to the participants through fiscal 2020.

A key consideration of the Compensation Committee in developing the Fiscal 2016 LTI Program was the success of the prior five-year, long-term incentive program which concluded as of the end of fiscal 2015 (the “Fiscal 2011 LTI Program”). The Fiscal 2011 LTI Program included performance-based RSAs, performance-based tandem cash awards, RSUs and stock options. During the five-year period of the Fiscal 2011 LTI Program, revenues grew at an annualized rate of 18.5%, which supported annualized pre-tax profit growth and diluted earnings per share growth of 73.0% and 47.5%, respectively. In addition, we realized strong annualized total shareholder return of 34.0% during the period. During this period, our industry-leading performance reflected the introduction of numerous new products and technologies, the benefits of selective licensing and other business arrangements, the expansion of lower-cost manufacturing facilities and further vertical integration The Compensation Committee concluded that the Fiscal 2011 LTI Program succeeded in focusing our executive officers on growing the Company and appropriately rewarded our executive officers for creating value for our shareholders.

The Compensation Committee intends for the Fiscal 2016 LTI Program to continue creating value for our shareholders using a long-term program that aligns pay with performance and includes a strong retention feature. In structuring the Fiscal 2016 LTI Program, the Compensation Committee considered the advice of FWC, its independent executive compensation consultant, regarding market practices, award mix and size, possible performance criteria and alternative program structures. The Compensation Committee also considered Mr. Duda’s recommendations for officers other than himself.

The Compensation Committee considered multiple approaches for the Fiscal 2016 LTI program, including the use of annual grants and alternative performance periods. After careful review, the Compensation Committee determined that the five-year program is appropriate after considering the success of the Fiscal 2011 LTI Program discussed above, as well as the lengthy sales and product development cycles and significant upfront capital requirements for many of the Company’s products. The Compensation Committee believes the five-year term will focus our executive officers on the Company’s long-term objectives and retain our top executive talent over the period.

25 

The Fiscal 2016 LTI Program is comprised entirely of equity awards in order to directly align the interests of our executive officers with those of our shareholders. The Compensation Committee believes that the award mix of 60% performance-based RSAs, at target performance, and 40% time-vested RSUs supports the Company’s operating performance and retention objectives, respectively. Unlike the Fiscal 2011 LTI Program,stockholders.

Our stock options and performance-based tandem cash awards are not components of the Fiscal 2016 LTI Program, in part due to accounting considerations, including the high costs ofownership policy requires significant stock options relative to historical grants. Instead, the Compensation Committee elected to place greater emphasis on the performance-based RSAs, which are subject to forfeiture if the performance goals are not met.

The Compensation Committee applied adjusted EBITDA as the RSA performance metric because it is one of the primary operating metrics trackedownership by the Company and its shareholders. The adjusted EBITDA performance goals set forth below align with the Company’s targeted 9% to 10% annual growth rate for EBITDA for the period. The adjustments to EBITDA for acquisitions and divestitures are designed to mitigate unintended windfalls to management for transactions and also to safeguard management from unintended penalties for shareholder-friendly transactions that negatively impact the fiscal 2020 performance results.

In general, the Compensation Committee targeted the Fiscal 2016 LTI Program awards in the 50th to 75th percentile range of competitive practice, which aligned with the Company’s relative positioning in terms of revenues, net income and market capitalization versus its peer group. In making these benchmarking determinations, the Compensation Committee assumed that each executive would achieve the target level of performance under the RSAs and included one-fifth of the grant date fair value of these shares in these comparative calculations. For Mr. Hrudicka, one-fourth of the grant date fair value of these shares was included due to his mid-cycle hiring date. In determining the size of the award to each of our executive officers theand directors.

Our Incentive Compensation Committee also considered other relevant factors, including the individual performance and experience of each executive, internal pay equity and consistency issues, expected future contributions of each executive, historicalRecoupment Policy requires us to recover incentive-based compensation levels and tenure.

The table below sets forth the number of target RSAs and RSUs awarded to Messrs. Duda, Hrudicka, Khoury, Kill and Koman (“Target Shares”). Mr. Glandon did not receive an award under the Fiscal 2016 LTI Program.


Executive
Number of Shares
Target RSAs*RSUs
Donald W. Duda180,000120,000
John R. Hrudicka48,00032,000
Joseph E. Khoury90,00060,000
Theodore P. Kill90,00060,000
Douglas A. Koman60,00040,000

* The number of shares earned will depend on performance and may be up to 150% of this number.

Performance-Based RSAs. The number of RSAs earned will vary based on performance relative to established goals for threshold performance, target performance and maximum performance. The executive will not earn any shares if threshold performance is not met. Performance will be based on the Company’s EBITDA for fiscal 2020, subject to certain adjustments. All positive EBITDA from acquisitions that close during the term of the program and that are not accretive in fiscal 2020 will be excluded. All positive EBITDA from acquisitions that close during fiscal 2019 or fiscal 2020 that are accretive in fiscal 2020 shall be included for purposes of determining fiscal 2020 EBITDA up to the target level and shall be excluded for purposes of determining fiscal 2020 EBITDA above the target level. For any divestitures approved by the Board during the period, the final four quarters of EBITDA from the divested business will be included in fiscal 2020 EBITDA. The performance measures and corresponding percentages of the target shares earned are set forth below.

Performance MeasureFiscal 2020 Adjusted EBITDAPercentage of Target RSAs Earned*
Threshold Performance$198.9 million50%
Target Performance$221.0 million100%
Maximum Performance$243.1 million150%

* Payouts are interpolated for performance falling between established performance measures.

26 

Dividends will not be paid on the RSAs until the shares have been earned. At such time, the executive will be entitled to a dividend equivalent payment based on the dividends declared during the restricted period and the number of shares earned.

In the event of an executive’s death or disability, he will earn all of the Target Shares. In the event of an executive’s qualified retirement, the executive will be eligible to earn a prorated number of shares based on the number of months during the 60-month performance period that have elapsed prior to retirement and Methode’s fiscal 2020 adjusted EBITDA. In connection with Mr. Koman’s retirement, he is eligible to earn 28.3% of his Target Shares at target performance. In the event of a change of control in which the successor company does not assume the RSAs, the executive will earn a prorated number of the Target Shares based on the number of months during the 60-month performance period that have elapsed prior to the change of control. If the successor company assumes the RSAs and, if the executive is terminated without cause or resigns for good reason within a period of time after the transaction (two years for Messrs. Duda and Hrudicka and one year for Messrs. Khoury and Kill), then the executive will earn a prorated number of the Target Shares based on the number of months during the 60-month performance period that have elapsed prior to termination of employment. The Compensation Committee believes these provisions regarding the treatment of the RSAs in the event of death, disability, retirement or a change of control reflect fairwe restate our financial statements due to material noncompliance.

‎Executive officers and reasonable treatment under these scenarios based on current governance best practicesdirectors are prohibited from pledging and competitive standards.

Time-Based RSUs. hedging our common stock.

The RSUs are subject to a vesting period based on continued service, with 30% vesting at the end of fiscal 2018, 30% at the end of fiscal 2019, and 40% vesting at the end of fiscal 2020. Following vesting, the delivery of the stock underlying the RSUs will be deferred until the earlier of the executive’s termination of employment or a change of control. Dividend equivalents will not be paid on the RSUs until the units have vested. Following vesting and until the delivery of the underlying common stock, each executive will be entitled to a quarterly payment in an amount equal to the aggregate per share cash dividend paid during the quarter multiplied by the number of vested RSUs held by the executive.

In the event of an executive’s death or disability, all unvested RSUs will become immediately and fully vested. In the event of an executive’s qualified retirement, a prorated number of RSUs will vest based on the months during the 60-month vesting period that have elapsed prior to retirement. In connection with Mr. Koman’s retirement, 11,333 of his RSUs vested. In the event of a change of control in which the successor companyCompany does not assume the RSUs, all unvested RSUs will become immediately and fully vested. If the successor company assumes the RSUs and, if the executive is terminated without cause or resigns for good reason within a period of time after the transaction (two years for Messrs. Duda and Hrudicka and one year for Messrs. Khoury and Kill), then all unvested RSUs will become immediately and fully vested. The Compensation Committee believes these provisions regarding the treatment of the RSUs in the event of death, disability, retirement or a change of control reflect fair and reasonable treatment under these scenarios based on current governance best practices and competitive standards.

provide excise tax gross-ups.

Significant Policies and Procedures

Stock Ownership PolicyGuidelines. Our Compensation Committee considers stock ownership by management and the directors to be an important means of linking management’stheir interests with those of our shareholders. After considering the importance ofstockholders. The guidelines for stock ownership our Compensation Committee maintains stock ownership guidelines for ouras a multiple of executive officers. The requirementsofficers’ base salaries are subject to a phase-in period in the event of a new hire or a promotion. Our Chief Executive Officer is expected to own stock with a value at least equal to six (6) times his base salary and all other executive officers are expected to own stock with a value at least equal to two (2) times their base salary. as follows:
Title
Guideline
Chief Executive Officer
Six times salary‎
Chief Operating Officer
Three times salary
Other Executive Officers‎
Two times salary
Vested and unvested time-based RSUs are included in the calculation of stock ownership for purposes of these guidelines. The value of each executive officer’s common stock holdings is determined as of the end of each fiscal year based on the average daily closing price of Methode’s common stock for such fiscal year. All of our named executive officers were in compliance with our stock ownership guidelines for fiscal 2017.

Insider Trading Policy2021, subject to the phase-in-period for new appointments and promotions.

Prohibition on Hedging and Pledging. Our Insider Trading Policy prohibits our directors, executive officers and certain key employees from engaging in certain transactions involving our common stock, including options trading, short sales, derivative transactions and hedging transactions. In addition, these directors, executive officers and key employees are prohibited from holding our common stock in a margin account or otherwise pledging our common stock as collateral for a loan.

Policy With Respect to Deductibility of Compensation. Section 162(m) of the Code generally denies corporate tax deductions for annual compensation exceeding $1 million paid to certain employees (generally the

27 

chief executive officer and the three other most highly compensated executive officers of a public company, but excluding the chief financial officer), unless that compensation qualifies as performance-based compensation under a shareholder approved plan and meets certain other technical requirements. While it is the general intention of our Compensation Committee to maximize deductibility, our Compensation Committee seeks to make decisions that are in the best interest of Methode and its shareholders, even if those decisions do not result in full deductibility under Section 162(m).

Clawback Policy. In the event we are required to restate our financial statements due to material noncompliance, our Incentive Compensation Recoupment Policy requires us to recover from our current or former executive officers certain amounts of incentive-based compensation paid within the prior three years.

years that were erroneously paid.

Market Benchmarking and Positioning of Fiscal 2021 Executive Compensation
We strive to provide compensation opportunities that are market competitive. In order to assist the Compensation Committee in achieving this objective for fiscal 2021, FW Cook was retained to conduct a review of our executive compensation peer group and benchmark our executive compensation program using a custom peer group and third-party survey data. The Compensation Committee considers this benchmarking information in reviewing each element of our compensation program.
After considering the advice of FW Cook, the Compensation Committee approved using the fiscal 2020 peer group subject to a few modifications for fiscal 2021. AVX Corporation was eliminated since it had been acquired. Three former peers, Dorman Products, Inc., Standard Motor Products, Inc. and Universal Electronics, Inc., were eliminated since they did not satisfy the Compensation Committee’s revised criteria for peer groups summarized below. Four new peer companies were added: Belden Corporation; Benchmark Electronics, Inc.; Delphi Technologies PLC; and Visteon Corporation. Each of the new peer companies satisfies the Compensation Committee’s revised criteria for the peer group.‎
27

The peer group used for benchmarking purposes in setting fiscal 2021 compensation was selected using the following revised criteria:
Size as measured by revenue – we generally targeted companies with revenue one-third to three times our annual revenue.
Size as measured by market capitalization – we generally targeted companies with market capitalization one-fourth to four times our market capitalization.
Similar-type businesses – we generally targeted companies that are multinational, compete against us for talent and engage in businesses with similar technology, products and markets.
For compensation decisions affecting fiscal 2021 compensation, the peer group included the following companies:
Belden Corporation
Gentherm Incorporated
OSI Systems, Inc.
Benchmark Electronics, Inc.
Kemet Corporation
Rogers Corporation
CTS Corporation
LCI Industries
Stoneridge, Inc.
Delphi Technologies PLC
Littelfuse, Inc.
TTM Technologies, Inc.
Franklin Electric Company, Inc.
MTS Systems Corporation
Visteon Corporation
In benchmarking our compensation program for fiscal 2021, the Compensation Committee also reviewed information compiled by FW Cook from major third-party executive pay surveys.
As a general policy, we targeted fiscal 2021 executive officer total compensation (salary, annual cash bonus and long-term incentive compensation), within the median range of competitive practice. ‎In making benchmarking determinations for fiscal 2021 compensation, the analysis assumed that each executive would achieve the target level of performance under the annual performance-based bonuses and RSA awards. In valuing the RSA and RSU awards outstanding under the 2015 LTI Program, the Compensation Committee included one-fifth of the target grant date fair value of these shares in the comparative calculations.
In setting each compensation component for our executive officers, the Compensation Committee considered the competitive market data, together with other relevant factors, including the individual performance, experience and strategic value of each executive, retention issues, internal pay equity and consistency issues, the Company’s performance, expected future contributions of each executive, historical compensation levels, tenure, promotions, and industry conditions. These and other factors may affect whether one or more of the compensation components for any of our executive officers is set above or below the median of competitive practice. In addition, annual cash bonus and long-term incentive compensation for one or more of our executive officers could be above or below this target range depending on the amounts earned under the performance-based awards.
Components of Fiscal 2021 Compensation
Each component of our compensation program is designed to help achieve our compensation objectives and to contribute to a compensation package that is competitive and appropriately rewards our executives for performance against annual and long-term performance objectives. Consistent with our pay-for-performance philosophy, our executive compensation program is generally structured so that a significant amount of each of our named executive officers’ compensation is variable compensation and “at risk” for non-payment if we fail, or the executive fails, to meet performance targets. Our annual performance-based bonuses and the RSA and Performance Unit awards under the 2021 LTI Program constitute variable compensation.
The table below sets forth details regarding the key elements of our ‎‎fiscal 2021 compensation program.
Component
Purpose
Salary
Attract, retain and motivate highly qualified executives.
Annual Performance-Based Bonuses
Provide a cash reward for contributing to the achievement of our short-term company objectives, and in certain cases, individual ‎objectives‎.
Transition Bonuses
Seek to retain key members of management in a highly competitive job market over multiple years in order to transition the Company from the pre-pandemic economy through the recovery.
28

Component
Purpose
LTI Program Awards
Focus the executive’s efforts on our long-term performance, encourage significant ownership of our common stock and assist in retention.
Other Benefits and Perquisites
Provide competitive levels of health and welfare protection and retirement and savings programs.
Salary. Our Compensation Committee establishes salaries on an annual basis taking into account the guideline benchmark range. In reviewing fiscal 2021 salaries for our named executive officers, our Compensation Committee considered the ongoing COVID-19 pandemic and reviewed advice from its independent compensation consultant regarding market practices and considered Mr. Duda’s recommendations for officers other than himself. In April 2020, the salaries of our named executive officers were reduced twenty percent (20%) in connection with cost-cutting measures related to the ‎COVID-19 pandemic. ‎In July 2020, the Compensation Committee decided not to increase the base salaries of our named executive officers for fiscal 2021 and to continue the twenty percent (20%) salary reduction. The executive officers’ full base salaries were reinstated at the end of August 2020 for Mr. Martin and in mid-September 2020 for our other named executive officers. In September 2020, the Compensation Committee increased Mr. Martin’s salary by approximately 14% in connection with his promotion to executive officer and the related increase in his responsibilities.‎‎
Annual Performance-Based Bonuses. In June and July of 2020, our Compensation Committee reviewed relevant information and data regarding possible performance measures and bonus opportunities for the executives’ fiscal 2021 annual performance-based bonuses.
In selecting the performance measures, the Compensation Committee considered the significant uncertainty regarding the impact of the COVID-19 pandemic on the Company’s business and financial results due to a variety of factors, including the duration and spread of the pandemic, governmental restrictions on business operations and international travel, the ability of our employees and global manufacturing facilities to operate efficiently and effectively, consumer demand, and the continued viability of our customers and suppliers. Additionally, the Compensation Committee considered the Company’s fiscal 2021 operating budget and strategic plan. After considering the significant pandemic uncertainties and challenges, the Compensation Committee adopted a performance measure for senior management that focused on the critical need to manage the impact of the COVID-19 pandemic instead of the pre-tax net income measure used in the past and which has since been reinstated for fiscal 2022. Additional performance measures for specific executives include securing awards for new product programs, as well as personal objectives related to our ESG and ERM programs, succession management and inventory management.
In setting the bonus opportunities, the Compensation Committee considered the guideline benchmark target, the individual performance and experience of each executive, retention issues, internal pay equity and industry conditions. The Compensation Committee reviewed advice from FW Cook regarding market practices and considered Mr. Duda’s recommendations for officers other than himself. The target amount payable was set at 100% of base salary for Mr. Duda, 75% for Mr. Khoury and 66% for our other executive officers. The threshold and maximum amounts payable were set at 50% and 200%, respectively, of the amount payable at the target level of performance, which aligns with competitive practice among our peer group.
Performance Measures Applicable to Multiple Executives. Set forth below is an outline of the performance measures applicable to multiple executives under the annual performance-based bonus awards.
Executives
Performance Measures
Donald W. Duda
Joseph E. Khoury
Andrea J. Barry
Secure new bookings for certain business with a minimum pre-tax margin. The performance levels are established based on the probability of securing bookings for the projected annual business opportunities offered by our customers based on their product development cycles. The performance levels are not established based on year-over-year growth as customer product development cycles vary significantly from year to year. The performance levels for such new business were $88.0 million at threshold, $93.0 million at target and $107.0 million at maximum. This performance measure was weighted at 70% of the target amount payable for these executives. The Company booked $161.5 million for such new business which caused these executives to earn 200% of their respective target bonus amount for this measure.
29

Executives
Performance Measures
Donald W. Duda
Ronald L.G. Tsoumas
Joseph E. Khoury
Andrea J. Barry
Effectively manage the impact of the COVID-19 pandemic on the Company as determined by the Compensation Committee based on criteria selected in early fiscal 2021. The Compensation Committee established that it would evaluate management’s performance based on actions taken on a global basis with respect to the following key areas: safety plans, staffing reorganization, supply chain management, cash management planning, succession planning and acquisition assessments. This performance measure was weighted at 30% of the target amount payable for Messrs. Duda and Khoury, 25% for Mr. Tsoumas and 15% for Ms. Barry.

In reviewing the actions taken by these executive officers to manage the COVID-19 pandemic and the relevant criteria, the Compensation Committee considered a variety of factors, including the following:

 • Safety. Management successfully prioritized the health and safety of the Company’s employees. The Company quickly implemented numerous safety protocols at its 40 global facilities, including its plants which were required to continue operating as essential businesses. The safety protocols related to hygiene and disinfections, testing, quarantines, contact tracing, social distancing, and personal protective equipment (PPE). At a time when supply of PPE was severely limited, management leveraged the Company’s global purchasing power to secure PPE for its entire workforce. Management rapidly implemented the sharing of best practices throughout the Company’s global facilities, resulting in effective and standardized safety guidelines and procedures, updated on a regular basis, promoting the health and safety of employees and enabling our facilities to remain open. As a result of these actions, the percentage of positive COVID-19 cases traceable to a Methode facility was extremely low and we were not required to shut down any of our facilities due to an outbreak among employees or by local authorities due to inadequate safety protocols.

 • Staffing. Management swiftly evaluated and redesigned the Company’s staffing requirements and structures to reflect the ongoing impact of the pandemic on the Company’s business and operations. Among other actions, management successfully implemented several important business consolidations and successfully managed pandemic-related labor issues at its facilities in Mexico. Management’s actions avoided significant interruption to our operations and resulted in substantial labor cost savings.

 • Supply Chain. Management effectively managed the Company’s global supply chain to minimize production and customer issues. The Company implemented processes to continuously monitor and strengthen the supply chain to proactively mitigate potential disruptions. As a result of these actions, and apart from issues related to the worldwide semi-conductor shortage, the Company did not experience any significant production issues during fiscal 2021. Additionally, the Company was able to fulfill its customer commitments at an exceptionally high level in spite of these challenges, and our strong customer satisfaction levels contributed to the Company’s record financial results.

 • Cash Management. Management instituted heightened and effective procedures and practices to successfully manage liquidity, cash, accounts receivable, accounts payable, capital expenditures and indebtedness during the pandemic.

 • Succession Planning. Management implemented an emergency succession plan to ensure continuity in the event a member of senior leadership was unable to serve due to COVID-19. The succession plan was vetted by the Nominating and Governance Committee in early fiscal 2021.

 • Acquisitions. Management continued to evaluate potential acquisition opportunities in support of Methode’s strategic priorities.

After thorough review, the Compensation Committee determined that these executive officers did an excellent job managing the unprecedented challenges and uncertainties of the COVID-19 pandemic on a global basis. The Compensation Committee noted that due to management’s timely and strategic response, the Company reported record net sales for fiscal 2021 despite the significant challenges from the COVID-19 pandemic. Because of these record results and based on management’s outstanding performance, the Compensation Committee approved the maximum level of payout‎ for this performance measure‎ and these executives each earned 200% of their respective target bonus amount for this measure.
30

Performance Measures Applicable to Individual Executives. Set forth below is an outline of the performance measures applicable to individual executives under the annual performance-based bonus awards.
Executive
Performance Measures
Ronald L.G. Tsoumas
(1) Achieve a net debt position of $141.5 million at threshold, $134.8 million at target and $114.5 million at maximum. For this purpose, net debt is defined as total debt minus cash. This performance measure was weighted at 50% of Mr. Tsoumas’ target bonus. As of the end of fiscal 2021, the Company’s net debt position was $6.9 million and Mr. Tsoumas earned 200% of his target bonus amount for this measure.

(2) Achieve at least two of the following objectives: (a) assist with the launch of a companywide ESG program to the satisfaction of the Nominating and Governance Committee and the CEO; (b) develop a robust ERM program to the satisfaction of the Nominating and Governance Committee and the CEO; (c) improve the global finance team and function, including expanding the use of the content management system and reducing turnover, to the satisfaction of the Audit Committee and the CEO; and (d) assist with the implementation of a new succession management/talent review process for the global finance team to the satisfaction of the CEO. This performance measure was weighted at 25% of Mr. Tsoumas’ target bonus. The target bonus will be earned if two or three objectives are achieved and the maximum bonus will be earned if all four objectives are achieved. All four objectives were achieved and Mr. Tsoumas earned 200% of his target bonus amount for this measure.
Andrea J. Barry
Achieve at least one of the following objectives: (a) complete the implementation of the Workday HR software system for all facilities in Mexico and India to the satisfaction of the CEO; and (b) implement the newly developed succession management and talent review process down to the vice president level on a global basis to the satisfaction of the CEO. This performance measure was weighted at 15% of Ms. Barry’s target bonus. The target bonus will be earned if one of these objectives is achieved and the maximum bonus will be earned if both objectives are achieved. Both objectives were achieved and Ms. Barry earned 200% of her target bonus amount for this measure.
Kevin M. Martin
(1) Secure new bookings for certain business in North America with a minimum pre-tax margin. The performance levels are established based on available development programs for these products, not on year-over-year growth. The performance levels for such new business were $53.8 million at threshold, $56.6 million at target and $65.1 million at maximum. This performance measure was weighted at 40% of Mr. Martin’s target bonus. The Company booked $69.1 million for such new business and Mr. Martin earned 200% of his target bonus‎ amount for this measure.

(2) Achieve EBITDA for a collection of business units at a threshold, target and maximum level of performance. This performance measure was weighted at 25% of Mr. Martin’s target bonus. The business units achieved EBITDA between the target and the maximum levels of performance and Mr. Martin earned 111% of his target bonus‎ amount for this measure.

(3) Complete the implementation of at least two of four systems and programs into the Grakon operations, including new product development systems, pricing models, and quotation programs, to the satisfaction of the CEO and the COO. This performance measure was weighted at 25% of Mr. Martin’s target bonus. The threshold bonus will be earned if two objectives are achieved, target bonus will be earned if three objectives are achieved and the maximum bonus will be earned if all four objectives are achieved. All four objectives were achieved and Mr. Martin earned 200% of his target bonus amount for this measure.

(4) Achieve inventory turns for the North American automotive business at a threshold, target and maximum level of performance as determined by the CEO and COO. This performance measure was weighted at 10% of Mr. Martin’s target bonus. The business achieved inventory turns below the threshold level of performance and Mr. Martin did not earn any of his target bonus amount for this measure.
31

Transition Awards. In June 2020, after considering the need to retain management talent in a highly competitive job market in order to transition the Company from the pre-pandemic economy through the extended recovery and to provide a bridge of unvested value for the period between the vesting of the 2015 LTI program awards and the adoption of the 2021 LTI Program, the Compensation ‎Committee granted transition awards to our named executive officers. The award is a cash opportunity equal to a multiple ‎of the executive’s fiscal 2021 base salary as follows: Mr. Duda, 2.0 times; Mr. ‎Khoury, 1.75 times; Mr. Tsoumas and Ms. Barry, 1.5 times; and Mr. Martin, 1.25 times.‎ The Compensation Committee determined that a cash award was appropriate after considering the Company’s cash flow, potential dilution, share preservation, the Company’s robust stock ownership guidelines and current executive stock ownership levels and the hold-until-retirement restricted stock units held by certain members of senior management, including our Chief Executive Officer. If the executive remains employed by the Company and maintains ‎satisfactory job ‎performance, forty percent (40%) of the transition award will be paid on ‎April 30, 2022,‎ and sixty percent (60%) will be paid ‎on April 29, 2023. If the executive is ‎‎terminated for cause, resigns or retires prior to April 29, 2023, the executive must repay any transition award amounts paid ‎prior to the ‎termination date.‎‎ If the executive is terminated without cause, dies or becomes disabled, the executive is entitled to any unpaid portion of the ‎transition award.‎‎ Additionally, if within two years of a change of control or during a period pending a change of control, the executive is terminated without good cause or the executive voluntarily terminates employment for good reason, the executive is entitled to any unpaid portion of the transition award.
2021 LTI Program. In September 2020, our Compensation Committee adopted a five-year, long-term incentive program (the “2021 LTI Program”) which consists of performance-based restricted stock awards (“RSAs”), performance units (“Performance Units”) and time-based restricted stock units (“RSUs”). The number of RSAs and Performance Units earned will be based on the achievement of established goals for the Company’s earnings before net interest, taxes, fixed asset depreciation and intangible asset amortization (“EBITDA”) for fiscal 2025. The RSUs are subject to a five-year vesting period based on continued service with no RSUs vesting prior to the end of fiscal 2023. The Performance Units represent an opportunity for the executives to receive a cash payment based on the price of our common stock only to the extent that fiscal 2025 EBITDA exceeds target performance for the RSAs. At the discretion of the Compensation Committee, the Performance Units may be settled in shares of our common stock.
After a comprehensive review of various design alternatives and market practices presented by the Compensation Committee’s independent executive compensation consultant, FW Cook, one of the critical determining factors the Compensation Committee considered in granting another five-year, long-term incentive program was the performance of the two prior five-year, long-term incentive programs which concluded as of the end of fiscal 2015 and fiscal 2020, respectively. Consistent with our prior five-year programs, the Compensation Committee intends these RSAs, Performance Units and RSUs to be the only equity-based awards made to our executive officers during this new five-year period which ends on May 3, 2025, i.e., fiscal 2021 through fiscal 2025.
After careful consideration, the Compensation Committee determined that another five-year program was appropriate after reviewing our shareholders’ strong say-on-pay support of the prior programs, the success of the prior programs, as well as the lengthy sales and product development cycles and significant upfront capital requirements for many of the Company’s products. The Compensation Committee considered the potential risks of the 2021 LTI Program and concluded that it does not create risks that are reasonably likely to have a material adverse effect on the Company. The Compensation Committee believed the longer term would focus our executive officers on the Company’s strategic long-term objectives, including the EV market, retain our top executive talent over the period in a highly competitive job market, and foster long-term strategic consistency, teamwork and collaboration among our executive officers.
The Compensation Committee believes the mix of 50% performance-based and 50% time-based awards supports the Company’s operating performance and retention objectives and is consistent with market practice. The Performance Units represent an opportunity for the executives to receive a cash payment based on the price of our common stock only to the extent that the Company’s fiscal 2025 EBITDA exceeds target performance for the RSAs in order to provide an additional stretch goal for outperformance. At the discretion of the Compensation Committee, the Performance Units may be settled in shares of ‎our common stock.
The Compensation Committee applied EBITDA, as adjusted, as the performance metric for the RSAs and the Performance Units because it is one of the primary operating metrics tracked by the Company and its stockholders. The target EBITDA performance goal set forth below aligns with the Company’s targeted EBITDA compound annual growth rate of approximately 8% for the five-year program period. Additionally, the inclusion of EBITDA from
32

accretive acquisitions is in line with the Company’s plans to grow organically and inorganically over the period. The adjustments to EBITDA for acquisitions and divestitures were designed to mitigate unintended windfalls to management for non-accretive acquisitions and to safeguard management from unintended penalties for stockholder-friendly divestitures that negatively impact the fiscal 2025 performance results. In order for an acquisition to qualify as accretive in fiscal 2025, the EBITDA of the acquired business must exceed the interest expense for the related debt and the net impact on earnings per share must be positive.
In general, the Compensation Committee targeted the 2021 LTI Program awards within the median range of competitive practice, as annualized over the five-year program period. In making these benchmarking determinations, the Compensation Committee assumed that each executive would achieve the target level of performance under the RSAs and included one-fifth of the market value of the RSA shares and RSUs in these comparative calculations. In determining the size of the award to each of our executive officers, the Compensation Committee also considered other relevant factors, including the individual performance and experience of each executive, internal pay equity and consistency issues, expected future contributions of each executive and historical compensation levels. The Compensation Committee considered Mr. Duda’s longevity and extensive service to the Company as our Chief Executive Officer for over fifteen years and his significant accomplishments.
The table below sets forth details regarding the target awards to the named executive officers. Consistent with our prior five-year programs, the Compensation Committee intends the RSAs, RSUs and Performance Units to be the only equity-based awards made to our executive officers during this new five-year period which ends on May 3, 2025, i.e., fiscal 2021 through fiscal 2025.
Executive
Number of Shares
Grant Date Market Value
Target RSAs
RSUs
Target RSAs*
RSUs
Donald W. Duda
375,000
375,000
$10,605,000
$10,605,000
Ronald L.G. Tsoumas
75,500
75,500
$2,135,140
$2,135,140
Joseph E. Khoury
144,000
144,000
$4,072,320
$4,072,320
Andrea J. Barry
52,500
52,500
$1,484,700
$1,484,700
Kevin M. Martin
50,500
50,500
$1,444,805
$1,444,805
*
In accordance with the accounting and SEC disclosure rules, the “Stock Awards” column of the Summary Compensation Table does not include any value attributable to the RSAs. For financial statement reporting purposes and based on the accounting rules, the Company will not record an expense for the RSAs until the Company determines with sufficient certainty that at least the threshold level of performance for fiscal 2025 EBITDA will be achieved. As noted above, the fiscal 2025 EBITDA target performance goal aligns with the Company’s targeted EBITDA compound annual growth rate of approximately 8% for organic and inorganic growth during the five-year program period and includes EBITDA from accretive acquisitions.
The table below sets forth details regarding the awards to the named executive officers for above-target performance.
Executive
Maximum Number of
Performance Units*
Donald W. Duda
187,500
Ronald L.G. Tsoumas
37,750
Joseph E. Khoury
72,000
Andrea J. Barry
26,250
Kevin M. Martin
25,250
*
Only earned in the event the Company’s fiscal 2025 EBITDA exceeds the RSA target performance goal.
RSAs. The RSAs may be earned based on the Company’s fiscal 2025 performance relative to established goals for threshold and target performance. The executives will not earn any shares of RSAs if threshold performance is not met. Performance will be based on Methode’s EBITDA for fiscal 2025, subject to certain adjustments, including adjustments for non-accretive acquisitions and divestitures.
The performance goals and corresponding percentages of RSAs eligible to be earned by these executives are set forth below. The target EBITDA performance goal aligns with the Company’s targeted EBITDA compound annual growth rate of approximately 8% for the five-year program period.
33

Performance Goal
Fiscal 2025 EBITDA, As Adjusted
Percentage of RSAs Earned*
Threshold Performance
$270 million
50%
Target Performance
$300 million
100%
*
Payouts are interpolated for performance falling between the threshold and target performance measures.
Dividends will not be paid on the RSAs until the shares have been earned. At such time, the executives will be entitled to a dividend equivalent payment based on the dividends declared during the restricted period and the number of shares earned.
In the event of an executive’s death or disability, the executive will earn all of the RSA shares. In general, in the event of an executive’s qualified retirement, the executive will be eligible to earn a prorated number of RSA shares based on the number of months elapsed since May 2, 2020 (the first day of fiscal 2021), and the Company’s fiscal 2025 EBITDA. If Mr. Duda retires after fiscal 2023, he will remain eligible to earn all of the RSA shares subject to the EBITDA achieved in fiscal 2025. In the event Messrs. Duda, Tsoumas or Khoury or Ms. Barry are terminated without cause after fiscal 2021 (as defined in the Company’s 2014 Long-Term Incentive Plan), the executive will be eligible to earn a prorated number of RSA shares based on the number of months ‎elapsed since May 2, 2020, and the EBITDA achieved in fiscal 2025‎.
In the event of a change of control of the Company in which either (i) the successor company does not assume or replace the RSAs or (ii) the successor company assumes or replaces the RSAs, and the executive is terminated without cause or resigns for good reason within the next two years, the executive will earn a prorated number of RSA shares. The proration for Messrs. Duda and Martin will be based on the number of months elapsed since the start of fiscal 2021. For Messrs. Tsoumas and Khoury and Ms. Barry, if the change of control or termination occurs in fiscal 2021, the executive will not earn any RSA shares and if it occurs in fiscal 2024 or 2025, the executive will earn all of the RSA shares. If the change of control or termination occurs in fiscal 2022 or 2023, the proration for Messrs. Tsoumas and Khoury and Ms. Barry will be based on the number of months elapsed since the start of fiscal 2021.
In accordance with the accounting and SEC disclosure rules, the “Stock Awards” column of the Summary Compensation Table does not include any value attributable to the RSAs. For financial statement reporting purposes and based on the accounting rules, the Company will not record an expense for the RSAs until the Company determines with sufficient certainty that at least the threshold level of performance for fiscal 2025 EBITDA will be achieved. As noted above, the fiscal 2025 EBITDA target performance goal aligns with the Company’s targeted EBITDA compound annual growth rate of approximately 8% for organic and inorganic growth during the five-year program period and includes EBITDA from accretive acquisitions.
Performance Units. If the Company’s fiscal 2025 EBITDA exceeds target performance, the executives are eligible to earn Performance Units based on performance relative to goals for target and maximum performance. The performance goals and corresponding percentages of Performance Units eligible to be earned by the executives are set forth ‎below.‎ The target EBITDA performance goal aligns with the Company’s targeted EBITDA compound annual growth rate of approximately 8% for the five-year program period.
Performance Goal
Fiscal 2025 EBITDA,
As Adjusted
Percentage of
Performance Units Earned*
Target Performance
$300 million
0%
Maximum Performance
$330 million
100%
*
Payouts are interpolated for performance falling between the target and maximum performance measures.
The ‎Performance Units will ‎‎be ‎settled and paid in cash based on the number of Performance Units earned and the price of the Company’s common stock at that time. At the discretion of the Compensation Committee, the Performance Units may be settled in shares of the Company’s common stock instead of cash.
Dividend equivalents will not be paid on any Performance Units settled in cash. If the Performance Units are settled in common stock, then the executives will be entitled to a dividend equivalent payment based on the dividends declared during the period between the date of the Committee’s decision to settle the Performance Units in common stock and the end of the restricted period, and the number of Performance Units earned. Dividend equivalents will not be paid on any Performance Units that are not earned.
34

In the event of an executive’s death or disability, or a change in control of the Company, all of the Performance Units will be forfeited to the Company. In general, in the event of an executive’s qualified retirement, the executive will be eligible to earn a prorated number of Performance Units based on the number of months elapsed since the start of fiscal 2021 and the Company’s fiscal 2025 EBITDA. If Mr. Duda retires after fiscal 2023, he will be eligible to earn all of the Performance Units subject to the fiscal 2025 EBITDA achieved. In the event Messrs. Duda, Tsoumas or Khoury or Ms. Barry are terminated without cause after fiscal 2021, the executive will be eligible to earn a prorated number of Performance Units based on the number of months ‎elapsed since the start of fiscal 2021, and the fiscal 2025 EBITDA achieved‎.
Time-Based RSUs. The RSUs are subject to a five-year vesting period based on continued service, with thirty percent (30%) vesting on April 29, 2023, and May 4, 2024, and forty percent (40%) vesting on May 3, 2025. Dividend equivalents will not be paid on the RSUs until the units have vested. At such time, the executives will be entitled to a dividend equivalent payment based on the dividends declared during the vesting period and the number of vested RSUs.
In the event of an executive’s death or disability, all unvested RSUs will become immediately and fully vested. In general, in the event of an executive’s qualified retirement, a prorated number of RSUs will vest based on the months elapsed since the start of fiscal 2021. If Mr. Duda retires after fiscal 2023, all unvested RSUs will immediately vest. ‎In the event Messrs. Duda, Tsoumas or Khoury or Ms. Barry are terminated without cause after fiscal 2021, the executive will earn a prorated number of RSUs based on the ‎‎number of months elapsed since the start of fiscal 2021.‎
In the event of a change of control of the Company in which either (i) the successor company does not assume or replace the RSUs or (ii) the successor company assumes or replaces the RSUs and then the executive is terminated without cause or resigns for good reason within two years, all unvested RSUs will become immediately and fully vested.
Other Benefits and Perquisites. Our U.S.-based executive officers are eligible to participate in all of our employee benefit plans, such as medical, dental, vision, group life, disability and, as applicable, our 401(k) savings plan (with a company contribution equal to three percent (3%) of salary, subject to certain limitations), in each case, on the same basis as our other employees. Our U.S.-based executive officers are provided deferred compensation opportunities through a non-qualified Deferred Compensation Plan. We have never contributed any amounts to the Deferred Compensation Plan on behalf of any of the named executive officers. For a description of the Deferred Compensation Plan, please see “Executive Compensation – Nonqualified Deferred Compensation,” below. In addition, a few perquisites are provided to the named executive officers. Perquisites may include a company car allowance, professional association dues and provision for an annual physical exam.
Change of Control Arrangements. We have entered into change of control agreements with Messrs. Duda, Tsoumas and Khoury and Ms. Barry that provide certain benefits upon termination in connection with a change of control event. These change of control agreements are designed to promote stability and continuity of senior management if a change of control event were to occur, both of which are in the best interest of the Company and our stockholders. These executives are not entitled to a gross-up payment for excise taxes under our change of control agreements. In addition, our change of control agreements are “double trigger” whereby these executives are only entitled to a severance payment if an executive is terminated without cause, or the executive terminates for good reason after a change of control. Our change of control provisions for these named executive officers are summarized below under “Executive Compensation − Potential Payments Upon Termination or Change of Control.”
Deductibility of Compensation
Internal Revenue Code Section 162(m) generally limits the deductibility of compensation in excess of $1 million paid to our named executive officers. Under the tax rules in effect before 2018, compensation that qualified as “performance-based” was deductible without regard to this $1 million limit. In prior years, the awards of options, performance-based RSAs, and annual performance-based cash bonuses to our named executive officers were structured in order to qualify for this performance-based compensation exception. However, the 2017 Tax Cuts and Jobs Act (the “Tax Act”), eliminated this performance-based compensation exception effective January 1, 2018, subject to a special rule that “grandfathers” certain prior awards. As a result, compensation that the Compensation Committee structured in 2017 and prior years with the intent of qualifying as performance-based compensation or otherwise being deductible under Section 162(m) that is paid on or after January 1, 2018 may not be fully deductible, depending on the application of the special grandfather rules. Moreover, from and after January 1, 2018, compensation awarded in excess of $1 million to our named executive officers generally will not be deductible.
35

Going forward, the Compensation Committee will continue to retain the flexibility to design compensation programs that are in the best long-term interests of the Company and our stockholders after considering a variety of factors, including deductibility.
36

COMPENSATION COMMITTEE REPORT

Our Compensation Committee has reviewed and discussed the Compensation Discussion and Analysis with management and, based on such review and discussion, our Compensation Committee recommended to our Board of Directors that the Compensation Discussion and Analysis be included in this proxy statement.

COMPENSATION COMMITTEE
Martha Goldberg Aronson, Chair
Bruce K. Crowther (Chair)‎

Warren L. Batts

Walter J. Aspatore‎
Brian J. Cadwallader
Darren M. Dawson

Isabelle C. Goossen
Paul G. Shelton

28 
37


EXECUTIVE COMPENSATION

TABLES

Summary Compensation Table

The following table sets forth certain summary information regarding the compensation awarded to, earned by or paid by us to, or for the account of, our Chief Executive Officer, our Chief Financial Officer our retired Chief Financial Officer and our three other most highly compensated executive officers (the “named executive officers”) for the three fiscal years ended April 29, 2017.

Name and

Principal Position

Fiscal

Year

Salary

($)

Bonus ($)(1)

Stock Awards

($) (2)

Option Awards

($) (2)

Non-Equity Incentive Plan

Compensation

($)

All Other
Compensation
($) (7)

Total

($)

    RSAs(3)RSUs(4) Tandem Cash (5)

Annual

Bonus (6)

  

Donald W. Duda

President and Chief Executive Officer

2017716,108----------955,541138,1691,809,818
2016695,588--6,080,4004,053,600----572,102311,11411,712,805
2015675,000115,000----599,6003,487,2001,147,500429,1306,453,430

John R. Hrudicka

Chief Financial Officer and
Vice President, Corporate Finance (8)

2017346,154--1,675,2001,116,800----396,30312,4813,546,938
          

Joseph E. Khoury

Senior Vice President (9)

2017362,518----------320,26114,482697,261
2016359,600--3,040,2002,026,800----184,12790,2215,700,948
2015352,32465,000----179,8801,046,160401,676107,3302,152,370
Theodore P. Kill, Vice President,
Worldwide Automotive Sales and
President of Dabir Surfaces
2017316,720----------156,74937,760511,229
2016310,034--2,704,5001,803,000----191,079113,8665,122,478
2015295,00065,000----179,8801,046,160230,100123,8801,940,020

Timothy R. Glandon

Vice President

2017295,000------------31,455326,455
2016295,000------------103,952398,952
2015295,00050,000----179,8801,046,160272,580119,0631,962,683

Douglas A. Koman

Retired Chief Financial Officer and

Vice President, Corporate Finance (8)

2017197,363----------138,30713,258348,928
2016365,855--2,026,8001,351,200----204,539223,8934,172,287
2015355,00090,000----239,8401,394,880362,165148,8172,590,702
          

May 1, 2021.
Name and
Principal Position
Fiscal
Year
Salary
($)(1)
Stock Awards
($)(2)
Non-Equity Incentive
Plan Compensation
($)(3)
All Other
Compensation ($)(4)
Total
($)
Donald W. Duda
President and Chief
Executive Officer
2021
725,596
10,605,000
1,565,600
435,358
13,331,554
2020
851,107
234,840
429,171
1,515,118
2019
759,719
455,832
174,027
1,389,578
Ronald L.G. Tsoumas
Chief Financial
Officer
2021
381,893
2,135,140
543,840
77,161
3,138,034
2020
467,504
81,576
80,978
630,058
2019
420,749
39,600
28,682
489,031
Joseph E. Khoury
Chief Operating
Officer(5)
2021
425,507
4,072,320
690,000
155,227
5,343,054
2020
460,005
103,500
148,249
711,754
2019
446,607
176,854
22,062
645,523
Andrea J. Barry
Executive Vice
President and Chief
Human Resources Officer
2021
283,639
1,484,700
403,920
20,819
2,193,078‎
Kevin M. Martin, Vice
President, North
America
2021
304,731
1,444,805
343,515
36,741
2,129,792‎‎
(1)
Reflects discretionary cash bonuses awardedFor fiscal 2021, the base salaries for our named executive officers were as follows: Mr. Duda, $782,800; Mr. Tsoumas, $412,000; Mr. Khoury, $446,608; Ms. Barry, $306,000; and Mr. Martin, $330,000 effective as of June 15, 2020. The amounts in earlythe table above reflect a 53-week fiscal 2015 byyear and a 20% ‎base salary reduction in connection with cost-cutting measures related to the Compensation Committee‎COVID-19 pandemic. The salary reduction terminated in lightAugust for Mr. Martin and in September for our other named executive officers.
(2)
Amounts include the grant date fair value of the Company’s strong fiscal 2014 performance.
(2)ReflectsRSA and RSU awards under the fair value at the date of grant.  The value is calculated2021 LTI Program determined in accordance with Accounting Standards Codification Topic 718, Stock Compensation (“ASC 718”). Details of the assumptions used in valuing the awards are set forth in Note 4the footnotes to our audited financial statements included in our Annual Report on Form 10-K for such fiscal year.
(3)These performance-based RSAs are eligible for vesting based on fiscal 2020 EBITDA relative to established goals for threshold, target and maximum performance.  At the time of the grants, we deemed achievement of target performance probable, and therefore the grant date fair values reflected above were calculated on that basis. If, instead, the RSA amounts had been calculated assuming the Company would achieve maximum performance, the grant date fair values for these RSAs would have been as follows: Mr. Duda, $9,120,600; Mr. Hrudicka, $2,512,800; Mr. Khoury, $4,560,300; Mr. Kill, $4,056,750 and Mr. Koman, $3,040,200.
(4)These10-K. The RSUs are generally subject to a five-year vesting period based on continued service, with 30% vesting at the end of fiscal 2018,2023, 30% vesting at the end of fiscal 20192024 and 40% vesting at the end of fiscal 2020.2025. The RSUsRSAs are eligible for vesting based on fiscal 2025 EBITDA, as adjusted, relative to established goals for threshold and target performance. In accordance with the SEC disclosure rules, the aggregate grant date fair value of the RSAs has been determined based on the probable satisfaction of the fiscal 2025 EBITDA performance conditions at the date of grant. In accordance with ASC 718, the grant date fair value of the RSAs is zero because the Company will not eligiblerecord an expense for the RSAs until the Company determines with sufficient certainty that at least the threshold level of performance for fiscal 2025 EBITDA will be achieved. The aggregate grant date fair value of the RSAs if they were to be converted into common stock until a changevest at the target level of control or the executive officer leaves Methode.
(5)Reflects amounts paid under the performance-based Tandem Cash Awards under theperformance would have been as follows: Mr. Duda, $10,605,000; Mr. Tsoumas, $2,135,140; Mr. Khoury, $4,072,320; Ms. Barry, $1,484,700; and Mr. Martin, $1,444,805. Additional details regarding these awards are set forth in “Compensation Discussion and Analysis – Components of Fiscal 20112021 Compensation – 2021 LTI Program.
(6)(3)
Amounts reflect annual performance-based cash bonuses. Additional details regarding these bonus awards are set forth in “Compensation Discussion and Analysis – Components of Fiscal 2021 Compensation – Annual Performance-Based Bonuses‎.”
(7)(4)
Amounts included in All Other Compensation reflect the following for fiscal 2017:2021:

Executive

Vested

RSU Dividend Equivalents ($)

401(k) Contribution ($)

Life Insurance

($)

Car Allowance ($)Executive Physical ($)Gift Card ($)
Mr. Duda112,8267,9503,5649,6004,17950
Mr. Hrudicka07,95042804,05350
Mr. Khoury10,8000003,6820
Mr. Kill10,8007,9503,04812,0003,91250
Mr. Glandon10,8007,9505528,4003,75350
Mr. Koman3,6004,3101,3484,00000

Executive
Vested
RSU Dividend
Equivalents ($)
401(k)
Contribution
($)
Life
Insurance
($)
Car
Allowance ($)
Mr. Duda
413,879
8,700
3,179
9,600
Mr. Tsoumas
60,877
8,700
1,584
6,000
Mr. Khoury
155,227
Ms. Barry
11,096
8,700
1,023
Mr. Martin
16,426
8,700
815
10,800
29 

(5)
In addition, for Mr. Koman, includes payments of $5,417 pursuant to the Consulting Agreement described in footnote (8) below.
(8)Effective as of July 25, 2016, Mr. Koman resigned as Chief Financial Officer and Mr. Hrudicka was hired and appointed to such office.  Mr. Koman retired as an employee of the Company on September 15, 2016.  On September 16, 2016, the Company and Mr. Koman entered into a Consulting Agreement pursuant to which Mr. Koman agreed to provide consulting services to the Company and was paid $250 per hour for such services.  This Consulting Agreement terminated on July 28, 2017.
(9)

Mr. Khoury is a Lebanese residentresident. In fiscal 2019 and 2020 we paid Mr. Khoury’s cash compensation in Euros. For purposes of the Summary Compensation Table, this cash compensation was converted from Euros to U.S. Dollars using the average exchange rate of 1.30481.1498 for fiscal 2015; 1.10852019 and 1.1083 for fiscal 2016; and 1.0926 for fiscal 2017.

2020.

38

Grants of Plan-Based Awards

The following table sets forth certain information regarding grants of plan-based awards to the named executive officers during the fiscal year ended April 29, 2017.

Name

Grant

Date

Estimated Future Payouts Under

Non-Equity Incentive Plan Awards(1)

Estimated Future Payouts Under Equity Incentive Plan Awards(2)All Other Stock Awards: Number of Shares of Stock or Units(3)

Grant

Date Fair Value of Stock and Option Awards

($) (4)

Threshold

($)

Target

($)

Maximum

($)

Threshold (#)Target (#)Maximum (#)
Donald W. Duda7/12/2016465,470716,1081,217,383----------
         
John R. Hrudicka7/25/2016193,050297,000504,90024,00048,00072,00032,0002,792,000
         
Joseph E. Khoury7/12/2016156,008240,012408,020----------
         
Theodore P. Kill7/12/2016184,247210,568263,210----------
         
Timothy R. Glandon7/12/2016----------------
         
Douglas A.7/12/201667,376103,653175,788----------
Koman         

May 1, 2021.
 
 
Estimated Future Payouts Under Non-Equity
Incentive Plan Awards
Estimated Future Payouts Under Equity
Incentive Plan Awards
All Other
Stock
Awards:
Number
of Shares
of Stock
or Units
Grant
Date Fair
Value of
Stock and
Option
Awards
($)(5)
Name
Grant
Date
Threshold
($)
Target
($)
Maximum
($)
Threshold
(#)
Target
(#)
Maximum
(#)
Donald W. Duda
9/27/2020(1)
187,500
375,000
375,000
0
9/27/2020(2)
0
5,032,500
9/27/2020(3)
375,000
10,605,000
7/7/2020(4)
391,400
782,800
1,565,600
Ronald L.G. Tsoumas
9/27/2020(1)
37,750
75,500
75,500
0
9/27/2020(2)
0
1,067,570
9/27/2020(3)
75,500
2,135,140
7/7/2020(4)
135,960
271,920
543,840
Joseph E. Khoury
9/27/2020(1)
72,000
144,000
144,000
0
9/27/2020(2)
0
2,036,160
9/27/2020(3)
144,000
4,072,320
7/7/2020(4)
172,500
345,000
690,000
Andrea J. Barry
9/27/2020(1)
26,250
52,500
52,500
0
9/27/2020(2)
0
742,350
 
 
 
 
 
9/27/2020(3)
52,500
1,484,700
7/7/2020(4)
100,980
201,960
403,920
Kevin M. Martin
9/29/2020(1)
25,250
50,500
50,500
0
9/29/2020(2)
0
722,402
9/29/2020(3)
50,500
1,444,805
9/16/2020(4)
108,900
217,800
435,600
(1)
Reflects the performance-based RSAs awarded under the 2021 LTI Program. Additional details regarding these awards are set forth in “Compensation Discussion and Analysis – Components of Fiscal 2021 Compensation – 2021 LTI Program.”‎
(2)
Reflects the Performance Units awarded under the 2021 LTI Program. Amounts shown have been determined based on the closing price for the Company’s common stock on the grant date, or if no trading occurred on such date, the closing price on the following date. Additional details regarding these awards are set forth in “Compensation Discussion and Analysis-2021 LTI Program.”‎
(3)
Reflects the time-based RSUs awarded under the 2021 LTI Program. Additional details regarding these awards are set forth in “Compensation Discussion and Analysis – Components of Fiscal 2021 Compensation – 2021 LTI Program.”‎
(4)
Reflects the annual performance-based cash bonus awards pursuant to the Methode Electronics, Inc. 2014 Omnibus Incentive Plan (the “2014 Plan”).   The executive officers’ bonus amounts are based on achieving certain performance measures.  For purposes of this table, for any award components that include only one level of performance, we have included such amount in each of the threshold, target and maximum columns.  For Mr. Koman, the amounts set forth above have been adjusted pro rata based on his retirement date.awards. Amounts earned in fiscal 20172021 by the executive officers under this award are reported in “Compensation Discussion and Analysis” and in the column titled “Non-Equity Incentive Plan Compensation-Annual Bonus” in the “Summary Compensation Table.” DetailsAdditional details regarding these bonus awards including the relevant performance measures, are set forth in “Compensation Discussion and Analysis.Analysis – Components of Fiscal 2021 Compensation – Annual Performance-Based Bonuses‎.
(2)Reflects restricted stock awards granted pursuant to the 2014 Plan which are eligible for vesting based on the achievement of certain financial targets for fiscal 2020 EBITDA.  The unvested restricted stock awards are not entitled to payment of dividends, provided that at the time the shares vest, the executive is entitled to a payment based on the dividends declared during the restricted period and the number of shares earned.
(3)Reflects restricted stock units granted pursuant to the 2014 Plan.  These restricted stock units vest 30% on each of April 28, 2018 and April 27, 2019 and 40% on May 2, 2020, provided that the named executive officer remains a Methode employee.  The unvested restricted stock units are not entitled to payment of dividends until they vest.  The restricted stock units are not eligible to be converted into common stock until a change in control or the executive officer leaves Methode.
(4)(5)
Amounts representshown includes the grant date fair value as of the date of grant calculatedRSA and RSU awards under the 2021 LTI Program determined in accordance with ASC 718. Details of the assumptions used in valuing these optionsthe awards are set forth in Note 4the footnotes to our audited financial statements included in our Annual Report on Form 10-K for such fiscal year. In accordance with the SEC disclosure rules, the aggregate grant date fair value of the RSAs has been determined based on the probable satisfaction of the fiscal year ended April 29, 2017.2025 EBITDA performance conditions at the date of grant. In accordance with ASC 718, the grant date fair value of the RSAs is zero because the satisfaction of the required performance condition was not deemed probable as of the grant date.‎

30 
Fiscal 2021 Incentive Awards

Alternative SummaryIn fiscal 2021, the Compensation Table

Committee awarded the named executive officers an annual performance-based bonus award, and long-term incentive awards under the 2021 LTI Program.

Annual Performance-Based Bonus Awards. As discussed in “Compensationthe Compensation Discussion and Analysis-Fiscal 2016 Long-Term Incentive Program,” inAnalysis, during fiscal 2016,2021, each of the named executive officers was awarded an annual performance-based cash bonus opportunity. The target amount payable was set at 100% of base salary for Mr. Duda, 75% for Mr. Khoury and 66% for our Compensation Committee adopted a five-year, long-term equity incentive program consisting of a mix of 60% performance-based RSAs, at target performance, and 40% time-based RSUs (the “Fiscal 2016 LTI Program”). Mr. Hrudicka received an award under the Fiscal 2016 LTI Program in fiscal 2017.other
39

named executive officers. The number of RSAs earned will vary based on performance relative to established goals for threshold target and maximum performance. Performance will be based on the Company’s earnings before net interest, taxes, fixed asset depreciationamounts payable were set at 50% and intangible asset amortization (“EBITDA”) for fiscal 2020, subject to certain adjustments for acquisitions and divestitures. The RSUs are subject to vesting based on continued service with no RSUs vesting prior to the end of fiscal 2018, subject to acceleration in certain limited circumstances. The Compensation Committee intends for the Fiscal 2016 LTI Program to cover all long-term equity incentive grants to the participants through fiscal 2020.

A key consideration200%, respectively, of the Compensation Committee in developing the Fiscal 2016 LTI Program was the success of the prior five-year, long-term incentive program adopted in fiscal 2011 (the “Fiscal 2011 LTI Program”). The Fiscal 2011 LTI Program included performance-based RSAs, performance-based tandem cash awards, RSUs and stock options. The vesting of the performance-based RSAs and tandem cash awards were based on the achievement of internal enterprise value hurdles at the end of fiscal 2015. The time-based RSUs vested annually through fiscal 2015. Stock options were granted annually from fiscal 2011 through fiscal 2015.

Under the SEC’s proxy statement disclosure rules, the grant date fair value of the number of RSAs eligible for vestingamount payable at the target level of performance. The annual performance measures included new business bookings, management of the uncertainties and challenges of the total number of RSUs awarded underCOVID-19 pandemic, financial objectives, and individual performance objectives. The amounts paid to the Fiscal 2016 LTI Program has been reportednamed executive officers pursuant to these awards are included in the Summary Compensation Table above in fiscal 2016 for Messrs. Duda, Khoury, Kill and Koman and in fiscal 2017 for Mr. Hrudicka. The amounts earned pursuant to the performance-based tandem cash awards under the column captioned “Non-Equity Incentive Plan Compensation.” Please see “Components of Fiscal 2011 2021 Compensation – Annual Performance-Based Bonuses‎”‎ in the Compensation Discussion and Analysis above for further information regarding these awards.

2021 LTI Program have been reportedAwards. As discussed in the Summary Compensation Table aboveDiscussion and Analysis, in fiscal 2015.

The Company is presenting the following Alternative Summary Compensation Table in order to illustrate howSeptember 2020, the Compensation Committee views annualized total compensation underadopted the Fiscal 2016 LTI Program and the Fiscal 20112021 LTI Program. ThePlease See “Components of Fiscal 2021 Compensation Committee believes that due to the front-loaded nature of the RSA and RSU awards and the reporting of the total tandem cash award values in fiscal 2015, the compensation amounts disclosed– 2021 Long-Term Incentive Program” in the Summary Compensation TableDiscussion and Analysis above for our named executive officers other than Mr. Hrudicka overstate compensation attributable to fiscals 2015 and 2016 and understate compensation attributable to fiscal 2017. For Mr. Hrudicka, the Compensation Committee believes that the compensation amounts disclosed in the Summary Compensation Table overstate his fiscal 2017 compensation.

The values inadditional information regarding this table differ from the values disclosed in the Summary Compensation Table on page 29 of this proxy statement in that the value of the RSAs and the RSUs have been annualized equally over the respective five-year periods of the programs. For Mr. Hrudicka, the value of the grants has been annualized over four years due to his mid-cycle hiring date. In addition, the amounts earned under the tandem cash awards and reported entirely as fiscal 2015 compensation in the Summary Compensation Table have been annualized, with one-fifth of the value reported in fiscal 2015. In both the Summary Compensation Table and the Alternative Summary Compensation Table, the values for the RSA and RSU awards reflect grant date fair values calculated in accordance with the applicable accounting rules. The Alternative Summary Compensation Table below has been revised as described and does not comply with SEC rules for the Summary Compensation Table. Shareholders should not view this alternative table as a substitute for the Summary Compensation Table on page 30 and should review this Alternative Summary Compensation Table together with the Summary Compensation Table and other compensation tables contained herein that have been prepared in accordance with SEC rules.

31 
program.

Alternative Summary Compensation Table

Name and

Principal Position

Fiscal

Year

 

 

Salary ($)

Bonus ($) (1)

Annualized Value of

Stock Awards ($)(2)

 

Option Awards ($)(3)

Non-Equity Incentive Plan Compensation ($)All Other Compensation ($)(10)Total ($)
    RSAsRSUs Annualized Value of Tandem Cash (8)

Annual

Bonus (9)

  

Donald W. Duda

President and Chief Executive Officer

2017716,108--1,216,080(4)810,720(5)----948,700138,1693,836,618

2016

2015

695,598

675,000

--

115,000

1,216,080(4)

388,000(6)

810,720(5)

194,000(7)

--

599,600

--

697,440

572,102

1,147,500

311,114

429,130

3,605,614

4,245,670

John R. Hrudicka

Chief Financial Officer and Vice President, Corporate Finance (11)

2017346,154--418,800(4)279,200(5)----396,30312,4811,452,938
          
          
          

Joseph E. Khoury

Senior Vice President (12)

2017362,518--608,040(4)405,360(5)----320,26114,4821,710,661

2016

2015

359,600

352,324

--

65,000

608,040(4)

116,400(6)

405,360(5)

58,200(7)

--

179,880

--

209,232

184,127

401,676

90,221

107,330

1,647,348

1,490,042

Theodore P. Kill

Vice President, Worldwide Automotive Sales and President of Dabir Surfaces

2017316,720--540,900(4)360,600(5)----156,74937,7601,412,279
2016310,034--540,900(4360,600(5)----191,079113,8661,516,479
2015295,00065,000116,400(6)58,200(7)179,880209,232230,100123,8801,277,692

Timothy R. Glandon

Vice President

2017295,000------------31,455326,455

2016

2015

295,000

295,000

--

50,000

--

116,400(6)

--

58,200(7)

--

179,880

--

209,232

--

272,580

103,952

119,063

398,952

1,300,355

Douglas A. Koman

Retired Chief Financial Officer and

Vice President, Corporate Finance (11)

2017197,363--405,360(4)270,240(5)----138,30713,2581,024,528
2016365,855--405,360(4)270,240(5)----204,539223,8931,469,887
2015355,00090,000155,200(6)77,600(7)239,840278,976362,165148,8171,707,598
          
    
 (1)Reflects discretionary cash bonuses awarded in early fiscal 2015 by the Compensation Committee in light of the Company’s strong fiscal 2014 performance. 
 (2)Reflects the annualized fair value at the date of grant.  See footnotes (2), (3) and (4) of the Summary Compensation Table for additional information. 
 (3)Reflects the fair value at the date of grant.  See footnote (2) to the Summary Compensation Table for additional information. 
 (4)These performance-based RSAs are eligible for vesting based on fiscal 2020 EBITDA relative to established goals for threshold, target and maximum performance.  The grant date fair values reflected above were calculated assuming the achievement of the target level of performance. 
 (5)These RSUs are subject to vesting based on continued service, with 30% vesting at the end of fiscal 2018, 30% vesting at the end of fiscal 2019 and 40% vesting at the end of fiscal 2020.  The RSUs are not eligible to be converted into common stock until a change of control or the executive officer leaves Methode. 
 (6)These performance-based RSAs vested based on fiscal 2015 internal enterprise value relative to established goals for threshold and target performance.    
 (7)These RSUs vested 20% each year on the last day of Methode’s fiscal year from fiscal 2011 through fiscal 2015.  The vested RSUs are not eligible to be converted into common stock until a change of control or the executive officer leaves Methode. 
 (8)Reflects the annualized amounts paid under the performance-based tandem cash awards under the Fiscal 2011 LTI Program.   
 (9)Amounts reflect annual performance-based cash bonuses. 
 (10)See footnote (7) of the Summary Compensation Table for information regarding the amounts included in All Other Compensation. 
 (11)See footnote (8) of the Summary Compensation Table for information regarding the hiring of Mr. Hrudicka and Mr. Koman’s retirement. 
 (12)Mr. Khoury is a Lebanese resident and we paid Mr. Khoury’s cash compensation in Euros.   For purposes of the Alternative Summary Compensation Table, this cash compensation was converted from Euros to U.S. Dollars.  See footnote (9) of the Summary Compensation Table for information regarding the exchange rates. 
                 
32 

Outstanding Equity Awards at Fiscal Year-End

The following table sets forth certain information regarding the outstanding equity awards of the named executive officers at April 29, 2017.

NameOption AwardsStock Awards

Number of Securities Underlying Unexercised Options

(#)

Exercisable

Number of Securities Underlying Unexercised Options

(#)

Unexercisable

Option Exercise Price

($)

Option Expiration DateNumber of Shares or Units of Stock That Have Not Vested (#)(2)Market Value of Share of Units of Stock That Have Not Vested ($)(3)Equity Incentive Plan Awards: Numbers of Unearned Shares, Units or Other Rights That Have Not Yet Vested (#)(4)Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Yet Vested ($)(3)
Donald W. Duda26,66713,333(1)37.017/7/2024120,0005,346,000270,00012,028,500
John R. Hrudicka---- ----32,0001,425,60072,0003,207,600
Joseph E. Khoury8,0004,000(1)37.017/7/202460,0002,673,000135,0006,014,250
Theodore P. Kill---- ----60,0002,673,000135,0006,014,250
Timothy R. Glandon8,0004,000(1)37.017/7/2024--------
Douglas A. Koman---- --------25,4991,135,980

May 1, 2021.
 
Option Awards(1)
Stock Awards
Name
Number of
Securities
Underlying
Unexercised
Options
(#)
Exercisable
Number of
Securities
Underlying
Unexercised
Options
(#)
Unexercisable
Option
Exercise
Price
($)
Option
Expiration
Date
Number of
Shares or
Units of
Stock That
Have Not
Vested (#)(2)
Market
Value of
Share of
Units of
Stock That
Have Not
Vested ($)(3)
Equity
Incentive
Plan
Awards:
Numbers of
Unearned
Shares,
Units or
Other Rights
That Have
Not Yet
Vested (#)(4)
Equity
Incentive
Plan
Awards:
Market or
Payout
Value of
Unearned
Shares,
Units or
Other Rights
That Have
Not Yet
Vested ($)(3)
Donald W. Duda
40,000
0
37.01
7/7/2024
375,000
16,848,750
375,000
16,848,750
Ronald L.G. Tsoumas
8,000
0
37.01
7/7/2024
75,500
3,392,215
75,500
3,392,215
Joseph E. Khoury
12,000
0
37.01
7/7/2024
144,000
6,469,920
144,000
6,469,920
Andrea J. Barry
52,500
2,358,825
52,500
2,358,825
Kevin M. Martin
50,500
2,268,965
50,500
2,268,965
(1)
These options were granted in July 7, 2014. One-third of these options vestvested on each of the first, second and third anniversaries of the grant date.
(2)
These RSUs are generally subject to a five-year vesting period based on continued service, with 30% vesting at the end of fiscal 2018,2023, 30% vesting at the end of fiscal 20192024 and 40% vesting at the end of fiscal 2020.2025. Additional details regarding these awards are set forth in “Compensation Discussion and Analysis – Components of Fiscal 2021 Compensation – 2021 LTI Program.”‎
(3)
Calculated based on the closing price of the Company’s common stock on April 28, 201730, 2021 of $44.55$44.93 per share.
(4)
These performance-based restricted stock awardsRSAs are eligible for vesting based on the achievementfiscal 2025 EBITDA, as adjusted, relative to established goals for threshold and target performance Additional details regarding these awards are set forth in “Compensation Discussion and Analysis – Components of certain financial targets for fiscal 2020 EBITDA.Fiscal 2021 Compensation – 2021 LTI Program.”‎

Option Exercises and Stock Vested

The following table sets forth certain information regarding option exercises by the

None of our named executive officers exercised stock options in fiscal 2021 and the vestingnone of our named executive officers hold restricted stock or restricted units that vested during fiscal 2017.

NameOption AwardsStock Awards
Number of Shares Acquired on Exercise (#)

Value Realized on Exercise

($) (1)

Number of Shares Acquired on Vesting (#) (2)

Value Realized on Vesting

($) (3)

Donald W. Duda40,000841,938----
John R. Hrudicka--------
Joseph E. Khoury16,000429,609----
Theodore P. Kill12,000226,452----
Timothy R. Glandon12,000236,381----
Douglas A. Koman42,666615,23011,333393,255

(1)Calculated based on market value of Methode’s common stock at the time of exercise, minus the exercise cost.
(2)Reflects RSUs awarded pursuant to our Fiscal 2016 LTI Program.  These shares vested in connection with Mr. Koman’s retirement in September 2016.
(3)Calculated based on the closing price of Methode’s common stock on September 15, 2016 of $34.70 per share.

33 
2021.
40


Nonqualified Deferred Compensation

The following table sets forth certain information regarding deferred compensation with respect to the named executive officers for fiscal 2017.

Name

Executive Contributions in Last Fiscal Year

($) (1)

Registrant Contributions in Last Fiscal Year

($)

Aggregate Earnings in Last

Fiscal Year

($)

Aggregate Withdrawals/ Distributions

($) (2)

Aggregate Balance at Last Fiscal Year-End

($)

 
Donald W. Duda0090031,071 
John R. Hrudicka00000 
Joseph E. Khoury00000 
Theodore P. Kill29,4500143,87401,203,393 
Timothy R. Glandon0060,473(122,408)423,416 
Douglas A. Koman00255,479(143,295)1,431,539 
 (1) All executive contributions were reported as compensation in the “Summary Compensation Table” under the “Salary” and/or “Non-Equity Incentive Plan Compensation” columns, depending on the source of the executive contribution.
 (2) Reflects distributions in accordance with the terms of each executive’s deferral election.
          

2021.

Name
Executive
Contributions in
Last Fiscal Year
($)(1)
Registrant
Contributions in
Last Fiscal Year
($)
Aggregate
Earnings in Last
Fiscal Year
($)
Aggregate
Withdrawals/
Distributions
($)(2)
Aggregate Balance
at Last Fiscal Year-
End
($)
Donald W. Duda
0
0
4
0
32,492
Ronald L.G. Tsoumas
31,252
0
2,601
0
1,223,102
Joseph E. Khoury
0
0
0
0
0
Andrea J. Barry
59,164
0
107,634
0
412,087
Kevin M. Martin
0
0
0
0
0
(1)
All executive contributions were reported as compensation in the “Summary Compensation Table” under the “Salary” and/or “Non-Equity Incentive Plan Compensation” columns, depending on the source of the executive contribution.
(2)
Reflects distributions in accordance with the terms of each executive’s deferral election.
The Methode Electronics, Inc. Nonqualified Deferred Compensation Plan (the “Deferred Compensation Plan”) allows a select group of management and highly compensated employees to defer up to 75% of their annual base salary and/or 100% of their annual bonus, and/or 100% of their tandem cash award, if applicable, with an aggregate minimum deferral of $3,000. Directors are allowed to defer up to 100% of their director compensation paid in cash or shares of Common Stock. The minimum period of deferral is three years. Participants are immediately 100% vested.

In addition to employee-directeddirected deferrals, we may make contributions to the Deferred Compensation Plan to make up for limits applicable under our qualified plans and may make additional discretionary contributions as well. Participants vest in company contributions in accordance with the schedule set forth in the applicable agreement or plan governing such contributions. We made no contributions to the Deferred Compensation Plan in fiscal 2017.

2021.

Participants may elect from a list of certain mutual funds to determine any amounts credited or debited from their accounts, although we are under no obligation to invest the deferred amounts in any specified fund. This list is made available to all participants and account balances are credited or debited based on the current market rates for these funds. Participants may reallocate account balances and/or future deferrals on a daily basis.

daily.

Participants are entitled to receive a distribution from their account balances at the earlier of the end of the elected deferral period or retirement, disability, termination of employment or a change of control. Accounts are distributed in a lump sum or, in certain circumstances, in installments over a period of up to 15 years. Participants can also petition the Compensation Committee to receive a full or partial payout from the Deferred Compensation Plan in the event of an unforeseeable financial emergency.

34 

Potential Payments Upon Termination or a Change of Control

In the event our named executive officers are terminated or Methode undergoes a change of control, our named executive officers are entitled to certain payments under their change of control agreements our stock plans and certain other benefit plans.

The following table summarizes payments payable to our named executive officers upon a change in control or the executive’s death, disability or qualified retirement under our outstanding equity and cash bonus awards.

Type of AwardTermination Scenario
Change in ControlDeath or Disability

Qualified Retirement(1)

Annual Performance-Based Cash BonusIf the successor company does not assume the award, or if the successor company assumes the award and the executive is terminated without cause or resigns for good reason prior to payment, the executive will be entitled to the bonus payable assuming achievement of the target level of performance.Entitled to the bonus payable assuming achievement of the target level of performance.Eligible to earn a prorated bonus based on the number of months elapsed since the start of the fiscal year and the actual performance achieved as of the end of such fiscal year.
Restricted Stock UnitsIf the successor company does not assume the RSUs, or if the successor company assumes the RSUs and the executive is terminated without cause or resigns for good reason within a period of time after the transaction (two years for Messrs. Duda and Hrudicka and one year for Messrs. Khoury and Kill), all unvested RSUs will become immediately and fully vested.All unvested RSUs will become immediately and fully vested.A prorated number of RSUs will vest based on the months elapsed since May 3, 2015.
Restricted Stock Awards

If the successor company does not assume the RSAs, or if the successor company assumes the RSAs and the executive is terminated without cause or resigns for good reason within a period of time after the transaction (two years for Messrs. Duda and Hrudicka and one year for Messrs. Khoury and Kill), the executive will earn a prorated number of the RSAs eligible for vesting assuming the achievement of the target level of performance based on the number of months elapsed since May 3, 2015.

In either case, the executive is also entitled to a payment based on the dividends declared during the restricted period and the number of shares vested.

The number of RSAs eligible for vesting assuming the achievement of the target level of performance will become immediately and fully vested.

The executive is also entitled to a payment based on the dividends declared during the restricted period and the number of shares vested.

Eligible to earn a prorated number of shares based on the number of months elapsed since May 3, 2015 and Methode’s fiscal 2020 adjusted EBITDA.

The executive is also entitled to a payment based on the dividends declared during the restricted period and the number of shares vested.

Stock OptionsImmediate vesting of outstanding option awards.Immediate vesting of all outstanding option awards.Immediate vesting of all outstanding option awards.

(1)An executive’s qualified retirement occurs at or after age 65, or after age 55 with our consent.

35 

Messrs. Duda, Hrudicka, KillTsoumas and GlandonKhoury and Ms. Barry are parties to change of control agreements with the Company. Mr. Khoury is not a party to a change of control agreement. Pursuant to these change of control agreements, if within two years of a change of control or during a period pending a change of control, we terminate the executive’s employment without good cause or the executive voluntarily terminates his or her employment for good reason, the executive is entitled to the following:

a lump sum payment in an amount equal to three times (two times in the casea multiple of Messrs. Hrudicka, Kill and Glandon) the executive’s annual salary;base salary (three times for Mr. Duda and two times for the other named executive officers);
a lump sum payment equal to threea multiple (three times (twofor Mr. Duda and two times infor the case of Messrs. Hrudicka, Kill and Glandon)other named executive officers) ‎of the lesser of: (a) the executive’s target bonus amount for the fiscal year in which executive’s employmentthe termination occurs, or (b) the bonus the executive earned in the prior fiscal year; and
continued participation in our welfare benefit plans for three years (twofor Mr. Duda and two years infor the case of Messrs. Hrudicka, Kill and Glandon)other named executive officers, or until the executive becomes covered under other welfare benefit plans providing substantially similar benefits.

41

Additionally, in the event of a change of control or the executive’s death, disability, qualified retirement, or termination without cause, all of our named executive officers are entitled to certain payments under the 2021 LTI Program, the annual performance-based bonus awards and their transition bonus awards.
The following table summarizes compensation payable to our named executive officers upon these various termination scenarios. For all awards other than the transition bonuses, the amounts payable under the “Change in Control” column are due if (i) the successor company does not assume the awards or (ii) the successor company assumes the awards and then the executive is terminated without cause or resigns for good reason. In each scenario in which the RSA shares and/or the RSUs vest, the executive is entitled to a payment based on the dividends declared during the vesting period and the number of shares or units vested.
Termination Scenario
Type of Award
Change in Control
Death or Disability
Termination Without
Cause
Retirement(1)
Annual Performance-Based Bonus
The target bonus is paid.
The target bonus is paid.
No bonus is paid.
A prorated bonus is paid based on the retirement date and year-end performance.
Restricted Stock Units (“RSUs”)
All RSUs are fully vested.
All RSUs are fully vested.
If Messrs. Duda, Tsoumas or Khoury or Ms. Barry are terminated after the end of fiscal 2021, a prorated number of RSUs will vest based on the ‎‎number of months elapsed since the start of fiscal 2021.‎
A prorated number of RSUs will vest based on the months elapsed since the start of fiscal 2021. If Mr. Duda retires after the end of fiscal 2023, all of his RSUs will fully vest.
Performance-Based Restricted Stock Awards (“RSAs”)
A prorated number of RSA shares will vest.

For Messrs. Duda and Martin, the proration will be based on the number of months elapsed since the start of fiscal 2021.

For Messrs. Tsoumas and Khoury and Ms. Barry, (A) if the termination occurs in fiscal 2021, all RSA shares are forfeited; (B) if the termination occurs in fiscal 2022 or 2023, the proration will be based on
All RSA shares are fully vested.
If Messrs. Duda, Tsoumas or Khoury or Ms. Barry are terminated without cause after the end of fiscal 2021, a prorated number of RSA shares will be eligible for vesting based on the number of months ‎elapsed since the start of fiscal 2021.

The number of RSA shares to actually vest will depend on the Company’s fiscal 2025 EBITDA‎.
A prorated number of RSA shares will be eligible for vesting based on the number of months elapsed since the start of fiscal 2021.

If Mr. Duda retires after fiscal 2023, all of his RSA shares will be eligible for vesting.

The number of RSA shares to actually vest will depend on the Company’s fiscal 2025 EBITDA‎.
42

Termination Scenario
Type of Award
Change in Control
Death or Disability
Termination Without
Cause
Retirement(1)
the number of months elapsed since the start of fiscal 2021; and (C) if the termination occurs in fiscal 2024 or 2025, all RSA shares will fully vest.
Performance Units
All of the Performance Units are forfeited to the Company.
All of the Performance Units are forfeited to the Company.
If Messrs. Duda, Tsoumas or Khoury or Ms. Barry are terminated without cause after the end of fiscal 2021, a prorated number of Performance Units will be eligible to be earned based on the number of months ‎elapsed since the start of fiscal 2021.

The number of Performance Units to actually be earned will depend on the Company’s fiscal 2025 EBITDA.
A prorated number of Performance Units will be eligible to be earned based on the number of months elapsed since the start of fiscal 2021.

If Mr. Duda retires after fiscal 2023, all of his Performance Units will be eligible to be earned.

The number of Performance Units to actually be earned will depend on the Company’s fiscal 2025 EBITDA.
Transition Awards
Following any change in control, if an executive is terminated without cause or resigns for good reason, the unpaid portion of the transition award will be paid.
The unpaid portion of the ‎transition award will be paid.‎‎
The unpaid portion of the ‎transition award will be paid.‎‎
The executive must repay any transition award amounts previously paid.‎‎
(1)
An executive’s qualified retirement occurs at or after age 65, or after age 55 with our consent. Mr. Duda is 65 years old. All of our other named executive officers are between 55 and 65 years old.
43

The following table shows the potential amounts payable to our currently serving named executive officers upon termination or a change of control of Methode. The information shown for Mr. Koman reflects the compensation received in connection with his qualified retirement in September 2016. The amounts shown assume that such termination was effective as of April 28, 2017 (the30, 2021, the last trading day of our 20172021 fiscal year),year, and reflect the price of our common stock on such date ($44.55) and reflects awards outstanding and unvested on such date.44.93). The table below does not reflect amounts payable to our named executive officers pursuant to plans or arrangements that are available generally to salaried employees, such as payments under the 401(k) Plan, the life insurance plan, the disability insurance plan and the vacation pay policy, payment of accrued base salary and accrued bonuses and, in the case of Mr. Khoury, payments under the Lebanese Labor Laws.employees. In addition, the table does not reflect the distribution of each officer’s account balancebalances in our Deferred Compensation Plan or the delivery of common stock underlying outstanding vested restricted stock units. For purposes of this table, we have assumed that our Compensation Committee has elected to accelerate all awards in each instance in which acceleration is subject to the discretion of our Compensation Committee.

36 

Name

Termination Scenario

(on 4/28/17)

Salary and Bonus Severance

($)

Payment of Annual Performance-Based Bonus
($)

Vesting of Option Awards

($)

Vesting of RSUs ($)Vesting of RSAs ($)(1)

Health and Welfare Benefits

($) (2)

Donald W. DudaUpon Change of Control (3)--716,108100,5335,346,0008,132,400--
 Resignation for Good Reason/Termination Without Cause Following Change of Control (4)4,296,648--------71,021
 Death or Disability--716,108100,5335,346,0008,132,400--
 Qualified Retirement--716,108100,5332,138,4003,363,120--
John R. HrudickaUpon Change of Control (3)--297,000--1,425,6002,151,360--
 Resignation for Good Reason/Termination Without Cause Following Change of Control (4)1,929,462--------71,021
 Death or Disability--297,000--1,425,6002,151,360--
 Qualified Retirement--297,000--570,240547,560--
Joseph E. KhouryUpon Change of Control (3)--240,01230,1602,673,0004,066,200--
 Resignation for Good Reason/ Termination Without Cause Following Change of Control------------
 Death or Disability--240,01230,1602,673,0004,066,200--
 Qualified Retirement--240,01230,1601,069,2001,681,560--
Theodore P. KillUpon Change of Control (3)--210,568--2,673,0004,066,200--
 Resignation for Good Reason/ Termination Without Cause Following Change of Control (4)1,054,576--------15,480
 Death or Disability--210,568--2,673,0004,066,200--
 Qualified Retirement--210,568--1,069,2001,681,560--
Timothy R. GlandonUpon Change of Control (3)----30,160------
 Resignation for Good Reason/ Termination Without Cause Following Change of Control (4)590,000--------47,347
 Death, Disability----30,160------
 Qualified Retirement----30,160------
Douglas A. KomanQualified Retirement--138,30726,894393,255794,047--
        

Name
Termination Scenario
(on 5/1/21)
Salary and
Bonus
Severance
($)
Annual
Performance
Based
Bonus
($)
Transition
Award
($)
Vesting of
RSUs ($)(1)
Vesting of
RSAs
($)(1)(2)
Vesting of
Performance
Units ($)(2)
Health and
Welfare
Benefits
($)(3)
Mr. Duda
Upon Change of Control(4)
782,800
16,972,500
3,394,500
Resignation for Good Reason/Termination Without Cause Following Change of Control(5)
3,052,920
1,570,000
51,861
Death or Disability
782,800
1,570,000
16,972,500
16,972,500
Qualified Retirement
1,565,600
0
3,394,500
3,394,500(6)
0
Termination Without Cause
1,570,000
0
0
0
Mr. Tsoumas
Upon Change of Control(4)
271,920
3,417,130
0
Resignation for Good Reason/Termination Without Cause Following Change of Control(5)
987,152
620,000
34,574
Death or Disability
271,920
620,000
3,417,130
3,417,130
Qualified Retirement
543,840
0
683,426
683,426(6)
0
Termination Without Cause
620,000
0
0
0
Mr. Khoury
Upon Change of Control(4)
345,000
6,517,170
0
Resignation for Good Reason/ Termination Without Cause Following Change of Control(5)
1,100,216
805,000
Death or Disability
345,000
805,000
6,517,170
6,517,170
Qualified Retirement
690,000
0
1,303,434
1,303,434(6)
0
Termination Without Cause
805,000
0
0
0
Ms. Barry
Upon Change of Control(4)
201,960
2,376,150
0
Resignation for Good Reason/ Termination Without Cause Following Change of Control(5)
724,166
460,000
51,162
Death or Disability
201,960
460,000
2,376,150
2,376,150
Qualified Retirement
403,920
0
475,230
475,230(6)
0
Termination Without Cause
460,000
0
0
0
Mr. Martin
Upon Change of Control(4)
217,800
2,285,630
457,126
Resignation for Good Reason/ Termination Without Cause Following Change of Control(5)
365,000
Death, Disability
217,800
365,000
2,285,630
2,285,630
Qualified Retirement
343,515
0
457,126
457,126(6)
0
Termination Without Cause
365,000
(1)
Amounts include an amount equal to the cash dividends declared during the period from the date of grant thru May 1, 2021, multiplied by the number of shares or units vested.
(2)
For purposes of this table, we have assumed that the target performance level will be achieved with respect to the RSAs.  Amounts include an amount equalRSAs and the Performance Units and that our Compensation Committee has elected to accelerate all awards subject to the cash dividends declared duringdiscretion of the period from the date of grant thru April 28, 2017, multiplied by the number of RSAs vestedCompensation Committee.
(2)(3)
Reflects the estimated lump-sum present value of all future premiums which will be paid on behalf of the executive under our health and welfare benefit plans.
(3)(4)
Includes amounts payable whereAssumes the successor company assumed an award and then terminated an executive without causedoes not assume the annual bonus awards, RSUs or the executive resigned with good reason.RSAs.
(4)(5)
These amounts are in addition to amounts payable under the preceding row “Upon Change of Control.”
For the transition awards, assumes the executive is terminated without good cause or voluntarily terminates employment for good reason within two years.
37 (6)
Assumes the target level of performance is achieved.
44


CEO PAY RATIO
As required by Section 953(b) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item 402(u) of SEC Regulation S-K, we are providing the following information about the ratio of the median annual total compensation of our employees to the annual total compensation of our Chief Executive Officer, Donald W. Duda.
To calculate the pay ratio, we identified the median employee based on our employee population as of February 1, 2021‎, which was approximately ‎7,200 employees in the United States, Mexico, Malta, China, Egypt, India, Belgium, Canada, the United Kingdom, Germany, Italy, Lebanon, the Netherlands, Switzerland, Singapore, France and Taiwan. For purposes of identifying the median employee, we considered annual base salary as of February 1, 2021, plus overtime, allowances and short-term incentive compensation for the trailing twelve months, each as reported in our payroll records and adjusted to US dollars. We did not make any cost-of-living adjustments to the pay of employees living in different jurisdictions than our CEO, but we did include certain adjustments for the annualization of pay for employees who were employed for only part of the period.
Based on this analysis, we determined that our median employee is a quality assistant located in Monterrey, Mexico. For fiscal 2021, the median of the annual total compensation of all of our employees (other than Mr. Duda) was ‎‎$7,532. Our median annual total compensation reflects that the bulk of our employees are in countries that have much lower prevailing wages than the United States.
Mr. Duda’s annual total compensation, as reported in the Summary Compensation Table, was $‎13,331,554. Mr. Duda’s total compensation included $10,605,000 of value attributable to the restricted stock units awarded under our new five-year long-term incentive program (“2021 LTI Program”). ‎As discussed above in “Compensation Discussion and Analysis – Components of Fiscal 2021 Compensation – 2021 LTI Program,” the Compensation Committee generally targeted the 2021 LTI Program equity awards within the median range of competitive practice, as annualized over the five-year program period. Consistent with our prior five-year programs, the Compensation Committee intends the awards under the 2021 LTI Program to be the only equity-based awards made to our CEO during this five-year period.
The pay ratio between our CEO and median employee is 1,770 to 1, which is higher than previous years largely as a result of the award cycle under our 2021 LTI Program and prior five-year program where equity awards are granted to the CEO once every five years.‎ The pay ratio between our CEO and median employee was 162 to 1, 131 to 1 and 148 to 1 in fiscal 2018, 2019 and 2020, respectively.
The assumptions used in the calculation of our estimated pay ratio are specific to our company and our employee population. As such, our pay ratio may not be comparable to the pay ratios of other companies, including companies in our compensation peer group.
45

OTHER INFORMATION

Delinquent Section 16(a) Beneficial Ownership Reporting Compliance

Reports

Under the securities laws, our directors and executive officers are required to report their initial ownership of our common stock and any subsequent changes in that ownership to the SEC. Specific due dates for these reports have been established and we are required to disclose in this proxy statement if a director or executive officer filed a late report. During fiscal 2017,2021, all such reports were timely filed.filed, except that, due to administrative oversight, transactions in a broker dividend reinvestment plan were reported in two late Form 4s for Timothy Glandon, our Vice President. As reported in the Form 4s, the transactions consisted of forty transactions involving the acquisition of 1,134 shares of our common stock in the aggregate. In making these disclosures, we have relied solely on written representations of our directors and executive officers and copies of the reports filed with the SEC.

Availability of Annual Report

Methode is providing its 2021 Annual Report on Form 10-K to shareholdersstockholders who receive this proxy statement. Methode will provide copies of the Annual Reportthese materials to brokers, dealers, banks, voting trustees and their nominees for the benefit of theirthe beneficial owners of record. Additional copies of this proxy statement and the Annual Report and Methode’s2021 Annual Report on Form 10-K for the fiscal year ended April 29, 2017 are available, without charge, upon written request to Methode Electronics, Inc., 74018750 West WilsonBryn Mawr Avenue, Suite 1000, Chicago, Illinois 60706,60631, Attention: Chief Financial Officer. You may also review Methode’s SEC filings by visiting the Investors page of‎ our website atwww.methode.com.

Shareholder www.methode.com.

Stockholder Proposals and Director Nominations

If you wish to submit a shareholderstockholder proposal for inclusion in our proxy materials for our 20182022 Annual Meeting, our Corporate Secretary must receive your proposal no later than April 3, 2018.March 29, 2022. Your proposal must be in writing and must comply with the proxy rules of the SEC.

Our advance notice by-law provisions require that any shareholderstockholder proposal or director nomination to be presented from the floor of our 20182022 Annual Meeting must be received by our Corporate Secretary not later than the 60th day nor earlier than the 90th day prior to September 14, 201815, 2022 (the first anniversary of the preceding year’s annual meeting)Annual Meeting). If the date of our 20182022 Annual Meeting is more than 30 days before or more than 60 days after September 14, 2018, shareholder15, 2022, stockholder proposals must be delivered no earlier than the 90th day prior to such annual meeting date and not later than the later of the 60th day prior to such annual meeting date or the 10th day following our public announcement of the meeting date for such annual meeting.Annual Meeting. Any shareholderstockholder proposal must be, under law, an appropriate subject for shareholderstockholder action in order to be brought before the meeting. In addition, in order to present a shareholderstockholder proposal or nominate a director at our 20182022 Annual Meeting, the shareholderstockholder must satisfy certain other requirements set forth in our Amended and Restated By-Laws. ShareholderStockholder proposals and director nominations should be directed to the Corporate Secretary of Methode Electronics, Inc. at 74018750 West WilsonBryn Mawr Avenue, Suite 1000, Chicago, Illinois 60706.

60631.

Other Matters

Neither our Board of Directors nor management knows of any other business that will be presented at the annual meeting.Annual Meeting. Should any other business properly come before the annual meeting,Annual Meeting, the persons named in the proxy will vote on such matters in accordance with their best judgment.

By Order of the Board of Directors,

Walter J. Aspatore
Chairman

Chicago, Illinois

August 1, 2017

38 

 (METHODE ELECTRONICS)

METHODE ELECTRONICS, INC.
7401 WEST WILSON AVENUE
CHICAGO, IL 60706-4548

VOTE BY INTERNET - www.proxyvote.com

Use the Internet to transmit your voting instructions for electronic delivery of information up until 11:59 P.M. Eastern Time the day before the annual meeting date. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form.

ELECTRONIC DELIVERY OF FUTURE PROXY MATERIALS

Methode Electronics, Inc. encourages you to take advantage of convenient ways to vote these shares. If voting by proxy, you may grant a proxy by mail, or choose one of the two methods described below. Your telephone or Internet proxy authorizes the named proxies to vote these shares in the same manner as if you marked, signed, and returned your proxy card. To grant your proxy by telephone or Internet, read the annual meeting proxy statement and then follow these easy steps:

VOTE BY PHONE - 1-800-690-6903

Use any touch-tone telephone to transmit your voting instructions up until 11:59 P.M. Eastern Time the day before the annual meeting date. Have your proxy card in hand when you call and then follow the simple instructions the vote voice provides you.

VOTE BY MAIL

Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.

TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS:

KEEP THIS PORTION FOR YOUR RECORDS
DETACH AND RETURN THIS PORTION ONLY
THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED.
The Board of Directors recommends you vote FOR the following:
1.Election of Directors
Nominees
For  Against  Abstain
1a.Walter J. AspatoreThe Board of Directors recommends you vote FOR proposals 2 and 3.ForAgainstAbstain
1b.Darren M. Dawson2The ratification of the Audit Committee's selection of Ernst & Young LLP to serve as our independent registered public accounting firm for the fiscal year ending April 28, 2018.
1c.Donald W. Duda
1d.Martha Goldberg Aronson
1e.Isabelle C. Goossen3The advisory approval of Methode's named executive officer compensation.
1f.Christopher J. Hornung ☐  ☐ 
1g. Paul G. SheltonThe Board of Directors recommends you vote 1 YEAR on the following proposal:1 year2 years3 yearsAbstain
1h.Lawrence B. Skatoff
4To recommend, by non-binding vote, the frequency of advisory votes on named executive officer compensation. ☐☐  ☐☐ 
NOTE:Such other business as may properly come before the meeting or any adjournment thereof.
Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by authorized officer.
Signature [PLEASE SIGN WITHIN BOX]DateSignature (Joint Owners)Date

0000341962_1     R1.0.1.15

Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting: The Notice & Proxy Statement and Annual Report are available atwww.proxyvote.com

METHODE ELECTRONICS, INC.
This proxy is solicited by the Board of Directors,
Annual Meeting of the Shareholders
The undersigned hereby appoints
Walter J. Aspatore Donald W. Duda and John R. Hrudicka, and each of them, with full power of substitution, as proxies to vote all shares of Methode Electronics, Inc. common stock which the undersigned is entitled to vote at the Annual Meeting of Methode Electronics, Inc. to be held on Thursday, September 14, 2017 at 11:00 a.m., Central Daylight Time, at Methode's corporate offices at 7401 West Wilson Avenue, Chicago, Illinois 60706, and at any adjournment or postponement thereof.
This proxy when properly signed will be voted in the manner directed herein by the undersigned shareholder. IF NO DIRECTION IS PROVIDED, THIS PROXY WILL BE VOTED AS RECOMMENDED BY THE BOARD OF DIRECTORS. If other business is presented at the Annual Meeting, this proxy shall be voted in accordance with the best judgment of the persons named as proxies above.
Continued and to be signed on reverse side

Chairman

0000341962_2     R1.0.1.15

Chicago, Illinois
July 27, 2021
46